<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.service.contract.soap.trials.v2.TrialResultsOutput xmlns:ns2="local" hits="10" offset="0" totalResults="1237"><Filters total="48"><Filter label="Trial Technologies" name="trialTechnologies" total="100"><FilterOption id="762" count="777" label="Small molecule therapeutic"></FilterOption><FilterOption id="585" count="607" label="Oral formulation"></FilterOption><FilterOption id="648" count="510" label="Intravenous formulation"></FilterOption><FilterOption id="761" count="466" label="Biological therapeutic"></FilterOption><FilterOption id="740" count="432" label="Infusion"></FilterOption><FilterOption id="595" count="430" label="Tablet formulation"></FilterOption><FilterOption id="586" count="300" label="Capsule formulation"></FilterOption><FilterOption id="746" count="290" label="Solution"></FilterOption><FilterOption id="751" count="288" label="Film coating"></FilterOption><FilterOption id="573" count="281" label="Immunoglobulin-G"></FilterOption><FilterOption id="898" count="249" label="Formulation powder"></FilterOption><FilterOption id="750" count="218" label="Freeze drying"></FilterOption><FilterOption id="85" count="209" label="Protein recombinant"></FilterOption><FilterOption id="647" count="205" label="Subcutaneous formulation"></FilterOption><FilterOption id="169" count="190" label="Monoclonal antibody humanized"></FilterOption><FilterOption id="1263" count="143" label="Immuno-oncology"></FilterOption><FilterOption id="1652" count="107" label="Prodrug"></FilterOption><FilterOption id="1647" count="102" label="Natural product"></FilterOption><FilterOption id="168" count="91" label="Monoclonal antibody human"></FilterOption><FilterOption id="594" count="84" label="Oral suspension formulation"></FilterOption><FilterOption id="593" count="80" label="Oral liquid formulation"></FilterOption><FilterOption id="80" count="71" label="Peptide"></FilterOption><FilterOption id="175" count="68" label="Drug combination"></FilterOption><FilterOption id="766" count="63" label="Parenteral formulation unspecified"></FilterOption><FilterOption id="805" count="55" label="Daily dosing"></FilterOption><FilterOption id="902" count="53" label="Orally disintegrating tablet"></FilterOption><FilterOption id="166" count="52" label="Chimeric monoclonal antibody"></FilterOption><FilterOption id="589" count="50" label="Sustained release formulation"></FilterOption><FilterOption id="180" count="48" label="Antibody fragment"></FilterOption><FilterOption id="651" count="47" label="Intramuscular formulation"></FilterOption><FilterOption id="745" count="44" label="Suspension"></FilterOption><FilterOption id="894" count="39" label="Liquid formulation"></FilterOption><FilterOption id="743" count="37" label="Granule"></FilterOption><FilterOption id="667" count="34" label="Peptidomimetic"></FilterOption><FilterOption id="630" count="34" label="Stereochemistry"></FilterOption><FilterOption id="171" count="32" label="Monoclonal antibody conjugated"></FilterOption><FilterOption id="596" count="30" label="Injectable formulation"></FilterOption><FilterOption id="603" count="30" label="Systemic formulation unspecified"></FilterOption><FilterOption id="66" count="27" label="Antibiotic"></FilterOption><FilterOption id="701" count="25" label="Nucleoside synthesis"></FilterOption><FilterOption id="680" count="24" label="Buccal formulation systemic"></FilterOption><FilterOption id="852" count="24" label="Intravesical formulation"></FilterOption><FilterOption id="348" count="23" label="PEGylated formulation"></FilterOption><FilterOption id="1646" count="22" label="Injectable controlled release formulation"></FilterOption><FilterOption id="742" count="22" label="Pellet"></FilterOption><FilterOption id="599" count="21" label="Nanoparticle formulation injectable"></FilterOption><FilterOption id="660" count="21" label="Oral sustained release formulation"></FilterOption><FilterOption id="90" count="21" label="Steroid"></FilterOption><FilterOption id="127" count="20" label="Cell culture"></FilterOption><FilterOption id="74" count="20" label="Glycoprotein"></FilterOption><FilterOption id="112" count="19" label="DNA technology"></FilterOption><FilterOption id="102" count="19" label="Nucleotide and derivatives"></FilterOption><FilterOption id="84" count="19" label="Protein fusion"></FilterOption><FilterOption id="128" count="18" label="Cell culture technique"></FilterOption><FilterOption id="1164" count="17" label="Antibody drug conjugate"></FilterOption><FilterOption id="641" count="17" label="Controlled release formulation"></FilterOption><FilterOption id="598" count="17" label="Liposome formulation injectable"></FilterOption><FilterOption id="723" count="16" label="Drug coating"></FilterOption><FilterOption id="649" count="16" label="Intraperitoneal formulation"></FilterOption><FilterOption id="207" count="15" label="Protein conjugated"></FilterOption><FilterOption id="616" count="12" label="Inhalant formulation"></FilterOption><FilterOption id="756" count="11" label="Pharmaceutical carrier"></FilterOption><FilterOption id="611" count="10" label="Dermatological formulation"></FilterOption><FilterOption id="620" count="9" label="Ophthalmic formulation"></FilterOption><FilterOption id="776" count="9" label="Oral gel formulation"></FilterOption><FilterOption id="208" count="9" label="Protein conjugation"></FilterOption><FilterOption id="558" count="9" label="Transdermal formulation"></FilterOption><FilterOption id="851" count="8" label="Intradermal formulation"></FilterOption><FilterOption id="349" count="8" label="Lipid"></FilterOption><FilterOption id="753" count="8" label="Microparticle formulation"></FilterOption><FilterOption id="51" count="8" label="Monoclonal antibody"></FilterOption><FilterOption id="103" count="8" label="Oligonucleotide"></FilterOption><FilterOption id="569" count="8" label="Oligonucleotide antisense"></FilterOption><FilterOption id="652" count="7" label="Intra-articular formulation"></FilterOption><FilterOption id="167" count="7" label="Monoclonal antibody murine"></FilterOption><FilterOption id="267" count="7" label="Multivalent antibody"></FilterOption><FilterOption id="662" count="7" label="Quick release formulation"></FilterOption><FilterOption id="857" count="6" label="Allogenic stem cell therapy"></FilterOption><FilterOption id="537" count="6" label="Chimeric antibody"></FilterOption><FilterOption id="1669" count="6" label="Emulsion formulation"></FilterOption><FilterOption id="731" count="6" label="Imaging"></FilterOption><FilterOption id="654" count="6" label="Intrathecal formulation"></FilterOption><FilterOption id="159" count="6" label="Oligosaccharide"></FilterOption><FilterOption id="724" count="6" label="Radiolabeling"></FilterOption><FilterOption id="617" count="5" label="Aerosol formulation inhalant"></FilterOption><FilterOption id="612" count="5" label="Emulsion dermatological"></FilterOption><FilterOption id="347" count="5" label="Intratumoral formulation"></FilterOption><FilterOption id="764" count="5" label="Local formulation unspecified"></FilterOption><FilterOption id="236" count="5" label="Macrolide"></FilterOption><FilterOption id="170" count="5" label="Multivalent monoclonal antibody"></FilterOption><FilterOption id="559" count="5" label="Oral controlled release formulation"></FilterOption><FilterOption id="135" count="5" label="T-lymphocyte"></FilterOption><FilterOption id="878" count="4" label="Adipose stem cell therapy"></FilterOption><FilterOption id="216" count="4" label="Antibody conjugated"></FilterOption><FilterOption id="582" count="4" label="Antibody polyclonal"></FilterOption><FilterOption id="570" count="4" label="Cell therapy"></FilterOption><FilterOption id="1247" count="4" label="Chimeric antigen receptor T cell therapy"></FilterOption><FilterOption id="590" count="4" label="Enteric coated formulation"></FilterOption><FilterOption id="864" count="4" label="Mesenchymal stem cell therapy"></FilterOption><FilterOption id="807" count="4" label="Monthly dosing"></FilterOption></Filter><Filter label="Indications" name="indications" total="100"><FilterOption id="3657" count="58" label="Metastatic breast cancer"></FilterOption><FilterOption id="2399" count="56" label="Adenocarcinoma"></FilterOption><FilterOption id="1828" count="51" label="Multiple myeloma"></FilterOption><FilterOption id="159" count="49" label="HIV-1 infection"></FilterOption><FilterOption id="3665" count="40" label="Metastatic non small cell lung cancer"></FilterOption><FilterOption id="49" count="38" label="Breast tumor"></FilterOption><FilterOption id="158" count="37" label="HIV infection"></FilterOption><FilterOption id="1069" count="36" label="Metastasis"></FilterOption><FilterOption id="1731" count="30" label="Acute myelogenous leukemia"></FilterOption><FilterOption id="3257" count="27" label="Stage IV melanoma"></FilterOption><FilterOption id="3246" count="26" label="Hormone refractory prostate cancer"></FilterOption><FilterOption id="3658" count="23" label="Metastatic colorectal cancer"></FilterOption><FilterOption id="307" count="23" label="Squamous cell carcinoma"></FilterOption><FilterOption id="3713" count="22" label="Advanced solid tumor"></FilterOption><FilterOption id="1771" count="22" label="Transitional cell carcinoma"></FilterOption><FilterOption id="4250" count="21" label="Metastatic renal cell carcinoma"></FilterOption><FilterOption id="1734" count="20" label="Chronic lymphocytic leukemia"></FilterOption><FilterOption id="84" count="20" label="Crohns disease"></FilterOption><FilterOption id="337" count="20" label="Ulcerative colitis"></FilterOption><FilterOption id="1749" count="19" label="Diffuse large B-cell lymphoma"></FilterOption><FilterOption id="1272" count="18" label="Myelodysplastic syndrome"></FilterOption><FilterOption id="255" count="18" label="Parkinsons disease"></FilterOption><FilterOption id="2243" count="16" label="Fallopian tube cancer"></FilterOption><FilterOption id="70" count="16" label="Liver cirrhosis"></FilterOption><FilterOption id="224" count="16" label="Myocardial infarction"></FilterOption><FilterOption id="799" count="16" label="Ovary tumor"></FilterOption><FilterOption id="3083" count="16" label="Peritoneal tumor"></FilterOption><FilterOption id="3510" count="16" label="Pulmonary artery hypertension"></FilterOption><FilterOption id="14" count="15" label="Alzheimers disease"></FilterOption><FilterOption id="55" count="15" label="Cardiac failure"></FilterOption><FilterOption id="80" count="15" label="Coronary artery disease"></FilterOption><FilterOption id="1542" count="14" label="Atrial fibrillation"></FilterOption><FilterOption id="1745" count="14" label="Follicle center lymphoma"></FilterOption><FilterOption id="153" count="14" label="Hepatitis C virus infection"></FilterOption><FilterOption id="3666" count="14" label="Metastatic stomach cancer"></FilterOption><FilterOption id="1728" count="13" label="Acute lymphoblastic leukemia"></FilterOption><FilterOption id="3667" count="13" label="Metastatic esophageal cancer"></FilterOption><FilterOption id="319" count="13" label="Non-Hodgkin lymphoma"></FilterOption><FilterOption id="1185" count="12" label="Chronic obstructive pulmonary disease"></FilterOption><FilterOption id="1767" count="12" label="Hepatocellular carcinoma"></FilterOption><FilterOption id="836" count="12" label="Insulin dependent diabetes"></FilterOption><FilterOption id="3256" count="12" label="Stage III melanoma"></FilterOption><FilterOption id="3676" count="11" label="Ischemic stroke"></FilterOption><FilterOption id="3866" count="11" label="Metastatic ovary cancer"></FilterOption><FilterOption id="3669" count="11" label="Metastatic pancreas cancer"></FilterOption><FilterOption id="17" count="10" label="Anemia"></FilterOption><FilterOption id="552" count="10" label="Bleeding"></FilterOption><FilterOption id="1765" count="10" label="Cholangiocarcinoma"></FilterOption><FilterOption id="2454" count="10" label="Glioblastoma"></FilterOption><FilterOption id="3466" count="10" label="Metastatic bladder cancer"></FilterOption><FilterOption id="3664" count="10" label="Metastatic prostate cancer"></FilterOption><FilterOption id="20" count="10" label="Pain"></FilterOption><FilterOption id="1867" count="10" label="Pulmonary hypertension"></FilterOption><FilterOption id="3673" count="9" label="Metastatic head and neck cancer"></FilterOption><FilterOption id="213" count="9" label="Multiple sclerosis"></FilterOption><FilterOption id="2637" count="9" label="Non-alcoholic steatohepatitis"></FilterOption><FilterOption id="1262" count="9" label="Non-small-cell lung cancer"></FilterOption><FilterOption id="427" count="9" label="Uterine cervix tumor"></FilterOption><FilterOption id="316" count="8" label="B-cell lymphoma"></FilterOption><FilterOption id="1705" count="8" label="Endometrioid carcinoma"></FilterOption><FilterOption id="837" count="8" label="Non-insulin dependent diabetes"></FilterOption><FilterOption id="291" count="8" label="Rheumatoid arthritis"></FilterOption><FilterOption id="1261" count="8" label="Small-cell lung cancer"></FilterOption><FilterOption id="23" count="7" label="Angina"></FilterOption><FilterOption id="31" count="7" label="Asthma"></FilterOption><FilterOption id="1735" count="7" label="Chronic myelocytic leukemia"></FilterOption><FilterOption id="152" count="7" label="Hepatitis B virus infection"></FilterOption><FilterOption id="161" count="7" label="Hodgkins disease"></FilterOption><FilterOption id="3771" count="7" label="Idiopathic pulmonary fibrosis"></FilterOption><FilterOption id="2989" count="7" label="Kidney transplant rejection"></FilterOption><FilterOption id="203" count="7" label="Lymphoma"></FilterOption><FilterOption id="1995" count="7" label="Primary biliary cholangitis"></FilterOption><FilterOption id="299" count="7" label="Schizophrenia"></FilterOption><FilterOption id="3258" count="6" label="Acute coronary syndrome"></FilterOption><FilterOption id="1729" count="6" label="B-cell acute lymphoblastic leukemia"></FilterOption><FilterOption id="760" count="6" label="Brain tumor"></FilterOption><FilterOption id="205" count="6" label="Melanoma"></FilterOption><FilterOption id="245" count="6" label="Osteoarthritis"></FilterOption><FilterOption id="318" count="6" label="Systemic lupus erythematosus"></FilterOption><FilterOption id="3678" count="6" label="Urethral cancer"></FilterOption><FilterOption id="3492" count="5" label="AL amyloidosis"></FilterOption><FilterOption id="2380" count="5" label="Bladder cancer"></FilterOption><FilterOption id="3919" count="5" label="Chronic liver failure"></FilterOption><FilterOption id="89" count="5" label="Cytomegalovirus infection"></FilterOption><FilterOption id="616" count="5" label="Graft versus host disease"></FilterOption><FilterOption id="2212" count="5" label="Hepatorenal syndrome"></FilterOption><FilterOption id="2318" count="5" label="Liver fibrosis"></FilterOption><FilterOption id="2273" count="5" label="Oligodendroglioma"></FilterOption><FilterOption id="3239" count="5" label="Portal hypertension"></FilterOption><FilterOption id="330" count="5" label="Restenosis"></FilterOption><FilterOption id="3395" count="4" label="Acute liver failure"></FilterOption><FilterOption id="1102" count="4" label="Atopic dermatitis"></FilterOption><FilterOption id="2432" count="4" label="Bronchiectasis"></FilterOption><FilterOption id="989" count="4" label="Colorectal tumor"></FilterOption><FilterOption id="3198" count="4" label="Larynx tumor"></FilterOption><FilterOption id="2983" count="4" label="Liver transplantation"></FilterOption><FilterOption id="3235" count="4" label="Merkel cell carcinoma"></FilterOption><FilterOption id="793" count="4" label="Mouth tumor"></FilterOption><FilterOption id="794" count="4" label="Pharynx tumor"></FilterOption><FilterOption id="2319" count="4" label="Polycythemia vera"></FilterOption></Filter><Filter label="Endpoint Index" name="trialEndpointIndex" total="100"><FilterOption id="8712" count="55" label="Breast tumor - Assessment of Overall Survival (OS)"></FilterOption><FilterOption id="8719" count="53" label="Breast tumor - Assessment of Response Rates (RR) - Assessment of Overall/Objective Response Rate (ORR)"></FilterOption><FilterOption id="8998" count="50" label="Breast tumor - Assessment of adverse events"></FilterOption><FilterOption id="7879" count="49" label="Leukemia - Assessment of Overall Survival (OS)"></FilterOption><FilterOption id="9247" count="48" label="HIV infection - Assessment of Safety and Tolerability - Assessment of adverse events/serious adverse events"></FilterOption><FilterOption id="8713" count="45" label="Breast tumor - Assessment of Progression Free Survival (PFS)"></FilterOption><FilterOption id="7908" count="44" label="Leukemia - Assessment of Response Rates (RR) - Assessment of Complete Response"></FilterOption><FilterOption id="9218" count="43" label="HIV infection - Assessment of Immune Response"></FilterOption><FilterOption id="8078" count="42" label="Leukemia - Assessment of adverse events"></FilterOption><FilterOption id="7538" count="42" label="Lymphoma - Assessment of Overall Survival (OS)"></FilterOption><FilterOption id="8489" count="40" label="Lung tumor - Assessment of Progression Free Survival (PFS)"></FilterOption><FilterOption id="8721" count="39" label="Breast tumor - Assessment of Response Rates (RR) - Assessment of Complete Response"></FilterOption><FilterOption id="8481" count="39" label="Lung tumor - Assessment of Overall Survival (OS)"></FilterOption><FilterOption id="9213" count="38" label="HIV infection - Assessment of Viral Load - Assessment of HIV RNA levels"></FilterOption><FilterOption id="7547" count="38" label="Lymphoma - Assessment of Progression Free Survival (PFS)"></FilterOption><FilterOption id="9215" count="36" label="HIV infection - Assessment of CD4 Cell Responses - Assessment of CD4 cell count/percentage"></FilterOption><FilterOption id="7354" count="34" label="Multiple myeloma - Assessment of Overall Survival (OS)"></FilterOption><FilterOption id="8722" count="33" label="Breast tumor - Assessment of Response Rates (RR) - Assessment of Clinical Benefit Rate (CBR)"></FilterOption><FilterOption id="8738" count="33" label="Breast tumor - Assessment of Response Rates (RR) - Assessment of duration of tumor response"></FilterOption><FilterOption id="7360" count="33" label="Multiple myeloma - Assessment of Progression Free Survival (PFS)"></FilterOption><FilterOption id="8077" count="32" label="Leukemia - Assessment of Safety and Tolerability"></FilterOption><FilterOption id="7563" count="32" label="Lymphoma - Assessment of Response Rates (RR) - Assessment of Complete Response"></FilterOption><FilterOption id="8720" count="31" label="Breast tumor - Assessment of Response Rates (RR) - Assessment of Partial Response (PR)"></FilterOption><FilterOption id="7569" count="31" label="Lymphoma - Assessment of Response Rates (RR) - Assessment of Overall/Objective Response Rate (ORR)"></FilterOption><FilterOption id="7367" count="31" label="Multiple myeloma - Assessment of Response Rates (RR) - Assessment of Overall/Objective Response Rate (ORR)"></FilterOption><FilterOption id="8996" count="30" label="Breast tumor - Assessment of Safety and Tolerability"></FilterOption><FilterOption id="7680" count="29" label="Lymphoma - Assessment of adverse events"></FilterOption><FilterOption id="7679" count="28" label="Lymphoma - Assessment of Safety and Tolerability"></FilterOption><FilterOption id="42921" count="28" label="Other gastrointestinal disease - Assessment of Safety and Tolerability"></FilterOption><FilterOption id="7909" count="27" label="Leukemia - Assessment of Response Rates (RR) - Assessment of Overall/Objective Response Rate (ORR)"></FilterOption><FilterOption id="8505" count="27" label="Lung tumor - Assessment of Objective Response - Assessment of objective response rate(ORR)"></FilterOption><FilterOption id="9153" count="27" label="Lung tumor - Imaging/Radiological Assessments - Assessment by Response Evaluation Criteria in Solid Tumors (RECIST) Criteria"></FilterOption><FilterOption id="7611" count="27" label="Lymphoma - Assessment of Response Rates (RR) - Assessment of tumor response rate (Duration of response)"></FilterOption><FilterOption id="6919" count="27" label="Melanoma - Assessment of Overall Survival (OS)"></FilterOption><FilterOption id="8109" count="25" label="Leukemia - Assessment of Mortality/Death Rates"></FilterOption><FilterOption id="7898" count="25" label="Leukemia - Assessment of Survival - Assessment of event free survival (EFS)"></FilterOption><FilterOption id="7489" count="25" label="Multiple myeloma - Assessment of Safety and Tolerability - Assessment of other adverse events"></FilterOption><FilterOption id="8744" count="24" label="Breast tumor - Assessment of Disease Progression"></FilterOption><FilterOption id="9246" count="24" label="HIV infection - Assessment of Safety and Tolerability"></FilterOption><FilterOption id="8640" count="24" label="Lung tumor - Assessment of Safety and Tolerability - Adverse events as graded by CTCAE/CTC"></FilterOption><FilterOption id="7027" count="24" label="Melanoma - Assessment of adverse events"></FilterOption><FilterOption id="8140" count="23" label="Leukemia - Protocol Specified Other Endpoints - Assessment of Clinical Efficacy"></FilterOption><FilterOption id="8639" count="23" label="Lung tumor - Assessment of Safety and Tolerability"></FilterOption><FilterOption id="8714" count="22" label="Breast tumor - Assessment of Disease Free Survival (DFS)"></FilterOption><FilterOption id="8725" count="22" label="Breast tumor - Assessment of Response Rates (RR) - Assessment of Stable Disease"></FilterOption><FilterOption id="8999" count="22" label="Breast tumor - Assessment of Safety and Tolerability - Assessment of safety as measured by NCI CTCAE/NCI-CTC criteria"></FilterOption><FilterOption id="9238" count="22" label="HIV infection - Assessment of Laboratory/Diagnostic Measures"></FilterOption><FilterOption id="9300" count="22" label="Leukemia - Assessment of Response Rates (RR) - Assessment of tumor response rate (Duration of response)"></FilterOption><FilterOption id="6924" count="22" label="Melanoma - Assessment of Progression Free Survival (PFS)"></FilterOption><FilterOption id="6940" count="22" label="Melanoma - Assessment of Response Rates (RR) - Assessment of overall/objective response rate"></FilterOption><FilterOption id="7373" count="22" label="Multiple myeloma - Assessment of Response Rates (RR) - Assessment of Complete Response"></FilterOption><FilterOption id="7372" count="22" label="Multiple myeloma - Assessment of Response Rates (RR) - Assessment of Partial Response (PR)"></FilterOption><FilterOption id="7488" count="22" label="Multiple myeloma - Assessment of Safety and Tolerability"></FilterOption><FilterOption id="7049" count="22" label="Prostate tumor - Assessment of Progression Free Survival (PFS)"></FilterOption><FilterOption id="8754" count="21" label="Breast tumor - Assessment of Mortality/Death Rates"></FilterOption><FilterOption id="9212" count="21" label="HIV infection - Assessment of Viral Load"></FilterOption><FilterOption id="9242" count="21" label="HIV infection - Assessment of lipid profiles"></FilterOption><FilterOption id="7891" count="21" label="Leukemia - Assessment of Progression Free Survival (PFS)"></FilterOption><FilterOption id="7907" count="21" label="Leukemia - Assessment of Response Rates (RR) - Assessment of Partial Response (PR)"></FilterOption><FilterOption id="7906" count="21" label="Leukemia - Assessment of Response Rates (RR)"></FilterOption><FilterOption id="10828" count="21" label="Ovary tumor - Assessment of Overall Survival (OS)"></FilterOption><FilterOption id="10830" count="21" label="Ovary tumor - Assessment of Progression Free Survival (PFS)"></FilterOption><FilterOption id="7045" count="21" label="Prostate tumor - Assessment of Overall Survival (OS)"></FilterOption><FilterOption id="11717" count="20" label="Bladder cancer - Assessment of Overall Survival (OS)"></FilterOption><FilterOption id="9122" count="20" label="Breast tumor - Assessment of Pharmacokinetic/Pharmacodynamic Parameters"></FilterOption><FilterOption id="7558" count="20" label="Lymphoma - Assessment of Survival - Assessment of event free survival (EFS)"></FilterOption><FilterOption id="7393" count="20" label="Multiple myeloma - Assessment of Response Rates (RR) - Assessment of tumor response rate (Duration of response)"></FilterOption><FilterOption id="10540" count="20" label="Renal cell carcinoma - Assessment of Overall Survival (OS)"></FilterOption><FilterOption id="10545" count="20" label="Renal cell carcinoma - Assessment of Progression Free Survival (PFS)"></FilterOption><FilterOption id="8430" count="19" label="Colorectal tumor - Assessment of Safety and Tolerability - Assessment of adverse events/serious adverse events"></FilterOption><FilterOption id="2622" count="19" label="Coronary artery disease - Assessment of Mortality/Death Rates - Cardiovascular mortality"></FilterOption><FilterOption id="7916" count="19" label="Leukemia - Assessment of Response Rates (RR) - Assessment of hematologic/bone marrow response"></FilterOption><FilterOption id="7564" count="19" label="Lymphoma - Assessment of Response Rates (RR) - Assessment of Partial Response (PR)"></FilterOption><FilterOption id="8759" count="18" label="Breast tumor - Patient Reported Outcomes/Quality of Life Assessments"></FilterOption><FilterOption id="8147" count="18" label="Leukemia - Assessment of Response Rates (RR) - Assessment of minimal residual disease"></FilterOption><FilterOption id="8663" count="18" label="Lung tumor - Assessment of Pharmacokinetic/Pharmacodynamic Parameters"></FilterOption><FilterOption id="7395" count="18" label="Multiple myeloma - Assessment of Disease Progression - Assessment of time to disease progression (TTP)"></FilterOption><FilterOption id="43670" count="18" label="Other gastrointestinal disease - Assessment of adverse events"></FilterOption><FilterOption id="7190" count="18" label="Prostate tumor - Assessment of Safety and Tolerability - Assessment of adverse events/serious adverse events"></FilterOption><FilterOption id="11728" count="17" label="Bladder cancer - Assessment of Response Rates (RR) - Assessment of objective/overall response rate (ORR)"></FilterOption><FilterOption id="37159" count="17" label="Breast tumor - Assessment of Laboratory/Diagnostic Measures"></FilterOption><FilterOption id="2492" count="17" label="Coronary artery disease - Assessment of Cardiovascular Events - Acute/New Myocardial infarction (MI)/MI (Q-wave and non-Q wave)"></FilterOption><FilterOption id="9415" count="17" label="Lymphoma - Assessment of Disease Progression"></FilterOption><FilterOption id="43526" count="17" label="Other gastrointestinal disease - Clinical Assessments"></FilterOption><FilterOption id="11773" count="16" label="Bladder cancer - Assessment of Safety and Tolerability - Assessment of adverse events/serious adverse events"></FilterOption><FilterOption id="8163" count="16" label="Colorectal tumor - Assessment of Progression Free Survival (PFS)"></FilterOption><FilterOption id="9255" count="16" label="HIV infection - Assessment of Therapy Related Outcomes - Assessment of treatment discontinuation"></FilterOption><FilterOption id="25660" count="16" label="Pulmonary artery hypertension - Assessment of Six Minute Walk Test"></FilterOption><FilterOption id="15212" count="16" label="Solid tumor - Assessment of Response Rates (RR) - Assessment of objective response rate (ORR)"></FilterOption><FilterOption id="15287" count="16" label="Solid tumor - Assessment of adverse events"></FilterOption><FilterOption id="15907" count="16" label="Ulcerative colitis - Ulcerative Colitis Assessed by Activity Indices - Assessment by Mayo clinic score (MCS)/ disease activity index (DAI)"></FilterOption><FilterOption id="11722" count="15" label="Bladder cancer - Assessment of Progression Free Survival (PFS)"></FilterOption><FilterOption id="2703" count="15" label="Coronary artery disease - Assessment of Vascular Indices or Parameters - Assessment of target lesion revascularization (TLR)"></FilterOption><FilterOption id="9272" count="15" label="HIV infection - Assessment of Mortality/Death Rates"></FilterOption><FilterOption id="7921" count="15" label="Leukemia - Assessment of Disease Relapse/Recurrence"></FilterOption><FilterOption id="11735" count="14" label="Bladder cancer - Assessment of Response Rates (RR) - Assessment of duration of response"></FilterOption><FilterOption id="9310" count="14" label="Breast tumor - Imaging/Radiological Assessments"></FilterOption><FilterOption id="8522" count="14" label="Lung tumor - Assessment of Response Rates (RR) - Assessment of duration of response"></FilterOption><FilterOption id="11780" count="13" label="Bladder cancer - Assessment of Pharmacokinetic/Pharmacodynamic Parameters"></FilterOption><FilterOption id="8151" count="13" label="Colorectal tumor - Assessment of Overall Survival (OS)"></FilterOption></Filter><Filter label="Trial Drug Phase Highest" name="trialDrugPhaseHighest" total="10"><FilterOption id="L" count="771" label="Launched"></FilterOption><FilterOption id="C3" count="113" label="Phase 3 Clinical"></FilterOption><FilterOption id="C2" count="102" label="Phase 2 Clinical"></FilterOption><FilterOption id="DX" count="61" label="Discontinued"></FilterOption><FilterOption id="R" count="19" label="Registered"></FilterOption><FilterOption id="C1" count="17" label="Phase 1 Clinical"></FilterOption><FilterOption id="NDR" count="15" label="No Development Reported"></FilterOption><FilterOption id="PR" count="12" label="Pre-registration"></FilterOption><FilterOption id="DR" count="5" label="Discovery"></FilterOption><FilterOption id="W" count="4" label="Withdrawn"></FilterOption></Filter><Filter label="Trial Company Sponsor" name="trialCompaniesSponsor" total="100"><FilterOption id="19446" count="99" label="Roche Holding AG"></FilterOption><FilterOption id="1039423" count="97" label="Hospital Clinic of Barcelona"></FilterOption><FilterOption id="26178" count="79" label="F Hoffmann-La Roche AG"></FilterOption><FilterOption id="18767" count="61" label="Pfizer Inc"></FilterOption><FilterOption id="1038736" count="46" label="PETHEMA Foundation"></FilterOption><FilterOption id="16450" count="36" label="Gilead Sciences Inc"></FilterOption><FilterOption id="15331" count="35" label="Celgene Corp"></FilterOption><FilterOption id="14881" count="30" label="Boehringer Ingelheim International GmbH"></FilterOption><FilterOption id="15414" count="24" label="Chugai Pharmaceutical Co Ltd"></FilterOption><FilterOption id="19453" count="20" label="Genentech Inc"></FilterOption><FilterOption id="1067538" count="20" label="Janssen Research &amp; Development LLC"></FilterOption><FilterOption id="1059823" count="18" label="Merck Sharp &amp; Dohme Corp"></FilterOption><FilterOption id="1042061" count="17" label="Spanish Breast Cancer Research Group"></FilterOption><FilterOption id="1091809" count="16" label="Janssen-Cilag International NV (BE)"></FilterOption><FilterOption id="27847" count="14" label="Boston Scientific Corp"></FilterOption><FilterOption id="1053612" count="14" label="Fundacion Clinic per a la Recerca Biomédica"></FilterOption><FilterOption id="23780" count="13" label="Actelion Ltd"></FilterOption><FilterOption id="14455" count="13" label="Bayer AG"></FilterOption><FilterOption id="22546" count="13" label="Boehringer Ingelheim GmbH"></FilterOption><FilterOption id="1043659" count="12" label="Grupo Espanol Multidisciplinario del Cancer Digestivo"></FilterOption><FilterOption id="1042371" count="12" label="Spanish Oncology Genito-Urinary Group"></FilterOption><FilterOption id="1103352" count="9" label="Boehringer Ingelheim Espana Sa"></FilterOption><FilterOption id="15065" count="9" label="Bristol-Myers Squibb Co"></FilterOption><FilterOption id="23119" count="9" label="European Organisation for Research and Treatment of Cancer (EORTC)"></FilterOption><FilterOption id="1017513" count="9" label="Fundació Clínic Per A La Recerca Biomèdica"></FilterOption><FilterOption id="21991" count="9" label="Takeda Oncology"></FilterOption><FilterOption id="28611" count="8" label="Actelion Pharmaceuticals Ltd"></FilterOption><FilterOption id="22554" count="8" label="Boehringer Ingelheim BV"></FilterOption><FilterOption id="22586" count="8" label="Boehringer Ingelheim Corp"></FilterOption><FilterOption id="22563" count="8" label="Boehringer Ingelheim Ltd"></FilterOption><FilterOption id="1020322" count="8" label="Daiichi Sankyo Inc"></FilterOption><FilterOption id="1052299" count="8" label="Fundación Pública Andaluza Para La Gestión De La Investigación En Salud De Sevilla"></FilterOption><FilterOption id="1039086" count="8" label="Germans Trias i Pujol Hospital"></FilterOption><FilterOption id="1122528" count="8" label="SCS Boehringer Ingelheim Comm.V"></FilterOption><FilterOption id="22598" count="8" label="Unilfarma Lda"></FilterOption><FilterOption id="22549" count="7" label="Boehringer Ingelheim Austria GmbH"></FilterOption><FilterOption id="17810" count="7" label="Eli Lilly &amp; Co"></FilterOption><FilterOption id="1051470" count="7" label="Fundacio Clinic Per A La Recerca Biomedica"></FilterOption><FilterOption id="1042252" count="7" label="Grupo Espanol de Linfomas y Transplante Autologo de Medula Osea"></FilterOption><FilterOption id="17259" count="7" label="Ipsen"></FilterOption><FilterOption id="1090417" count="7" label="Roche Singapore Pte Ltd"></FilterOption><FilterOption id="22556" count="6" label="Boehringer Ingelheim France SARL"></FilterOption><FilterOption id="1009440" count="6" label="Intercept Pharmaceuticals Inc"></FilterOption><FilterOption id="19063" count="6" label="Pharmacyclics Inc"></FilterOption><FilterOption id="1065375" count="6" label="Puma Biotechnology Inc"></FilterOption><FilterOption id="1045513" count="6" label="Spanish Lung Cancer Group"></FilterOption><FilterOption id="1063251" count="5" label="BeiGene Co Ltd"></FilterOption><FilterOption id="22545" count="5" label="Boehringer Ingelheim AB"></FilterOption><FilterOption id="22555" count="5" label="Boehringer Ingelheim Ellas AE"></FilterOption><FilterOption id="22560" count="5" label="Boehringer Ingelheim Italia SpA"></FilterOption><FilterOption id="1046331" count="5" label="Fundacion SEIMC-GESIDA"></FilterOption><FilterOption id="1003065" count="5" label="Hospital Vall D'Hebron"></FilterOption><FilterOption id="1091820" count="5" label="Roche China Co Ltd"></FilterOption><FilterOption id="25439" count="5" label="United Therapeutics Corp"></FilterOption><FilterOption id="13601" count="4" label="Abbott Laboratories"></FilterOption><FilterOption id="1148005" count="4" label="BeiGene USA, Inc"></FilterOption><FilterOption id="1005244" count="4" label="Biogen Inc"></FilterOption><FilterOption id="31522" count="4" label="BIOTRONIK SE &amp; Co"></FilterOption><FilterOption id="1122527" count="4" label="Boehringer Ingelheim Finland Ky"></FilterOption><FilterOption id="1056497" count="4" label="CETLAM Group"></FilterOption><FilterOption id="1035512" count="4" label="EMD Serono Inc"></FilterOption><FilterOption id="1056260" count="4" label="Grupo Espanol de Investigacion en Cancer de Ovario"></FilterOption><FilterOption id="1069025" count="4" label="Grupo Espanol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa"></FilterOption><FilterOption id="1040940" count="4" label="Hospital Universitari de Bellvitge"></FilterOption><FilterOption id="1017771" count="4" label="Institut d'Investigacions Biomediques August Pi I Sunyer"></FilterOption><FilterOption id="17437" count="4" label="Johnson &amp; Johnson Sdn Bhd"></FilterOption><FilterOption id="1084801" count="4" label="Medica Scientia Innovation Research"></FilterOption><FilterOption id="26327" count="4" label="Roche Diagnostics GmbH"></FilterOption><FilterOption id="1082374" count="4" label="ROCHE Espana"></FilterOption><FilterOption id="24652" count="4" label="Shire plc"></FilterOption><FilterOption id="1073757" count="4" label="Spanish Society of Cardiology"></FilterOption><FilterOption id="1076372" count="4" label="Stryker Neurovascular"></FilterOption><FilterOption id="29151" count="4" label="Universitair Medisch Centrum Utrecht"></FilterOption><FilterOption id="14109" count="3" label="Amgen Inc"></FilterOption><FilterOption id="24968" count="3" label="Arena Pharmaceuticals Inc"></FilterOption><FilterOption id="14296" count="3" label="ARIAD Pharmaceuticals Inc"></FilterOption><FilterOption id="25902" count="3" label="Array BioPharma Inc"></FilterOption><FilterOption id="1013295" count="3" label="Astellas Pharma Inc"></FilterOption><FilterOption id="30062" count="3" label="AstraZeneca AB"></FilterOption><FilterOption id="14190" count="3" label="AstraZeneca plc"></FilterOption><FilterOption id="15133" count="3" label="Bristol-Myers Squibb International Corp"></FilterOption><FilterOption id="1067616" count="3" label="Clinica Universidad de Navarra"></FilterOption><FilterOption id="19620" count="3" label="Eisai Inc"></FilterOption><FilterOption id="14913" count="3" label="Eisai Ltd"></FilterOption><FilterOption id="1046616" count="3" label="European Organization for Research and Treatment of Cancer"></FilterOption><FilterOption id="16581" count="3" label="Grifols SA"></FilterOption><FilterOption id="1089015" count="3" label="Grupo Espanol Multidisciplinar de Melanoma"></FilterOption><FilterOption id="1056537" count="3" label="Grupo Espanol de Linfoma y Trasplante de Medula Osea"></FilterOption><FilterOption id="17002" count="3" label="Human Genome Sciences Inc"></FilterOption><FilterOption id="1072647" count="3" label="Institut de Recherches Internationales Servier (France)"></FilterOption><FilterOption id="18101" count="3" label="Merck KGaA"></FilterOption><FilterOption id="27954" count="3" label="Merrimack Pharmaceuticals Inc"></FilterOption><FilterOption id="15938" count="3" label="Millennium Pharmaceuticals Ltd"></FilterOption><FilterOption id="29741" count="3" label="Morphotek Inc"></FilterOption><FilterOption id="1064629" count="3" label="Prothena Corp plc"></FilterOption><FilterOption id="1109598" count="3" label="Roche Products India Pvt Ltd"></FilterOption><FilterOption id="25554" count="3" label="Seattle Genetics Inc"></FilterOption><FilterOption id="20300" count="3" label="Takeda Pharmaceutical Co Ltd"></FilterOption><FilterOption id="1020514" count="2" label="Abraxis BioScience Inc"></FilterOption><FilterOption id="13979" count="2" label="Alexion Pharmaceuticals Inc"></FilterOption></Filter><Filter label="Trial Recruitment Status" name="trialRecruitmentStatus" total="7"><FilterOption id="4" count="549" label="Completed"></FilterOption><FilterOption id="2" count="327" label="Recruiting"></FilterOption><FilterOption id="3" count="216" label="No longer recruiting"></FilterOption><FilterOption id="6" count="117" label="Terminated"></FilterOption><FilterOption id="1" count="22" label="Not yet recruiting"></FilterOption><FilterOption id="5" count="5" label="Suspended"></FilterOption><FilterOption id="12" count="1" label="Status not specified"></FilterOption></Filter><Filter label="Trial Commercially Significant" name="trialIsCommerciallySignificant" total="2"><FilterOption id="YES" count="697" label="Yes"></FilterOption><FilterOption id="NO" count="540" label="No"></FilterOption></Filter><Filter label="Trial Indications Pioneer" name="trialIndicationsPioneer" total="100"><FilterOption id="2399" count="18" label="Adenocarcinoma"></FilterOption><FilterOption id="3657" count="12" label="Metastatic breast cancer"></FilterOption><FilterOption id="3665" count="11" label="Metastatic non small cell lung cancer"></FilterOption><FilterOption id="1069" count="10" label="Metastasis"></FilterOption><FilterOption id="3713" count="9" label="Advanced solid tumor"></FilterOption><FilterOption id="3658" count="8" label="Metastatic colorectal cancer"></FilterOption><FilterOption id="3669" count="8" label="Metastatic pancreas cancer"></FilterOption><FilterOption id="307" count="8" label="Squamous cell carcinoma"></FilterOption><FilterOption id="159" count="6" label="HIV-1 infection"></FilterOption><FilterOption id="3673" count="6" label="Metastatic head and neck cancer"></FilterOption><FilterOption id="1771" count="6" label="Transitional cell carcinoma"></FilterOption><FilterOption id="3246" count="5" label="Hormone refractory prostate cancer"></FilterOption><FilterOption id="3667" count="5" label="Metastatic esophageal cancer"></FilterOption><FilterOption id="3666" count="5" label="Metastatic stomach cancer"></FilterOption><FilterOption id="3510" count="5" label="Pulmonary artery hypertension"></FilterOption><FilterOption id="1731" count="4" label="Acute myelogenous leukemia"></FilterOption><FilterOption id="1765" count="4" label="Cholangiocarcinoma"></FilterOption><FilterOption id="84" count="4" label="Crohns disease"></FilterOption><FilterOption id="2454" count="4" label="Glioblastoma"></FilterOption><FilterOption id="1767" count="4" label="Hepatocellular carcinoma"></FilterOption><FilterOption id="158" count="4" label="HIV infection"></FilterOption><FilterOption id="3676" count="4" label="Ischemic stroke"></FilterOption><FilterOption id="3466" count="4" label="Metastatic bladder cancer"></FilterOption><FilterOption id="3866" count="4" label="Metastatic ovary cancer"></FilterOption><FilterOption id="4250" count="4" label="Metastatic renal cell carcinoma"></FilterOption><FilterOption id="1272" count="4" label="Myelodysplastic syndrome"></FilterOption><FilterOption id="799" count="4" label="Ovary tumor"></FilterOption><FilterOption id="1867" count="4" label="Pulmonary hypertension"></FilterOption><FilterOption id="1261" count="4" label="Small-cell lung cancer"></FilterOption><FilterOption id="3257" count="4" label="Stage IV melanoma"></FilterOption><FilterOption id="427" count="4" label="Uterine cervix tumor"></FilterOption><FilterOption id="3395" count="3" label="Acute liver failure"></FilterOption><FilterOption id="14" count="3" label="Alzheimers disease"></FilterOption><FilterOption id="2193" count="3" label="Anal tumor"></FilterOption><FilterOption id="2380" count="3" label="Bladder cancer"></FilterOption><FilterOption id="49" count="3" label="Breast tumor"></FilterOption><FilterOption id="3919" count="3" label="Chronic liver failure"></FilterOption><FilterOption id="989" count="3" label="Colorectal tumor"></FilterOption><FilterOption id="3689" count="3" label="Compensated liver cirrhosis"></FilterOption><FilterOption id="1705" count="3" label="Endometrioid carcinoma"></FilterOption><FilterOption id="2243" count="3" label="Fallopian tube cancer"></FilterOption><FilterOption id="2212" count="3" label="Hepatorenal syndrome"></FilterOption><FilterOption id="70" count="3" label="Liver cirrhosis"></FilterOption><FilterOption id="3235" count="3" label="Merkel cell carcinoma"></FilterOption><FilterOption id="1240" count="3" label="Mesothelioma"></FilterOption><FilterOption id="3664" count="3" label="Metastatic prostate cancer"></FilterOption><FilterOption id="3467" count="3" label="Metastatic renal cancer"></FilterOption><FilterOption id="793" count="3" label="Mouth tumor"></FilterOption><FilterOption id="1828" count="3" label="Multiple myeloma"></FilterOption><FilterOption id="319" count="3" label="Non-Hodgkin lymphoma"></FilterOption><FilterOption id="3083" count="3" label="Peritoneal tumor"></FilterOption><FilterOption id="794" count="3" label="Pharynx tumor"></FilterOption><FilterOption id="3239" count="3" label="Portal hypertension"></FilterOption><FilterOption id="1995" count="3" label="Primary biliary cholangitis"></FilterOption><FilterOption id="3256" count="3" label="Stage III melanoma"></FilterOption><FilterOption id="2567" count="2" label="Anaplastic astrocytoma"></FilterOption><FilterOption id="1729" count="2" label="B-cell acute lymphoblastic leukemia"></FilterOption><FilterOption id="316" count="2" label="B-cell lymphoma"></FilterOption><FilterOption id="1815" count="2" label="Bacterial pneumonia"></FilterOption><FilterOption id="1516" count="2" label="Biliary cancer"></FilterOption><FilterOption id="2432" count="2" label="Bronchiectasis"></FilterOption><FilterOption id="651" count="2" label="Cancer"></FilterOption><FilterOption id="2217" count="2" label="Cholestasis"></FilterOption><FilterOption id="1735" count="2" label="Chronic myelocytic leukemia"></FilterOption><FilterOption id="97" count="2" label="Diabetes mellitus"></FilterOption><FilterOption id="100" count="2" label="Diabetic nephropathy"></FilterOption><FilterOption id="1011" count="2" label="Esophagus tumor"></FilterOption><FilterOption id="1127" count="2" label="Fibrosis"></FilterOption><FilterOption id="1745" count="2" label="Follicle center lymphoma"></FilterOption><FilterOption id="616" count="2" label="Graft versus host disease"></FilterOption><FilterOption id="152" count="2" label="Hepatitis B virus infection"></FilterOption><FilterOption id="161" count="2" label="Hodgkins disease"></FilterOption><FilterOption id="170" count="2" label="Huntingtons chorea"></FilterOption><FilterOption id="3771" count="2" label="Idiopathic pulmonary fibrosis"></FilterOption><FilterOption id="3198" count="2" label="Larynx tumor"></FilterOption><FilterOption id="2318" count="2" label="Liver fibrosis"></FilterOption><FilterOption id="3240" count="2" label="Medullary thyroid cancer"></FilterOption><FilterOption id="3668" count="2" label="Metastatic lung cancer"></FilterOption><FilterOption id="3465" count="2" label="Metastatic urinary tract cancer"></FilterOption><FilterOption id="213" count="2" label="Multiple sclerosis"></FilterOption><FilterOption id="273" count="2" label="Myeloproliferative disorder"></FilterOption><FilterOption id="224" count="2" label="Myocardial infarction"></FilterOption><FilterOption id="230" count="2" label="Neoplasm"></FilterOption><FilterOption id="1262" count="2" label="Non-small-cell lung cancer"></FilterOption><FilterOption id="2273" count="2" label="Oligodendroglioma"></FilterOption><FilterOption id="3351" count="2" label="Papillary thyroid tumor"></FilterOption><FilterOption id="396" count="2" label="Papillomavirus infection"></FilterOption><FilterOption id="279" count="2" label="Pruritus"></FilterOption><FilterOption id="286" count="2" label="Renal disease"></FilterOption><FilterOption id="194" count="2" label="Sarcoma"></FilterOption><FilterOption id="337" count="2" label="Ulcerative colitis"></FilterOption><FilterOption id="3678" count="2" label="Urethral cancer"></FilterOption><FilterOption id="738" count="2" label="Urinary tract tumor"></FilterOption><FilterOption id="4" count="1" label="Acquired immune deficiency syndrome"></FilterOption><FilterOption id="1728" count="1" label="Acute lymphoblastic leukemia"></FilterOption><FilterOption id="2562" count="1" label="Adult respiratory distress syndrome"></FilterOption><FilterOption id="3492" count="1" label="AL amyloidosis"></FilterOption><FilterOption id="3769" count="1" label="Anaplastic thyroid cancer"></FilterOption><FilterOption id="17" count="1" label="Anemia"></FilterOption><FilterOption id="2453" count="1" label="Astrocytoma"></FilterOption></Filter><Filter label="Registry Id" name="trialRegistries" total="24"><FilterOption id="1000" count="1228" label="CT.gov"></FilterOption><FilterOption id="1001" count="850" label="EudraCT"></FilterOption><FilterOption id="1030" count="155" label="RSRM CTR"></FilterOption><FilterOption id="1006" count="112" label="JapicCTI"></FilterOption><FilterOption id="1023" count="76" label="UKCRN"></FilterOption><FilterOption id="1019" count="72" label="DRKS"></FilterOption><FilterOption id="1035" count="47" label="Singapore HSA CTR"></FilterOption><FilterOption id="1012" count="34" label="CTRI"></FilterOption><FilterOption id="1039" count="32" label="CDE"></FilterOption><FilterOption id="1004" count="27" label="WHO ICTRP"></FilterOption><FilterOption id="1021" count="24" label="NMRR"></FilterOption><FilterOption id="1033" count="21" label="Mexico CTR"></FilterOption><FilterOption id="1009" count="20" label="HKClinicalTrials.com"></FilterOption><FilterOption id="1002" count="17" label="ISRCTN"></FilterOption><FilterOption id="1011" count="9" label="ANZCTR"></FilterOption><FilterOption id="1010" count="6" label="CRiS"></FilterOption><FilterOption id="1038" count="6" label="PHRR"></FilterOption><FilterOption id="1015" count="3" label="NTR"></FilterOption><FilterOption id="1003" count="3" label="UMIN"></FilterOption><FilterOption id="1008" count="2" label="Hong Kong CCTCTR"></FilterOption><FilterOption id="1040" count="2" label="REec"></FilterOption><FilterOption id="1016" count="1" label="PACTR"></FilterOption><FilterOption id="1020" count="1" label="ReBec"></FilterOption><FilterOption id="1013" count="1" label="RPCEC"></FilterOption></Filter><Filter label="Trial Reason for Discontinuation" name="trialReasonForDiscontinuation" total="7"><FilterOption id="5" count="29" label="Patient Enrollment Issues"></FilterOption><FilterOption id="1" count="28" label="Lack of Efficacy"></FilterOption><FilterOption id="2" count="26" label="Not Reported"></FilterOption><FilterOption id="4" count="17" label="Other"></FilterOption><FilterOption id="8" count="15" label="Sponsor/Business Decision"></FilterOption><FilterOption id="7" count="6" label="Safety Issues"></FilterOption><FilterOption id="3" count="3" label="Operational Issues"></FilterOption></Filter><Filter label="Active Controls" name="trialActiveControls" total="100"><FilterOption id="44383" count="28" label="carboplatin"></FilterOption><FilterOption id="3803" count="27" label="paclitaxel"></FilterOption><FilterOption id="3199" count="25" label="gemcitabine"></FilterOption><FilterOption id="2953" count="23" label="docetaxel"></FilterOption><FilterOption id="12205" count="16" label="capecitabine"></FilterOption><FilterOption id="6386" count="15" label="trastuzumab"></FilterOption><FilterOption id="6736" count="12" label="rituximab"></FilterOption><FilterOption id="7310" count="10" label="ritonavir"></FilterOption><FilterOption id="49219" count="10" label="tenofovir disoproxil fumarate + emtricitabine (fixed dose), Gilead Sciences"></FilterOption><FilterOption id="37370" count="8" label="azacitidine"></FilterOption><FilterOption id="8047" count="8" label="bevacizumab"></FilterOption><FilterOption id="14681" count="8" label="lopinavir + ritonavir"></FilterOption><FilterOption id="15954" count="7" label="bortezomib"></FilterOption><FilterOption id="3072" count="7" label="etoposide phosphate"></FilterOption><FilterOption id="3536" count="7" label="pemetrexed disodium"></FilterOption><FilterOption id="32981" count="6" label="darunavir"></FilterOption><FilterOption id="7934" count="6" label="doxorubicin (liposomal, STEALTH), Alza"></FilterOption><FilterOption id="13022" count="6" label="epirubicin"></FilterOption><FilterOption id="3313" count="6" label="fulvestrant"></FilterOption><FilterOption id="3792" count="6" label="oxaliplatin"></FilterOption><FilterOption id="10309" count="5" label="abiraterone"></FilterOption><FilterOption id="27572" count="5" label="lenalidomide"></FilterOption><FilterOption id="2784" count="5" label="letrozole"></FilterOption><FilterOption id="28532" count="5" label="pertuzumab"></FilterOption><FilterOption id="12973" count="5" label="sunitinib"></FilterOption><FilterOption id="14493" count="5" label="tenofovir disoproxil fumarate"></FilterOption><FilterOption id="6408" count="5" label="vinorelbine"></FilterOption><FilterOption id="15254" count="4" label="atazanavir"></FilterOption><FilterOption id="47000" count="4" label="bendamustine"></FilterOption><FilterOption id="13239" count="4" label="decitabine"></FilterOption><FilterOption id="10172" count="4" label="efavirenz"></FilterOption><FilterOption id="53981" count="4" label="enzalutamide"></FilterOption><FilterOption id="48181" count="4" label="lamivudine + abacavir, GlaxoSmithKline"></FilterOption><FilterOption id="33591" count="4" label="lapatinib"></FilterOption><FilterOption id="29016" count="4" label="paclitaxel (albumin-bound nanoparticle, intravenous), Celgene"></FilterOption><FilterOption id="72699" count="3" label="atezolizumab"></FilterOption><FilterOption id="2836" count="3" label="clopidogrel"></FilterOption><FilterOption id="72148" count="3" label="darunavir + cobicistat (fixed dose, HIV infection), Janssen R&amp;D/ Gilead"></FilterOption><FilterOption id="13340" count="3" label="everolimus"></FilterOption><FilterOption id="3081" count="3" label="exemestane"></FilterOption><FilterOption id="6156" count="3" label="fludarabine"></FilterOption><FilterOption id="2871" count="3" label="irinotecan"></FilterOption><FilterOption id="11519" count="3" label="mitoxantrone"></FilterOption><FilterOption id="53227" count="3" label="obinutuzumab"></FilterOption><FilterOption id="23625" count="3" label="peginterferon alfa-2a"></FilterOption><FilterOption id="70667" count="3" label="pembrolizumab"></FilterOption><FilterOption id="54488" count="3" label="raltegravir"></FilterOption><FilterOption id="5369" count="3" label="ribavirin"></FilterOption><FilterOption id="44313" count="3" label="simvastatin"></FilterOption><FilterOption id="4529" count="3" label="temozolomide"></FilterOption><FilterOption id="8050" count="3" label="thalidomide, Celgene"></FilterOption><FilterOption id="4577" count="3" label="topotecan"></FilterOption><FilterOption id="12150" count="3" label="vincristine sulfate (liposomal injection), Spectrum Pharmaceuticals"></FilterOption><FilterOption id="15130" count="3" label="vinflunine"></FilterOption><FilterOption id="44375" count="3" label="warfarin"></FilterOption><FilterOption id="99926" count="2" label="18F-GTP1"></FilterOption><FilterOption id="53547" count="2" label="aflibercept (intravitreal, wet AMD, macular edema, diabetic retinopathy), Regeneron/Bayer"></FilterOption><FilterOption id="3321" count="2" label="anastrozole"></FilterOption><FilterOption id="54601" count="2" label="carfilzomib"></FilterOption><FilterOption id="62275" count="2" label="cobicistat"></FilterOption><FilterOption id="55798" count="2" label="crizotinib"></FilterOption><FilterOption id="53200" count="2" label="daratumumab"></FilterOption><FilterOption id="59062" count="2" label="dolutegravir"></FilterOption><FilterOption id="51371" count="2" label="elvitegravir"></FilterOption><FilterOption id="62277" count="2" label="emtricitabine + tenofovir disoproxil fumarate + elvitegravir + cobicistat (single tablet regimen, HIV/AIDS), Gilead Sciences"></FilterOption><FilterOption id="4728" count="2" label="emtricitabine"></FilterOption><FilterOption id="13928" count="2" label="enoxaparin sodium"></FilterOption><FilterOption id="13486" count="2" label="entecavir"></FilterOption><FilterOption id="28773" count="2" label="eribulin mesylate"></FilterOption><FilterOption id="30682" count="2" label="etravirine"></FilterOption><FilterOption id="44292" count="2" label="fluconazole"></FilterOption><FilterOption id="24471" count="2" label="fosamprenavir"></FilterOption><FilterOption id="55237" count="2" label="ibrutinib"></FilterOption><FilterOption id="6850" count="2" label="infliximab"></FilterOption><FilterOption id="36630" count="2" label="ipilimumab"></FilterOption><FilterOption id="3474" count="2" label="lamivudine"></FilterOption><FilterOption id="5267" count="2" label="leuprorelin acetate"></FilterOption><FilterOption id="3669" count="2" label="mycophenolate mofetil"></FilterOption><FilterOption id="3700" count="2" label="nevirapine"></FilterOption><FilterOption id="61287" count="2" label="niraparib"></FilterOption><FilterOption id="54804" count="2" label="nivolumab"></FilterOption><FilterOption id="4196" count="2" label="ramipril"></FilterOption><FilterOption id="52857" count="2" label="rilpivirine hydrochloride"></FilterOption><FilterOption id="4259" count="2" label="saquinavir"></FilterOption><FilterOption id="29831" count="2" label="sorafenib"></FilterOption><FilterOption id="44314" count="2" label="tamoxifen"></FilterOption><FilterOption id="44401" count="2" label="vancomycin"></FilterOption><FilterOption id="6242" count="1" label="abacavir"></FilterOption><FilterOption id="14163" count="1" label="adalimumab"></FilterOption><FilterOption id="2503" count="1" label="amphotericin B (liposomal iv, visceral leishmaniasis), Drugs for Neglected Diseases initiative"></FilterOption><FilterOption id="7867" count="1" label="amprenavir"></FilterOption><FilterOption id="52967" count="1" label="apixaban"></FilterOption><FilterOption id="50484" count="1" label="apomorphine hydrochloride (Parkinson's disease), Britannia"></FilterOption><FilterOption id="74263" count="1" label="atazanavir sulfate + cobicistat (fixed-dose combination, HIV infection), Bristol-Myers Squibb"></FilterOption><FilterOption id="16905" count="1" label="atomoxetine"></FilterOption><FilterOption id="11141" count="1" label="basiliximab"></FilterOption><FilterOption id="100071" count="1" label="BMS-986177"></FilterOption><FilterOption id="50935" count="1" label="cabozantinib S-malate"></FilterOption><FilterOption id="16915" count="1" label="calcium levofolinate"></FilterOption><FilterOption id="63194" count="1" label="carbidopa + levodopa (Parkinsons disease, immediate/extended release), Impax"></FilterOption></Filter><Filter label="Exclusion Criteria Index" name="trialExclusionCriteriaIndex" total="100"><FilterOption id="6859" count="71" label="HIV infection - Pregnant or Breast Feeding Subjects"></FilterOption><FilterOption id="6554" count="62" label="Leukemia - Subjects with Co-morbid Conditions"></FilterOption><FilterOption id="6258" count="57" label="Breast tumor - Subjects co-morbid with cardiovascular diseases/disorders"></FilterOption><FilterOption id="6294" count="55" label="Breast tumor - Subjects with History of/Active Malignancy/Cancer"></FilterOption><FilterOption id="4702" count="45" label="Lymphoma - Subjects with Co-morbid Conditions"></FilterOption><FilterOption id="6845" count="44" label="HIV infection - Subjects with Co-morbid Conditions - Subjects co-morbid with hepatobiliary diseases/disorders"></FilterOption><FilterOption id="6247" count="42" label="Breast tumor - Subjects by disease severity - Subjects with Brain/Leptomeningeal metastases"></FilterOption><FilterOption id="6272" count="42" label="Breast tumor - Subjects co-morbid with inflammatory disorders"></FilterOption><FilterOption id="6331" count="42" label="Breast tumor - Subjects with History of/Scheduled to Receive Therapy - Subjects with history of/scheduled for chemotherapy"></FilterOption><FilterOption id="6820" count="40" label="HIV infection - Subjects with Opportunistic/Other Infections"></FilterOption><FilterOption id="6892" count="40" label="HIV infection - Subjects with history of/scheduled to receive therapy for other indication"></FilterOption><FilterOption id="6377" count="38" label="Breast tumor - Subjects with history of/planned radiotherapy"></FilterOption><FilterOption id="6534" count="38" label="Leukemia - Subjects with History of/Active Malignancy/Cancer"></FilterOption><FilterOption id="6393" count="36" label="Breast tumor - Subjects with History of/Scheduled to Receive Therapy"></FilterOption><FilterOption id="5132" count="36" label="Lung tumor - Subjects co-morbid with cardiovascular diseases/disorders"></FilterOption><FilterOption id="5193" count="36" label="Lung tumor - Subjects with History of/Active Malignancy/Cancer"></FilterOption><FilterOption id="6065" count="36" label="Multiple myeloma - Subjects with Co-morbid Conditions"></FilterOption><FilterOption id="6259" count="34" label="Breast tumor - Subjects co-morbid with Respiratory Diseases/Disorders - Subjects co-morbid with pulmonary diseases/disorders"></FilterOption><FilterOption id="5365" count="34" label="Lung tumor - Protocol Specified Other Exclusion Criteria - Protocol specified exclusion criteria for females"></FilterOption><FilterOption id="20282" count="33" label="Lung tumor - Subjects co-morbid with inflammatory disorders"></FilterOption><FilterOption id="4692" count="33" label="Lymphoma - Subjects with History of/Active Malignancy/Cancer"></FilterOption><FilterOption id="6302" count="31" label="Breast tumor - Subjects with Hypersensitivity/Contraindications to Drugs/Excipients - Subjects with hypersensitivity/contraindication to any investigational agents"></FilterOption><FilterOption id="6843" count="31" label="HIV infection - Subjects with Co-morbid Conditions"></FilterOption><FilterOption id="17557" count="29" label="Breast tumor - Subjects with Abnormal Laboratory Findings"></FilterOption><FilterOption id="6941" count="29" label="HIV infection - Subjects with Hypersensitivity/Contraindications to Drugs/Excipients - Hypersensitivity/Contraindications to study medications or its excipients"></FilterOption><FilterOption id="6660" count="29" label="Leukemia - Subjects with History of Treatment with Non-chemotherapeutic Drugs"></FilterOption><FilterOption id="4769" count="29" label="Lymphoma - Subjects with History of/Scheduled to Receive Therapy - Subjects with history of/scheduled for chemotherapy"></FilterOption><FilterOption id="6474" count="28" label="Breast tumor - Protocol Specified Other Exclusion Criteria - Protocol specified exclusion criteria for females"></FilterOption><FilterOption id="6082" count="28" label="Multiple myeloma - Subjects with History of/Active Malignancy/Cancer"></FilterOption><FilterOption id="20290" count="27" label="Breast tumor - Subjects with History of/Scheduled for Intervention/Surgery - Subjects with history of/scheduled for surgery"></FilterOption><FilterOption id="5125" count="27" label="Lung tumor - Subjects with Evidence of Metastasis - Subjects with central nervous system metastases"></FilterOption><FilterOption id="5345" count="27" label="Lung tumor - Subjects with History of/Scheduled to Receive Therapy - Subjects with history of/scheduled to receive an investigational drug"></FilterOption><FilterOption id="6260" count="26" label="Breast tumor - Subjects co-morbid with gastrointestinal diseases/disorders"></FilterOption><FilterOption id="6361" count="25" label="Breast tumor - Subjects with History of/Scheduled for Anti-neoplastic Therapy - Subjects with history of/scheduled for targeted therapy"></FilterOption><FilterOption id="20292" count="25" label="Breast tumor - Subjects with History of/Scheduled for Anti-neoplastic Therapy - Subjects with history of/scheduled to receive an investigational drug"></FilterOption><FilterOption id="5139" count="25" label="Lung tumor - Subjects co-morbid with Respiratory Diseases/Disorders - Subjects co-morbid with pulmonary diseases/disorders"></FilterOption><FilterOption id="5270" count="25" label="Lung tumor - Subjects with History of/Scheduled to Receive Therapy - Subjects with history of/scheduled for chemotherapy"></FilterOption><FilterOption id="5282" count="25" label="Lung tumor - Subjects with History of/Scheduled to Receive Therapy - Subjects with history of/scheduled for radiation therapy"></FilterOption><FilterOption id="10704" count="25" label="Solid tumor - Subjects with Co-morbid Conditions"></FilterOption><FilterOption id="6246" count="24" label="Breast tumor - Subjects by disease severity - Metastatic/TNM Stage IV Breast Cancer"></FilterOption><FilterOption id="6328" count="24" label="Breast tumor - Subjects with History of/Scheduled for Anti-neoplastic Therapy"></FilterOption><FilterOption id="6850" count="24" label="HIV infection - Subjects with History of/Active Malignancy/Cancer"></FilterOption><FilterOption id="6530" count="24" label="Leukemia - Leukemia Subjects with Advanced Disease - Subjects with central nervous system involvement of leukemia"></FilterOption><FilterOption id="5291" count="24" label="Lung tumor - Subjects with History of/Scheduled for Other Treatments"></FilterOption><FilterOption id="6767" count="24" label="Lymphoma - Lymphoma Subjects with Advanced Disease - Subjects with central nervous system involvement of lymphoma"></FilterOption><FilterOption id="4730" count="24" label="Lymphoma - Subjects with Abnormal Organ Function - Subjects with abnormal/unacceptable liver function"></FilterOption><FilterOption id="24372" count="24" label="Other gastrointestinal disease - Subjects with Protocol Specified Reproductive Status - Pregnancy/Lactation/Women of childbearing potential/Intend to become pregnant/Without adequate contraception"></FilterOption><FilterOption id="9003" count="23" label="Bladder cancer - Subjects with Co-morbid Conditions"></FilterOption><FilterOption id="6253" count="23" label="Breast tumor - Subjects with Co-morbid Conditions - Subjects with central nervous system diseases"></FilterOption><FilterOption id="6504" count="23" label="Leukemia - Subjects with Acute Myeloid Leukemia - Subjects with promyelocytic leukemia (M3)"></FilterOption><FilterOption id="6618" count="23" label="Leukemia - Subjects with History of/Scheduled to Receive Therapy - Subjects with history of/scheduled for chemotherapy"></FilterOption><FilterOption id="4909" count="23" label="Prostate tumor - Subjects with History of/Active Malignancy/Cancer"></FilterOption><FilterOption id="6951" count="22" label="HIV infection - Subjects with AIDS/AIDS Defining Events"></FilterOption><FilterOption id="5128" count="22" label="Lung tumor - Subjects with Co-morbid Conditions - Subjects with central nervous system diseases/disorders"></FilterOption><FilterOption id="4718" count="22" label="Lymphoma - Subjects co-morbid with infections - Subjects co-morbid with HIV infection"></FilterOption><FilterOption id="20289" count="21" label="Breast tumor - Subjects with History of/Scheduled for Disease Specific Pharmacological Therapy - Subjects with history of biologic therapy"></FilterOption><FilterOption id="4739" count="21" label="Lymphoma - Subjects with Abnormal Organ Function - Subjects with abnormal/unacceptable cardiac function"></FilterOption><FilterOption id="5414" count="21" label="Melanoma - Subjects with History of/Active Malignancy/Cancer"></FilterOption><FilterOption id="6257" count="20" label="Breast tumor - Subjects co-morbid with endocrine/metabolic diseases/disorders"></FilterOption><FilterOption id="6418" count="20" label="Breast tumor - Subjects with Protocol Specified Compliance Status - Subjects with noncompliance to study protocol"></FilterOption><FilterOption id="6963" count="20" label="HIV infection - Subjects with history of/scheduled to receive therapy for other indication - Subjects with history/scheduled to receive immunomodulators for other indication"></FilterOption><FilterOption id="6659" count="20" label="Leukemia - Subjects with History of/Scheduled to Receive Therapy - Subjects with history of stem cell therapy"></FilterOption><FilterOption id="5349" count="20" label="Lung tumor - Subjects with Protocol Specified Compliance Status - Subjects unable/unwilling to comply with protocol requirements"></FilterOption><FilterOption id="5430" count="20" label="Melanoma - Subjects co-morbid with cardiovascular diseases/disorders"></FilterOption><FilterOption id="5405" count="20" label="Melanoma - Subjects with Evidence of Metastasis - Subjects with central nervous system metastasis"></FilterOption><FilterOption id="9810" count="20" label="Ovary tumor - Subjects with Co-morbid Conditions"></FilterOption><FilterOption id="6261" count="19" label="Breast tumor - Subjects with Co-morbid Conditions - Subjects co-morbid with hepatobiliary diseases/disorders"></FilterOption><FilterOption id="6252" count="19" label="Breast tumor - Subjects with Co-morbid Conditions"></FilterOption><FilterOption id="5841" count="19" label="Colorectal tumor - Subjects with History of/Active Malignancy/Cancer"></FilterOption><FilterOption id="5149" count="19" label="Lung tumor - Subjects co-morbid with gastrointestinal diseases/disorders"></FilterOption><FilterOption id="4831" count="19" label="Lymphoma - Protocol Specified Other Exclusion Criteria - Protocol specified exclusion criteria for females"></FilterOption><FilterOption id="4810" count="19" label="Lymphoma - Subjects with History of Treatment with Non-chemotherapeutic Drugs"></FilterOption><FilterOption id="4762" count="19" label="Lymphoma - Subjects with History of/Scheduled to Receive Therapy - Subject with history of radiotherapy"></FilterOption><FilterOption id="25164" count="19" label="Other gastrointestinal disease - Subjects with Abnormal Laboratory Findings - Subjects with abnormal renal function tests"></FilterOption><FilterOption id="25158" count="19" label="Other gastrointestinal disease - Subjects with History of/Active Malignancy/Cancer"></FilterOption><FilterOption id="4847" count="19" label="Prostate tumor - Subjects with Advanced/Metastatic Prostate Cancer - Subjects with brain metastasis"></FilterOption><FilterOption id="6834" count="18" label="HIV infection - Subjects co-morbid with Psychiatric Disease/Disorder"></FilterOption><FilterOption id="5163" count="18" label="Lung tumor - Subjects with Co-morbid Conditions - Subjects co-morbid with hepatobiliary diseases/disorders"></FilterOption><FilterOption id="4731" count="18" label="Lymphoma - Subjects with Abnormal Organ Function - Subjects with abnormal/unacceptable renal function"></FilterOption><FilterOption id="5547" count="18" label="Melanoma - Subjects with History of/Scheduled for Other Treatments"></FilterOption><FilterOption id="6091" count="18" label="Multiple myeloma - Subjects with Co-morbid Conditions - Subjects co-morbid with hepatobiliary diseases/disorders"></FilterOption><FilterOption id="6124" count="18" label="Multiple myeloma - Subjects with History of/Scheduled to Receive Therapy"></FilterOption><FilterOption id="24468" count="18" label="Other gastrointestinal disease - Subjects co-morbid with cardiovascular diseases/disorders"></FilterOption><FilterOption id="9809" count="18" label="Ovary tumor - Subjects with History of/Active Malignancy/Cancer"></FilterOption><FilterOption id="6217" count="17" label="Breast tumor - Subjects with Other forms of Breast Cancer - Subjects with bilateral breast cancer"></FilterOption><FilterOption id="5856" count="16" label="Colorectal tumor - Subjects co-morbid with inflammatory disorders"></FilterOption><FilterOption id="5921" count="16" label="Colorectal tumor - Subjects with Hypersensitivity/Contraindications to Drugs/Excipients - Hypersensitivity/Contraindications to study medications or its excipients"></FilterOption><FilterOption id="6645" count="16" label="Leukemia - Subjects with History of/Scheduled to Receive Therapy - Subjects with history of radiotherapy"></FilterOption><FilterOption id="5285" count="16" label="Lung tumor - Subjects with History of/Scheduled for Intervention/Surgery - Subjects with history of/scheduled for surgery"></FilterOption><FilterOption id="5470" count="16" label="Melanoma - Subjects co-morbid with inflammatory disorders"></FilterOption><FilterOption id="6133" count="16" label="Multiple myeloma - Subjects with History of/Scheduled to Receive Therapy - Subjects with history of radiotherapy"></FilterOption><FilterOption id="25163" count="16" label="Other gastrointestinal disease - Subjects with Abnormal Laboratory Findings - Subjects with abnormal hematological tests"></FilterOption><FilterOption id="11871" count="15" label="Anemia - Subjects with history of/scheduled to receive therapy for other indication"></FilterOption><FilterOption id="9016" count="15" label="Bladder cancer - Subjects with Abnormal Organ Function - Subjects with abnormal/unacceptable cardiac function"></FilterOption><FilterOption id="5826" count="15" label="Colorectal tumor - Subjects with Metastatic Colorectal Cancer - Subjects with brain metastases or leptomeningeal carcinomatosis"></FilterOption><FilterOption id="6862" count="15" label="HIV infection - Subjects with Abnormal Laboratory Findings - Subjects with abnormal renal function tests"></FilterOption><FilterOption id="25162" count="15" label="Other gastrointestinal disease - Subjects with Abnormal Laboratory Findings - Abnormal liver function test"></FilterOption><FilterOption id="24465" count="15" label="Other gastrointestinal disease - Subjects with history of psychiatric disease/disorder - Subjects with history of/current alcohol/drug/substance abuse"></FilterOption><FilterOption id="4967" count="15" label="Prostate tumor - Subjects with History of/Scheduled to Receive Therapy - Subjects with history of/scheduled for chemotherapy"></FilterOption><FilterOption id="9002" count="14" label="Bladder cancer - Subjects with History of/Active Malignancy/Cancer"></FilterOption></Filter><Filter label="Trial Date Enrollment End By Month" name="trialDateEnrollmentEndByMonth" total="100"><FilterOption count="14" label="201509"></FilterOption><FilterOption count="13" label="201905"></FilterOption><FilterOption count="12" label="201904"></FilterOption><FilterOption count="11" label="201705"></FilterOption><FilterOption count="11" label="201712"></FilterOption><FilterOption count="9" label="201803"></FilterOption><FilterOption count="9" label="201812"></FilterOption><FilterOption count="9" label="201902"></FilterOption><FilterOption count="8" label="201402"></FilterOption><FilterOption count="8" label="201512"></FilterOption><FilterOption count="8" label="201605"></FilterOption><FilterOption count="8" label="201809"></FilterOption><FilterOption count="7" label="201110"></FilterOption><FilterOption count="7" label="201210"></FilterOption><FilterOption count="7" label="201310"></FilterOption><FilterOption count="7" label="201504"></FilterOption><FilterOption count="7" label="201506"></FilterOption><FilterOption count="7" label="201601"></FilterOption><FilterOption count="7" label="201603"></FilterOption><FilterOption count="7" label="201612"></FilterOption><FilterOption count="7" label="201702"></FilterOption><FilterOption count="7" label="201706"></FilterOption><FilterOption count="7" label="201708"></FilterOption><FilterOption count="7" label="201709"></FilterOption><FilterOption count="7" label="201710"></FilterOption><FilterOption count="7" label="201807"></FilterOption><FilterOption count="7" label="201810"></FilterOption><FilterOption count="6" label="201202"></FilterOption><FilterOption count="6" label="201411"></FilterOption><FilterOption count="6" label="201505"></FilterOption><FilterOption count="6" label="201510"></FilterOption><FilterOption count="6" label="201511"></FilterOption><FilterOption count="6" label="201801"></FilterOption><FilterOption count="6" label="201802"></FilterOption><FilterOption count="6" label="201804"></FilterOption><FilterOption count="6" label="201805"></FilterOption><FilterOption count="6" label="201811"></FilterOption><FilterOption count="6" label="201906"></FilterOption><FilterOption count="5" label="200905"></FilterOption><FilterOption count="5" label="201003"></FilterOption><FilterOption count="5" label="201108"></FilterOption><FilterOption count="5" label="201307"></FilterOption><FilterOption count="5" label="201312"></FilterOption><FilterOption count="5" label="201401"></FilterOption><FilterOption count="5" label="201404"></FilterOption><FilterOption count="5" label="201409"></FilterOption><FilterOption count="5" label="201502"></FilterOption><FilterOption count="5" label="201507"></FilterOption><FilterOption count="5" label="201608"></FilterOption><FilterOption count="5" label="201609"></FilterOption><FilterOption count="5" label="201703"></FilterOption><FilterOption count="5" label="201711"></FilterOption><FilterOption count="5" label="201808"></FilterOption><FilterOption count="5" label="201901"></FilterOption><FilterOption count="5" label="201903"></FilterOption><FilterOption count="4" label="200810"></FilterOption><FilterOption count="4" label="200906"></FilterOption><FilterOption count="4" label="200910"></FilterOption><FilterOption count="4" label="201106"></FilterOption><FilterOption count="4" label="201107"></FilterOption><FilterOption count="4" label="201203"></FilterOption><FilterOption count="4" label="201301"></FilterOption><FilterOption count="4" label="201302"></FilterOption><FilterOption count="4" label="201305"></FilterOption><FilterOption count="4" label="201306"></FilterOption><FilterOption count="4" label="201405"></FilterOption><FilterOption count="4" label="201408"></FilterOption><FilterOption count="4" label="201410"></FilterOption><FilterOption count="4" label="201412"></FilterOption><FilterOption count="4" label="201503"></FilterOption><FilterOption count="4" label="201602"></FilterOption><FilterOption count="4" label="201610"></FilterOption><FilterOption count="4" label="201701"></FilterOption><FilterOption count="4" label="201704"></FilterOption><FilterOption count="4" label="201707"></FilterOption><FilterOption count="3" label="200703"></FilterOption><FilterOption count="3" label="200901"></FilterOption><FilterOption count="3" label="200902"></FilterOption><FilterOption count="3" label="200903"></FilterOption><FilterOption count="3" label="200908"></FilterOption><FilterOption count="3" label="201001"></FilterOption><FilterOption count="3" label="201009"></FilterOption><FilterOption count="3" label="201103"></FilterOption><FilterOption count="3" label="201104"></FilterOption><FilterOption count="3" label="201105"></FilterOption><FilterOption count="3" label="201112"></FilterOption><FilterOption count="3" label="201204"></FilterOption><FilterOption count="3" label="201206"></FilterOption><FilterOption count="3" label="201209"></FilterOption><FilterOption count="3" label="201309"></FilterOption><FilterOption count="3" label="201311"></FilterOption><FilterOption count="3" label="201508"></FilterOption><FilterOption count="3" label="201607"></FilterOption><FilterOption count="3" label="201806"></FilterOption><FilterOption count="2" label="200601"></FilterOption><FilterOption count="2" label="200612"></FilterOption><FilterOption count="2" label="200706"></FilterOption><FilterOption count="2" label="200712"></FilterOption><FilterOption count="2" label="200801"></FilterOption><FilterOption count="2" label="200803"></FilterOption></Filter><Filter label="Funder Type" name="trialFunderType" total="5"><FilterOption id="CMP" count="919" label="Company"></FilterOption><FilterOption id="ACA" count="470" label="Academic"></FilterOption><FilterOption id="GOV" count="16" label="Government"></FilterOption><FilterOption id="OTH" count="12" label="Others"></FilterOption><FilterOption id="NGO" count="5" label="Non-Government"></FilterOption></Filter><Filter label="Trial Region" name="trialRegions" total="10"><FilterOption id="NSWE" count="1237" label="Northern, Southern &amp; Western Europe"></FilterOption><FilterOption id="USCA" count="610" label="US &amp; Canada"></FilterOption><FilterOption id="EEUR" count="528" label="Eastern Europe"></FilterOption><FilterOption id="AUNZ" count="352" label="Australia &amp; New Zealand"></FilterOption><FilterOption id="EAPO" count="318" label="East Asia &amp; Pacific Ocean"></FilterOption><FilterOption id="MENA" count="300" label="Middle East &amp; North Africa"></FilterOption><FilterOption id="SOAM" count="239" label="South America"></FilterOption><FilterOption id="CAAC" count="170" label="Central America &amp; Caribbean"></FilterOption><FilterOption id="CSAF" count="96" label="Central &amp; Southern Africa"></FilterOption><FilterOption id="SOCA" count="58" label="Southern &amp; Central Asia"></FilterOption></Filter><Filter label="Patient Segment Index" name="trialPatientSegmentIndex" total="100"><FilterOption id="7126" count="72" label="HIV infection - Subjects with HIV Infection - Subjects with HIV-1 Infection"></FilterOption><FilterOption id="3954" count="52" label="Breast tumor - Subjects with Advanced/Metastatic Breast Cancer/Stage IV Breast Cancer"></FilterOption><FilterOption id="3952" count="40" label="Breast tumor - Subjects with Locally Advanced Breast Cancer"></FilterOption><FilterOption id="3937" count="38" label="Breast tumor - Subjects with HER-2 Negative Breast Cancer"></FilterOption><FilterOption id="3634" count="38" label="Lung tumor - Subjects with Advanced Stage Lung Cancer - Subjects with metastatic/stage IV lung cancer"></FilterOption><FilterOption id="3936" count="35" label="Breast tumor - Subjects with HER-2 Positive Breast Cancer"></FilterOption><FilterOption id="3977" count="34" label="Leukemia - Subjects with Acute Myeloid Leukemia (AML)"></FilterOption><FilterOption id="3617" count="34" label="Lung tumor - Subjects with Non Small Cell Lung Cancer (NSCLC)"></FilterOption><FilterOption id="3931" count="31" label="Breast tumor - Subjects with Hormone Receptor Positive Breast Cancer - Estrogen receptor positive (ER+) breast cancer"></FilterOption><FilterOption id="3965" count="29" label="Breast tumor - Subjects with Treatment Resistant Disease"></FilterOption><FilterOption id="10295" count="28" label="Lung tumor - Subjects with Advanced Stage Lung Cancer - Subjects with locally advanced/stage III lung cancer"></FilterOption><FilterOption id="3975" count="26" label="Leukemia - Subjects with Acute Leukemia Unspecified Type"></FilterOption><FilterOption id="3530" count="26" label="Lymphoma - Subjects with Treatment Resistant Disease"></FilterOption><FilterOption id="3926" count="26" label="Multiple myeloma - Subjects with Relapsed/Recurrent Multiple Myeloma"></FilterOption><FilterOption id="3564" count="26" label="Prostate tumor - Subjects with Advanced/Metastatic Prostate Cancer"></FilterOption><FilterOption id="3472" count="25" label="Lymphoma - Subjects with B Cell Non Hodgkin's Lymphoma - Subjects with diffuse large B cell lymphoma"></FilterOption><FilterOption id="3525" count="24" label="Lymphoma - Subjects with Relapse/Recurrent Lymphoma"></FilterOption><FilterOption id="3680" count="24" label="Melanoma - Subjects with Stage IV Melanoma"></FilterOption><FilterOption id="3923" count="24" label="Multiple myeloma - Subjects with Treatment Resistant Disease"></FilterOption><FilterOption id="3956" count="22" label="Breast tumor - Subjects with Un-resectable/Non-operable Breast Cancer"></FilterOption><FilterOption id="3667" count="22" label="Melanoma - Subjects with Advanced/Metastatic Cancer"></FilterOption><FilterOption id="3824" count="21" label="Colorectal tumor - Subjects with TNM stage IV/Metastatic/Advanced Colorectal Cancer"></FilterOption><FilterOption id="3502" count="21" label="Lymphoma - Subjects with Specific Grade of Lymphoma - Subjects with Aggressive (high grade) Lymphoma"></FilterOption><FilterOption id="7961" count="21" label="Solid tumor - Subjects with Advanced/Metastatic Solid Tumors"></FilterOption><FilterOption id="7810" count="20" label="Bladder cancer - Subjects with Metastatic Bladder Cancer"></FilterOption><FilterOption id="3950" count="20" label="Breast tumor - Subjects with Early Stage Breast Cancer"></FilterOption><FilterOption id="12845" count="20" label="Breast tumor - Subjects with gene variants - ERBB2_HUMAN_Amplification"></FilterOption><FilterOption id="3999" count="20" label="Leukemia - Subjects with Treatment Resistant Disease"></FilterOption><FilterOption id="3932" count="19" label="Breast tumor - Subjects with Hormone Receptor Positive Breast Cancer - Progesterone receptor positive (PR+) breast cancer"></FilterOption><FilterOption id="3944" count="19" label="Breast tumor - Subjects with Stage II Breast Cancer"></FilterOption><FilterOption id="7108" count="19" label="HIV infection - Subjects on Prior/Concurrent Antiretroviral Therapy"></FilterOption><FilterOption id="3980" count="19" label="Leukemia - Subjects with Chronic Lymphocytic Leukemia (CLL)"></FilterOption><FilterOption id="4003" count="19" label="Leukemia - Subjects with Relapsed/Recurrent Leukemia"></FilterOption><FilterOption id="3500" count="19" label="Lymphoma - Subjects with Specific Grade of Lymphoma - Subjects with Indolent (slow-growing, low grade) Lymphoma"></FilterOption><FilterOption id="3870" count="19" label="Multiple myeloma - Subjects with Symptomatic Disease"></FilterOption><FilterOption id="7415" count="19" label="Renal cell carcinoma - Subjects with Metastatic Renal Cell Carcinoma"></FilterOption><FilterOption id="7809" count="18" label="Bladder cancer - Subjects with Stage IV Bladder Cancer"></FilterOption><FilterOption id="3966" count="18" label="Breast tumor - Subjects with Relapsed/Recurrent Breast cancer"></FilterOption><FilterOption id="3473" count="18" label="Lymphoma - Subjects with B Cell Non Hodgkin's Lymphoma - Subjects with follicular lymphoma"></FilterOption><FilterOption id="3489" count="18" label="Lymphoma - Subjects with B Cell Non Hodgkin's Lymphoma"></FilterOption><FilterOption id="3583" count="18" label="Prostate tumor - Subjects with Castrate Resistant Prostate Cancer"></FilterOption><FilterOption id="3938" count="17" label="Breast tumor - Subjects with Triple Negative Breast Cancer"></FilterOption><FilterOption id="7107" count="17" label="HIV infection - Treatment Naive Subjects"></FilterOption><FilterOption id="12053" count="17" label="Lung tumor - Treatment Naive Subjects"></FilterOption><FilterOption id="3698" count="17" label="Melanoma - Subjects with Surgically Non-resectable Melanoma"></FilterOption><FilterOption id="3979" count="16" label="Leukemia - Subjects with Acute Lymphocytic Leukemia (ALL)"></FilterOption><FilterOption id="3647" count="16" label="Lung tumor - Subjects with Treatment Resistant Disease"></FilterOption><FilterOption id="12018" count="16" label="Prostate tumor - Subjects with adenocarcinoma of prostate"></FilterOption><FilterOption id="7967" count="16" label="Solid tumor - Subjects with Treatment Resistant Disease"></FilterOption><FilterOption id="7806" count="15" label="Bladder cancer - Subjects with Locally Advanced Bladder Cancer"></FilterOption><FilterOption id="3945" count="15" label="Breast tumor - Subjects with Stage III Breast Cancer"></FilterOption><FilterOption id="461" count="15" label="Hepatitis C virus infection - Subjects with Chronic Hepatitis C Infection"></FilterOption><FilterOption id="7879" count="15" label="Ovary tumor - Subjects with Ovarian Epithelial Tumor"></FilterOption><FilterOption id="3814" count="14" label="Colorectal tumor - Subjects with Colon Cancer"></FilterOption><FilterOption id="3813" count="14" label="Colorectal tumor - Subjects with Rectal Cancer"></FilterOption><FilterOption id="7109" count="14" label="HIV infection - Subjects on Prior/Concurrent Antiretroviral Therapy - Subjects on prior/concurrent nucleoside reverse transcriptase inhibitors"></FilterOption><FilterOption id="3623" count="14" label="Lung tumor - Subjects with Advanced Stage Lung Cancer"></FilterOption><FilterOption id="3565" count="14" label="Prostate tumor - Subjects with Stage IV Prostate Cancer"></FilterOption><FilterOption id="7414" count="14" label="Renal cell carcinoma - Advanced Stage Renal Cell Carcinoma"></FilterOption><FilterOption id="8010" count="14" label="Stomach tumor - Subjects with Advanced/Metastatic Gastric Cancer"></FilterOption><FilterOption id="3955" count="13" label="Breast tumor - Subjects with Resectable/Operable Breast Cancer"></FilterOption><FilterOption id="3946" count="13" label="Breast tumor - Subjects with Stage III Breast Cancer - TNM stage IIIA Breast cancer"></FilterOption><FilterOption id="368" count="13" label="Coronary artery disease - Subjects with Myocardial Ischemia"></FilterOption><FilterOption id="3501" count="13" label="Lymphoma - Subjects with Specific Grade of Lymphoma - Subjects with Moderately Aggressive (intermediate grade) Lymphoma"></FilterOption><FilterOption id="15979" count="13" label="Other gastrointestinal disease - Subjects with specific disease - Subjects with Liver Cirrhosis"></FilterOption><FilterOption id="11242" count="13" label="Pulmonary artery hypertension - Subjects with Idiopathic PAH (IPAH)"></FilterOption><FilterOption id="11954" count="12" label="Bladder cancer - Subjects with Urothelial cell/Transitional Cell Bladder Cancer"></FilterOption><FilterOption id="3426" count="12" label="Crohns disease - Subjects with Treatment Resistant Disease"></FilterOption><FilterOption id="7112" count="12" label="HIV infection - Subjects on Prior/Concurrent Antiretroviral Therapy - Subjects on prior/concurrent HAART"></FilterOption><FilterOption id="3681" count="12" label="Melanoma - Subjects with Evidence of Metastasis"></FilterOption><FilterOption id="12005" count="11" label="Breast tumor - Subjects with invasive breast cancer"></FilterOption><FilterOption id="77" count="11" label="Cardiac failure - Subjects with NYHA Functional Class - Moderate/NYHA Functional Class III Heart Failure Subjects"></FilterOption><FilterOption id="201" count="11" label="Coronary artery disease - Subjects Undergoing/Underwent Percutaneous Coronary Intervention (PCI)"></FilterOption><FilterOption id="19047" count="11" label="Melanoma - Treatment Naive Subjects"></FilterOption><FilterOption id="7402" count="11" label="Renal cell carcinoma - Subjects with Clear Cell Renal Cell Carcinoma"></FilterOption><FilterOption id="7814" count="10" label="Bladder cancer - Subjects with Unresectable Bladder Cancer"></FilterOption><FilterOption id="3943" count="10" label="Breast tumor - Subjects with Stage I Breast Cancer"></FilterOption><FilterOption id="7700" count="10" label="End stage renal disease - Subjects with Non-Dialysis Dependant Chronic Kidney Disease(NDD-CKD) - Subjects with stage 3 chronic kidney disease"></FilterOption><FilterOption id="3774" count="10" label="Head and neck tumor - Subjects with Advanced/Metastatic Head and Neck Cancer"></FilterOption><FilterOption id="7877" count="10" label="Lung tumor - Subjects with Non Small Cell Lung Cancer (NSCLC) - Subjects with non-squamous cell lung cancer"></FilterOption><FilterOption id="3650" count="10" label="Lung tumor - Subjects with Recurrent/Relapsed Lung Cancer"></FilterOption><FilterOption id="3496" count="10" label="Lymphoma - Subjects with specific Ann Arbor stage - Subjects with Ann Arbor Stage II Lymphoma"></FilterOption><FilterOption id="8073" count="10" label="Pancreas tumor - Subjects with Advanced/Metastatic Pancreatic Cancer"></FilterOption><FilterOption id="3586" count="10" label="Prostate tumor - Subjects with Treatment Resistant Disease"></FilterOption><FilterOption id="11631" count="10" label="Stroke - Subjects with Ischemic Stroke"></FilterOption><FilterOption id="302" count="9" label="Acute coronary syndrome - ST Segment Elevation Myocardial Infarction(STEMI) Subjects"></FilterOption><FilterOption id="7808" count="9" label="Bladder cancer - Subjects with Stage III Bladder Cancer"></FilterOption><FilterOption id="3970" count="9" label="Breast tumor - Others - Subjects with node positive breast cancer"></FilterOption><FilterOption id="3934" count="9" label="Breast tumor - Subjects with Hormone Receptor Negative Breast Cancer - Estrogen receptor negative (ER-) breast cancer"></FilterOption><FilterOption id="3935" count="9" label="Breast tumor - Subjects with Hormone Receptor Negative Breast Cancer - Progesterone receptor negative (PR-) breast cancer"></FilterOption><FilterOption id="78" count="9" label="Cardiac failure - Subjects with NYHA Functional Class - Severe/NYHA Functional Class IV Heart Failure Subjects"></FilterOption><FilterOption id="178" count="9" label="Coronary artery disease - Subjects with Unstable Coronary Artery Disease - ST elevation myocardial infarction (STEMI)"></FilterOption><FilterOption id="3404" count="9" label="Crohns disease - Subjects with Active Crohns Disease"></FilterOption><FilterOption id="7111" count="9" label="HIV infection - Subjects on Prior/Concurrent Antiretroviral Therapy - Subjects on prior/concurrent protease inhibitors"></FilterOption><FilterOption id="12889" count="9" label="Leukemia - Subjects with gene variants - BCR_ABL1_HUMAN_Fusion"></FilterOption><FilterOption id="3710" count="9" label="Melanoma - Subjects with Treatment Resistant Disease"></FilterOption><FilterOption id="18822" count="9" label="Other gastrointestinal disease - Subjects with specific disease - Nonalcoholic steatohepatitis (NASH) subjects"></FilterOption><FilterOption id="11487" count="9" label="Stem cell transplantation - Subjects with H/O Hematological Malignancies Indicated for SCT"></FilterOption><FilterOption id="8784" count="9" label="Ulcerative colitis - Subjects with Active Ulcerative Colitis"></FilterOption><FilterOption id="7820" count="8" label="Bladder cancer - Subjects with Treatment Resistant Disease"></FilterOption></Filter><Filter label="Primary Completion Filter by Month" name="trialPrimaryCompletionDateByMonth" total="100"><FilterOption count="35" label="201912"></FilterOption><FilterOption count="20" label="202012"></FilterOption><FilterOption count="17" label="201810"></FilterOption><FilterOption count="16" label="201906"></FilterOption><FilterOption count="16" label="202001"></FilterOption><FilterOption count="15" label="201812"></FilterOption><FilterOption count="15" label="201908"></FilterOption><FilterOption count="15" label="201910"></FilterOption><FilterOption count="15" label="202011"></FilterOption><FilterOption count="14" label="201612"></FilterOption><FilterOption count="14" label="202006"></FilterOption><FilterOption count="13" label="201905"></FilterOption><FilterOption count="13" label="201909"></FilterOption><FilterOption count="13" label="202007"></FilterOption><FilterOption count="13" label="202106"></FilterOption><FilterOption count="13" label="202109"></FilterOption><FilterOption count="12" label="201803"></FilterOption><FilterOption count="12" label="201911"></FilterOption><FilterOption count="12" label="202003"></FilterOption><FilterOption count="12" label="202103"></FilterOption><FilterOption count="11" label="201409"></FilterOption><FilterOption count="11" label="201512"></FilterOption><FilterOption count="11" label="201607"></FilterOption><FilterOption count="11" label="201709"></FilterOption><FilterOption count="11" label="201808"></FilterOption><FilterOption count="11" label="201907"></FilterOption><FilterOption count="11" label="202005"></FilterOption><FilterOption count="11" label="202009"></FilterOption><FilterOption count="10" label="201604"></FilterOption><FilterOption count="10" label="201704"></FilterOption><FilterOption count="10" label="201707"></FilterOption><FilterOption count="9" label="201111"></FilterOption><FilterOption count="9" label="201712"></FilterOption><FilterOption count="9" label="201809"></FilterOption><FilterOption count="9" label="202004"></FilterOption><FilterOption count="8" label="201006"></FilterOption><FilterOption count="8" label="201112"></FilterOption><FilterOption count="8" label="201207"></FilterOption><FilterOption count="8" label="201310"></FilterOption><FilterOption count="8" label="201408"></FilterOption><FilterOption count="8" label="201505"></FilterOption><FilterOption count="8" label="201609"></FilterOption><FilterOption count="8" label="201705"></FilterOption><FilterOption count="8" label="201710"></FilterOption><FilterOption count="8" label="201801"></FilterOption><FilterOption count="8" label="201805"></FilterOption><FilterOption count="8" label="201807"></FilterOption><FilterOption count="8" label="201811"></FilterOption><FilterOption count="8" label="201904"></FilterOption><FilterOption count="7" label="201001"></FilterOption><FilterOption count="7" label="201106"></FilterOption><FilterOption count="7" label="201301"></FilterOption><FilterOption count="7" label="201307"></FilterOption><FilterOption count="7" label="201406"></FilterOption><FilterOption count="7" label="201411"></FilterOption><FilterOption count="7" label="201506"></FilterOption><FilterOption count="7" label="201605"></FilterOption><FilterOption count="7" label="201610"></FilterOption><FilterOption count="7" label="201611"></FilterOption><FilterOption count="7" label="201703"></FilterOption><FilterOption count="7" label="201711"></FilterOption><FilterOption count="7" label="202002"></FilterOption><FilterOption count="7" label="202104"></FilterOption><FilterOption count="7" label="202112"></FilterOption><FilterOption count="6" label="200812"></FilterOption><FilterOption count="6" label="201204"></FilterOption><FilterOption count="6" label="201302"></FilterOption><FilterOption count="6" label="201305"></FilterOption><FilterOption count="6" label="201312"></FilterOption><FilterOption count="6" label="201407"></FilterOption><FilterOption count="6" label="201410"></FilterOption><FilterOption count="6" label="201501"></FilterOption><FilterOption count="6" label="201502"></FilterOption><FilterOption count="6" label="201507"></FilterOption><FilterOption count="6" label="201602"></FilterOption><FilterOption count="6" label="201606"></FilterOption><FilterOption count="6" label="201706"></FilterOption><FilterOption count="6" label="201802"></FilterOption><FilterOption count="6" label="202010"></FilterOption><FilterOption count="6" label="202204"></FilterOption><FilterOption count="5" label="200807"></FilterOption><FilterOption count="5" label="200905"></FilterOption><FilterOption count="5" label="201011"></FilterOption><FilterOption count="5" label="201012"></FilterOption><FilterOption count="5" label="201203"></FilterOption><FilterOption count="5" label="201209"></FilterOption><FilterOption count="5" label="201311"></FilterOption><FilterOption count="5" label="201402"></FilterOption><FilterOption count="5" label="201405"></FilterOption><FilterOption count="5" label="201504"></FilterOption><FilterOption count="5" label="201601"></FilterOption><FilterOption count="5" label="201608"></FilterOption><FilterOption count="5" label="201804"></FilterOption><FilterOption count="5" label="201901"></FilterOption><FilterOption count="5" label="201903"></FilterOption><FilterOption count="5" label="202008"></FilterOption><FilterOption count="5" label="202110"></FilterOption><FilterOption count="4" label="200809"></FilterOption><FilterOption count="4" label="200911"></FilterOption><FilterOption count="4" label="201103"></FilterOption></Filter><Filter label="Trial Country" name="trialCountries" total="100"><FilterOption id="ES" count="1237" label="Spain"></FilterOption><FilterOption id="DE" count="613" label="Germany"></FilterOption><FilterOption id="FR" count="611" label="France"></FilterOption><FilterOption id="IT" count="591" label="Italy"></FilterOption><FilterOption id="US" count="575" label="US"></FilterOption><FilterOption id="GB" count="561" label="UK"></FilterOption><FilterOption id="BE" count="466" label="Belgium"></FilterOption><FilterOption id="CA" count="421" label="Canada"></FilterOption><FilterOption id="PL" count="369" label="Poland"></FilterOption><FilterOption id="NL" count="348" label="Netherlands"></FilterOption><FilterOption id="AU" count="347" label="Australia"></FilterOption><FilterOption id="AT" count="293" label="Austria"></FilterOption><FilterOption id="CZ" count="275" label="Czech Republic"></FilterOption><FilterOption id="IL" count="243" label="Israel"></FilterOption><FilterOption id="HU" count="240" label="Hungary"></FilterOption><FilterOption id="RU" count="238" label="Russian Federation"></FilterOption><FilterOption id="KR" count="232" label="South Korea"></FilterOption><FilterOption id="SE" count="220" label="Sweden"></FilterOption><FilterOption id="CH" count="198" label="Switzerland"></FilterOption><FilterOption id="DK" count="194" label="Denmark"></FilterOption><FilterOption id="PT" count="192" label="Portugal"></FilterOption><FilterOption id="BR" count="188" label="Brazil"></FilterOption><FilterOption id="TW" count="160" label="Taiwan"></FilterOption><FilterOption id="JP" count="156" label="Japan"></FilterOption><FilterOption id="GR" count="151" label="Greece"></FilterOption><FilterOption id="AR" count="146" label="Argentina"></FilterOption><FilterOption id="MX" count="141" label="Mexico"></FilterOption><FilterOption id="RO" count="125" label="Romania"></FilterOption><FilterOption id="TR" count="122" label="Turkey"></FilterOption><FilterOption id="UA" count="114" label="Ukraine"></FilterOption><FilterOption id="FI" count="109" label="Finland"></FilterOption><FilterOption id="NZ" count="108" label="New Zealand"></FilterOption><FilterOption id="BG" count="106" label="Bulgaria"></FilterOption><FilterOption id="IE" count="103" label="Ireland"></FilterOption><FilterOption id="CN" count="101" label="China"></FilterOption><FilterOption id="ZA" count="94" label="South Africa"></FilterOption><FilterOption id="SK" count="93" label="Slovakia"></FilterOption><FilterOption id="SG" count="92" label="Singapore"></FilterOption><FilterOption id="NO" count="91" label="Norway"></FilterOption><FilterOption id="HK" count="82" label="Hong Kong"></FilterOption><FilterOption id="CL" count="79" label="Chile"></FilterOption><FilterOption id="RS" count="76" label="Serbia"></FilterOption><FilterOption id="TH" count="70" label="Thailand"></FilterOption><FilterOption id="PE" count="65" label="Peru"></FilterOption><FilterOption id="HR" count="63" label="Croatia"></FilterOption><FilterOption id="CO" count="61" label="Colombia"></FilterOption><FilterOption id="IN" count="56" label="India"></FilterOption><FilterOption id="LV" count="51" label="Latvia"></FilterOption><FilterOption id="PR" count="51" label="Puerto Rico"></FilterOption><FilterOption id="X5" count="47" label="Europe"></FilterOption><FilterOption id="LT" count="47" label="Lithuania"></FilterOption><FilterOption id="MY" count="45" label="Malaysia"></FilterOption><FilterOption id="EE" count="44" label="Estonia"></FilterOption><FilterOption id="SI" count="30" label="Slovenia"></FilterOption><FilterOption id="PH" count="22" label="Philippines"></FilterOption><FilterOption id="XD" count="20" label="North America"></FilterOption><FilterOption id="BA" count="19" label="Bosnia and Herzegovina"></FilterOption><FilterOption id="PA" count="19" label="Panama"></FilterOption><FilterOption id="X2" count="18" label="Asia"></FilterOption><FilterOption id="CR" count="15" label="Costa Rica"></FilterOption><FilterOption id="EG" count="15" label="Egypt"></FilterOption><FilterOption id="GE" count="15" label="Georgia"></FilterOption><FilterOption id="GT" count="14" label="Guatemala"></FilterOption><FilterOption id="XE" count="12" label="South America"></FilterOption><FilterOption id="LU" count="11" label="Luxembourg"></FilterOption><FilterOption id="SA" count="11" label="Saudi Arabia"></FilterOption><FilterOption id="BY" count="10" label="Belarus"></FilterOption><FilterOption id="MA" count="8" label="Morocco"></FilterOption><FilterOption id="VN" count="8" label="Vietnam"></FilterOption><FilterOption id="DZ" count="7" label="Algeria"></FilterOption><FilterOption id="KP" count="7" label="North Korea"></FilterOption><FilterOption id="DO" count="6" label="Dominican Republic"></FilterOption><FilterOption id="MK" count="6" label="Macedonia, The Former Yugoslav Republic of"></FilterOption><FilterOption id="VE" count="6" label="Venezuela"></FilterOption><FilterOption id="EC" count="5" label="Ecuador"></FilterOption><FilterOption id="SV" count="5" label="El Salvador"></FilterOption><FilterOption id="EU" count="5" label="EU"></FilterOption><FilterOption id="LB" count="5" label="Lebanon"></FilterOption><FilterOption id="IS" count="4" label="Iceland"></FilterOption><FilterOption id="AE" count="4" label="United Arab Emirates"></FilterOption><FilterOption id="UY" count="4" label="Uruguay"></FilterOption><FilterOption id="AL" count="3" label="Albania"></FilterOption><FilterOption id="BS" count="3" label="Bahamas"></FilterOption><FilterOption id="ID" count="3" label="Indonesia"></FilterOption><FilterOption id="TN" count="3" label="Tunisia"></FilterOption><FilterOption id="X0" count="2" label="Africa"></FilterOption><FilterOption id="CY" count="2" label="Cyprus"></FilterOption><FilterOption id="JO" count="2" label="Jordan"></FilterOption><FilterOption id="KZ" count="2" label="Kazakhstan"></FilterOption><FilterOption id="KW" count="2" label="Kuwait"></FilterOption><FilterOption id="MT" count="2" label="Malta"></FilterOption><FilterOption id="MD" count="2" label="Moldova, Republic of"></FilterOption><FilterOption id="PK" count="2" label="Pakistan"></FilterOption><FilterOption id="PW" count="2" label="Palau"></FilterOption><FilterOption id="UG" count="2" label="Uganda"></FilterOption><FilterOption id="XW" count="2" label="Western Europe"></FilterOption><FilterOption id="X1" count="1" label="Americas"></FilterOption><FilterOption id="BH" count="1" label="Bahrain"></FilterOption><FilterOption id="BN" count="1" label="Brunei"></FilterOption><FilterOption id="MM" count="1" label="Burma"></FilterOption></Filter><Filter label="Trial Patient Selection" name="trialTermsPatientSelection" total="17"><FilterOption id="EAMAA" count="1171" label="Middle-aged Adults (45-64 yrs)"></FilterOption><FilterOption id="EAYAD" count="1145" label="Young Adults (18-44 yrs)"></FilterOption><FilterOption id="EAAAD" count="1137" label="Aged Adults (65-79 yrs)"></FilterOption><FilterOption id="EAELD" count="969" label="Elderly Adults (80 and over)"></FilterOption><FilterOption id="EGFEM" count="100" label="Female"></FilterOption><FilterOption id="EAADL" count="67" label="Adolescents (13-17 yrs)"></FilterOption><FilterOption id="EACHI" count="49" label="Children (6-12 yrs)"></FilterOption><FilterOption id="EVHVA" count="40" label="Healthy volunteers accepted"></FilterOption><FilterOption id="EGMAL" count="38" label="Male"></FilterOption><FilterOption id="EAPRE" count="17" label="Preschool Children (2-5 yrs)"></FilterOption><FilterOption id="ECASI" count="13" label="Asian Ancestry"></FilterOption><FilterOption id="EAINF" count="12" label="Infants (6-23 months)"></FilterOption><FilterOption id="EANEW" count="12" label="Newborn Infants (up to 5 months)"></FilterOption><FilterOption id="ECJAP" count="9" label="Japanese Ancestry"></FilterOption><FilterOption id="ECAFR" count="4" label="African Ancestry"></FilterOption><FilterOption id="EVHVO" count="4" label="Healthy volunteers only"></FilterOption><FilterOption id="ECEUR" count="1" label="European Ancestry"></FilterOption></Filter><Filter label="Trial Terms Design" name="trialTermsDesign" total="25"><FilterOption id="SSTINV" count="1137" label="Interventional"></FilterOption><FilterOption id="SIPTRE" count="1053" label="Treatment"></FilterOption><FilterOption id="SIARND" count="840" label="Randomized"></FilterOption><FilterOption id="SISPRL" count="821" label="Parallel Assignment"></FilterOption><FilterOption id="SIMOPN" count="647" label="Open Label"></FilterOption><FilterOption id="SIMMBD" count="435" label="Multiple Blind"></FilterOption><FilterOption id="SICPLC" count="407" label="Placebo Control"></FilterOption><FilterOption id="SICACT" count="296" label="Active Control"></FilterOption><FilterOption id="SISSNG" count="254" label="Single Group Assignment"></FilterOption><FilterOption id="SIANON" count="198" label="Non-Randomized"></FilterOption><FilterOption id="SICNOC" count="158" label="No Control"></FilterOption><FilterOption id="SSTOBS" count="100" label="Observational"></FilterOption><FilterOption id="SOTPRO" count="75" label="Prospective"></FilterOption><FilterOption id="SOSCOH" count="68" label="Cohort"></FilterOption><FilterOption id="SIPPRE" count="67" label="Prevention"></FilterOption><FilterOption id="SIMSBD" count="48" label="Single Blind"></FilterOption><FilterOption id="SISXOV" count="26" label="Crossover Assignment"></FilterOption><FilterOption id="SOTRET" count="20" label="Retrospective"></FilterOption><FilterOption id="SIPDIA" count="13" label="Diagnosis"></FilterOption><FilterOption id="SOSCSC" count="10" label="Case Control"></FilterOption><FilterOption id="SODXSC" count="8" label="Cross-sectional"></FilterOption><FilterOption id="SODLNG" count="5" label="Longitudinal"></FilterOption><FilterOption id="SICDSC" count="3" label="Dose Comparison"></FilterOption><FilterOption id="SISFCT" count="2" label="Factorial Assignment"></FilterOption><FilterOption id="SISEAA" count="1" label="Expanded Access Assignment"></FilterOption></Filter><Filter label="Trial Source" name="trialSources" total="3"><FilterOption id="CTGOVOTHERS" count="721" label="ClinicalTrials.gov and others"></FilterOption><FilterOption id="CTGOV" count="499" label="ClinicalTrials.gov only"></FilterOption><FilterOption id="OTHERS" count="8" label="Others only"></FilterOption></Filter><Filter label="Trial Actions Secondary Interventions Primary" name="trialActionsSecondaryInterventionsPrimary" total="100"><FilterOption id="1545" count="487" label="Anticancer"></FilterOption><FilterOption id="55685" count="258" label="Anticancer monoclonal antibody"></FilterOption><FilterOption id="2953" count="256" label="Anti-inflammatory"></FilterOption><FilterOption id="62255" count="203" label="Anticancer protein kinase inhibitor"></FilterOption><FilterOption id="991" count="184" label="Antiviral"></FilterOption><FilterOption id="1589" count="179" label="Apoptosis stimulator"></FilterOption><FilterOption id="767" count="154" label="Cell cycle inhibitor"></FilterOption><FilterOption id="7293" count="123" label="Synergist"></FilterOption><FilterOption id="61" count="120" label="Angiogenesis inhibitor"></FilterOption><FilterOption id="393" count="119" label="Immunostimulant"></FilterOption><FilterOption id="7761" count="112" label="T-lymphocyte stimulator"></FilterOption><FilterOption id="50" count="84" label="Anticancer alkylating agent"></FilterOption><FilterOption id="140" count="82" label="DNA synthesis inhibitor"></FilterOption><FilterOption id="1569" count="71" label="Anticancer antimetabolite"></FilterOption><FilterOption id="1596" count="60" label="Immunomodulator"></FilterOption><FilterOption id="2657" count="55" label="Antihypertensive"></FilterOption><FilterOption id="2575" count="50" label="Microtubule inhibitor"></FilterOption><FilterOption id="2576" count="46" label="Microtubule stabilizer"></FilterOption><FilterOption id="2660" count="42" label="Vasoprotectant"></FilterOption><FilterOption id="382" count="39" label="TNF alpha synthesis inhibitor"></FilterOption><FilterOption id="747" count="34" label="HIV replication inhibitor"></FilterOption><FilterOption id="396" count="34" label="Immunosuppressant"></FilterOption><FilterOption id="2946" count="32" label="Analgesic"></FilterOption><FilterOption id="750" count="26" label="DNA intercalator"></FilterOption><FilterOption id="1615" count="26" label="Neuroprotectant"></FilterOption><FilterOption id="15184" count="24" label="Systemic antipsoriatic product"></FilterOption><FilterOption id="539" count="23" label="Immunotoxin"></FilterOption><FilterOption id="12379" count="23" label="Therapeutic vaccine"></FilterOption><FilterOption id="1594" count="22" label="Antibacterial"></FilterOption><FilterOption id="62254" count="20" label="Anticancer hormone antagonist"></FilterOption><FilterOption id="664" count="20" label="Fibrosuppressant"></FilterOption><FilterOption id="399" count="20" label="Hypoglycemic agent"></FilterOption><FilterOption id="2947" count="19" label="Antiparkinsonian"></FilterOption><FilterOption id="388" count="17" label="Vasodilator"></FilterOption><FilterOption id="70" count="14" label="Anticonvulsant agent"></FilterOption><FilterOption id="2941" count="14" label="Antidepressant"></FilterOption><FilterOption id="284" count="14" label="Nootropic agent"></FilterOption><FilterOption id="312" count="14" label="Platelet aggregation inhibitor"></FilterOption><FilterOption id="2659" count="13" label="Cardioprotectant"></FilterOption><FilterOption id="449" count="12" label="Antiarrhythmic agent"></FilterOption><FilterOption id="2943" count="12" label="Antipsychotic"></FilterOption><FilterOption id="55684" count="11" label="Anticancer antibody"></FilterOption><FilterOption id="71" count="11" label="Antihypercholesterolemic agent"></FilterOption><FilterOption id="5704" count="11" label="B-lymphocyte adhesion inhibitor"></FilterOption><FilterOption id="5710" count="11" label="B-lymphocyte migration inhibitor"></FilterOption><FilterOption id="5580" count="11" label="Chemotaxis inhibitor"></FilterOption><FilterOption id="659" count="11" label="Coagulation inhibitor"></FilterOption><FilterOption id="1332" count="11" label="Gastrointestinal system agent"></FilterOption><FilterOption id="610" count="11" label="Hematopoietic stimulator"></FilterOption><FilterOption id="695" count="11" label="Metastasis inhibitor"></FilterOption><FilterOption id="439" count="11" label="RNA synthesis inhibitor"></FilterOption><FilterOption id="59620" count="11" label="Unspecified drug target"></FilterOption><FilterOption id="646" count="10" label="Bronchodilator"></FilterOption><FilterOption id="3980" count="10" label="HIV fusion inhibitor"></FilterOption><FilterOption id="12372" count="10" label="Protein subunit vaccine"></FilterOption><FilterOption id="32411" count="9" label="Hepatitis B virus replication inhibitor"></FilterOption><FilterOption id="12378" count="9" label="Prophylactic vaccine"></FilterOption><FilterOption id="104" count="8" label="Bacterial cell wall synthesis inhibitor"></FilterOption><FilterOption id="285" count="8" label="Norepinephrine uptake inhibitor"></FilterOption><FilterOption id="15187" count="8" label="Systemic dermatological antibacterial product"></FilterOption><FilterOption id="1532" count="8" label="Viral replication inhibitor"></FilterOption><FilterOption id="7292" count="8" label="Vulnerary agent"></FilterOption><FilterOption id="1590" count="7" label="Apoptosis inhibitor"></FilterOption><FilterOption id="3984" count="7" label="Bacterial nucleic acid synthesis inhibitor"></FilterOption><FilterOption id="863" count="7" label="Bile acid modulator"></FilterOption><FilterOption id="966" count="7" label="Cardiac agent"></FilterOption><FilterOption id="805" count="7" label="Folate modulator"></FilterOption><FilterOption id="1748" count="7" label="Fungicide"></FilterOption><FilterOption id="15128" count="7" label="Ophthalmological agent"></FilterOption><FilterOption id="937" count="6" label="Androgen synthesis inhibitor"></FilterOption><FilterOption id="74" count="6" label="Antioxidant agent"></FilterOption><FilterOption id="137" count="6" label="Diuretic agent"></FilterOption><FilterOption id="151" count="6" label="Dopamine uptake inhibitor"></FilterOption><FilterOption id="7760" count="6" label="T-lymphocyte inhibitor"></FilterOption><FilterOption id="524" count="5" label="Adjuvant"></FilterOption><FilterOption id="7294" count="5" label="Antisense oligonucleotide inhibitor"></FilterOption><FilterOption id="89" count="5" label="Bone resorption inhibitor"></FilterOption><FilterOption id="7211" count="5" label="CNS diagnostic agent"></FilterOption><FilterOption id="11593" count="5" label="DNA repair inhibitor"></FilterOption><FilterOption id="1129" count="5" label="Non-steroid hormone receptor antagonist"></FilterOption><FilterOption id="26035" count="5" label="siRNA agent"></FilterOption><FilterOption id="53558" count="5" label="Stem cell modulator"></FilterOption><FilterOption id="2970" count="4" label="Anti-emetic"></FilterOption><FilterOption id="4007" count="4" label="Antidiarrhoeal"></FilterOption><FilterOption id="2638" count="4" label="Antiparasitic"></FilterOption><FilterOption id="2942" count="4" label="Anxiolytic"></FilterOption><FilterOption id="65" count="4" label="Class I antiarrhythmic agent"></FilterOption><FilterOption id="66" count="4" label="Class II antiarrhythmic agent"></FilterOption><FilterOption id="2939" count="4" label="CNS modulator"></FilterOption><FilterOption id="161" count="4" label="Ergosterol synthesis inhibitor"></FilterOption><FilterOption id="166" count="4" label="Fibrinolysis stimulator"></FilterOption><FilterOption id="4790" count="4" label="Genetically engineered autologous cell therapy"></FilterOption><FilterOption id="3272" count="4" label="Growth hormone release inhibitor"></FilterOption><FilterOption id="12596" count="4" label="Osteoclast inhibitor"></FilterOption><FilterOption id="5555" count="4" label="PET contrast agent"></FilterOption><FilterOption id="339" count="4" label="Protein synthesis inhibitor"></FilterOption><FilterOption id="5720" count="4" label="Radiodiagnostic"></FilterOption><FilterOption id="15178" count="4" label="Systemic dermatological antifungal product"></FilterOption><FilterOption id="882" count="3" label="5-HETE modulator"></FilterOption><FilterOption id="3" count="3" label="5-HT uptake inhibitor"></FilterOption></Filter><Filter label="Trial Endpoint Achieved" name="trialEndpointsAchieved" total="3"><FilterOption id="UNSPECIFIED" count="291" label="Unspecified"></FilterOption><FilterOption id="YES" count="178" label="Yes"></FilterOption><FilterOption id="NO" count="89" label="No"></FilterOption></Filter><Filter label="Endpoint Index Secondary" name="trialEndpointIndexSecondary" total="100"><FilterOption id="8712" count="51" label="Breast tumor - Assessment of Overall Survival (OS)"></FilterOption><FilterOption id="8719" count="44" label="Breast tumor - Assessment of Response Rates (RR) - Assessment of Overall/Objective Response Rate (ORR)"></FilterOption><FilterOption id="7538" count="36" label="Lymphoma - Assessment of Overall Survival (OS)"></FilterOption><FilterOption id="8721" count="35" label="Breast tumor - Assessment of Response Rates (RR) - Assessment of Complete Response"></FilterOption><FilterOption id="8998" count="35" label="Breast tumor - Assessment of adverse events"></FilterOption><FilterOption id="7879" count="34" label="Leukemia - Assessment of Overall Survival (OS)"></FilterOption><FilterOption id="9218" count="33" label="HIV infection - Assessment of Immune Response"></FilterOption><FilterOption id="9247" count="32" label="HIV infection - Assessment of Safety and Tolerability - Assessment of adverse events/serious adverse events"></FilterOption><FilterOption id="8738" count="31" label="Breast tumor - Assessment of Response Rates (RR) - Assessment of duration of tumor response"></FilterOption><FilterOption id="8481" count="31" label="Lung tumor - Assessment of Overall Survival (OS)"></FilterOption><FilterOption id="8720" count="29" label="Breast tumor - Assessment of Response Rates (RR) - Assessment of Partial Response (PR)"></FilterOption><FilterOption id="8078" count="29" label="Leukemia - Assessment of adverse events"></FilterOption><FilterOption id="8713" count="28" label="Breast tumor - Assessment of Progression Free Survival (PFS)"></FilterOption><FilterOption id="7354" count="28" label="Multiple myeloma - Assessment of Overall Survival (OS)"></FilterOption><FilterOption id="8722" count="27" label="Breast tumor - Assessment of Response Rates (RR) - Assessment of Clinical Benefit Rate (CBR)"></FilterOption><FilterOption id="8489" count="27" label="Lung tumor - Assessment of Progression Free Survival (PFS)"></FilterOption><FilterOption id="9215" count="26" label="HIV infection - Assessment of CD4 Cell Responses - Assessment of CD4 cell count/percentage"></FilterOption><FilterOption id="9213" count="24" label="HIV infection - Assessment of Viral Load - Assessment of HIV RNA levels"></FilterOption><FilterOption id="7908" count="24" label="Leukemia - Assessment of Response Rates (RR) - Assessment of Complete Response"></FilterOption><FilterOption id="7611" count="24" label="Lymphoma - Assessment of Response Rates (RR) - Assessment of tumor response rate (Duration of response)"></FilterOption><FilterOption id="9153" count="23" label="Lung tumor - Imaging/Radiological Assessments - Assessment by Response Evaluation Criteria in Solid Tumors (RECIST) Criteria"></FilterOption><FilterOption id="7547" count="23" label="Lymphoma - Assessment of Progression Free Survival (PFS)"></FilterOption><FilterOption id="7563" count="22" label="Lymphoma - Assessment of Response Rates (RR) - Assessment of Complete Response"></FilterOption><FilterOption id="7680" count="22" label="Lymphoma - Assessment of adverse events"></FilterOption><FilterOption id="6919" count="22" label="Melanoma - Assessment of Overall Survival (OS)"></FilterOption><FilterOption id="7679" count="21" label="Lymphoma - Assessment of Safety and Tolerability"></FilterOption><FilterOption id="7360" count="21" label="Multiple myeloma - Assessment of Progression Free Survival (PFS)"></FilterOption><FilterOption id="8725" count="20" label="Breast tumor - Assessment of Response Rates (RR) - Assessment of Stable Disease"></FilterOption><FilterOption id="8999" count="20" label="Breast tumor - Assessment of Safety and Tolerability - Assessment of safety as measured by NCI CTCAE/NCI-CTC criteria"></FilterOption><FilterOption id="8996" count="20" label="Breast tumor - Assessment of Safety and Tolerability"></FilterOption><FilterOption id="9300" count="20" label="Leukemia - Assessment of Response Rates (RR) - Assessment of tumor response rate (Duration of response)"></FilterOption><FilterOption id="8505" count="20" label="Lung tumor - Assessment of Objective Response - Assessment of objective response rate(ORR)"></FilterOption><FilterOption id="7393" count="20" label="Multiple myeloma - Assessment of Response Rates (RR) - Assessment of tumor response rate (Duration of response)"></FilterOption><FilterOption id="8754" count="19" label="Breast tumor - Assessment of Mortality/Death Rates"></FilterOption><FilterOption id="8522" count="19" label="Lung tumor - Assessment of Response Rates (RR) - Assessment of duration of response"></FilterOption><FilterOption id="6924" count="19" label="Melanoma - Assessment of Progression Free Survival (PFS)"></FilterOption><FilterOption id="6940" count="19" label="Melanoma - Assessment of Response Rates (RR) - Assessment of overall/objective response rate"></FilterOption><FilterOption id="10828" count="19" label="Ovary tumor - Assessment of Overall Survival (OS)"></FilterOption><FilterOption id="8714" count="18" label="Breast tumor - Assessment of Disease Free Survival (DFS)"></FilterOption><FilterOption id="7909" count="18" label="Leukemia - Assessment of Response Rates (RR) - Assessment of Overall/Objective Response Rate (ORR)"></FilterOption><FilterOption id="8077" count="18" label="Leukemia - Assessment of Safety and Tolerability"></FilterOption><FilterOption id="7898" count="18" label="Leukemia - Assessment of Survival - Assessment of event free survival (EFS)"></FilterOption><FilterOption id="7027" count="18" label="Melanoma - Assessment of adverse events"></FilterOption><FilterOption id="7367" count="18" label="Multiple myeloma - Assessment of Response Rates (RR) - Assessment of Overall/Objective Response Rate (ORR)"></FilterOption><FilterOption id="8744" count="17" label="Breast tumor - Assessment of Disease Progression"></FilterOption><FilterOption id="9242" count="17" label="HIV infection - Assessment of lipid profiles"></FilterOption><FilterOption id="7569" count="17" label="Lymphoma - Assessment of Response Rates (RR) - Assessment of Overall/Objective Response Rate (ORR)"></FilterOption><FilterOption id="7489" count="17" label="Multiple myeloma - Assessment of Safety and Tolerability - Assessment of other adverse events"></FilterOption><FilterOption id="10540" count="17" label="Renal cell carcinoma - Assessment of Overall Survival (OS)"></FilterOption><FilterOption id="11728" count="16" label="Bladder cancer - Assessment of Response Rates (RR) - Assessment of objective/overall response rate (ORR)"></FilterOption><FilterOption id="8109" count="16" label="Leukemia - Assessment of Mortality/Death Rates"></FilterOption><FilterOption id="9122" count="15" label="Breast tumor - Assessment of Pharmacokinetic/Pharmacodynamic Parameters"></FilterOption><FilterOption id="2622" count="15" label="Coronary artery disease - Assessment of Mortality/Death Rates - Cardiovascular mortality"></FilterOption><FilterOption id="9238" count="15" label="HIV infection - Assessment of Laboratory/Diagnostic Measures"></FilterOption><FilterOption id="9212" count="15" label="HIV infection - Assessment of Viral Load"></FilterOption><FilterOption id="8663" count="15" label="Lung tumor - Assessment of Pharmacokinetic/Pharmacodynamic Parameters"></FilterOption><FilterOption id="8640" count="15" label="Lung tumor - Assessment of Safety and Tolerability - Adverse events as graded by CTCAE/CTC"></FilterOption><FilterOption id="7558" count="15" label="Lymphoma - Assessment of Survival - Assessment of event free survival (EFS)"></FilterOption><FilterOption id="7372" count="15" label="Multiple myeloma - Assessment of Response Rates (RR) - Assessment of Partial Response (PR)"></FilterOption><FilterOption id="7190" count="15" label="Prostate tumor - Assessment of Safety and Tolerability - Assessment of adverse events/serious adverse events"></FilterOption><FilterOption id="8759" count="14" label="Breast tumor - Patient Reported Outcomes/Quality of Life Assessments"></FilterOption><FilterOption id="8430" count="14" label="Colorectal tumor - Assessment of Safety and Tolerability - Assessment of adverse events/serious adverse events"></FilterOption><FilterOption id="2492" count="14" label="Coronary artery disease - Assessment of Cardiovascular Events - Acute/New Myocardial infarction (MI)/MI (Q-wave and non-Q wave)"></FilterOption><FilterOption id="7907" count="14" label="Leukemia - Assessment of Response Rates (RR) - Assessment of Partial Response (PR)"></FilterOption><FilterOption id="8147" count="14" label="Leukemia - Assessment of Response Rates (RR) - Assessment of minimal residual disease"></FilterOption><FilterOption id="7564" count="14" label="Lymphoma - Assessment of Response Rates (RR) - Assessment of Partial Response (PR)"></FilterOption><FilterOption id="43526" count="14" label="Other gastrointestinal disease - Clinical Assessments"></FilterOption><FilterOption id="10545" count="14" label="Renal cell carcinoma - Assessment of Progression Free Survival (PFS)"></FilterOption><FilterOption id="11717" count="13" label="Bladder cancer - Assessment of Overall Survival (OS)"></FilterOption><FilterOption id="11780" count="13" label="Bladder cancer - Assessment of Pharmacokinetic/Pharmacodynamic Parameters"></FilterOption><FilterOption id="11735" count="13" label="Bladder cancer - Assessment of Response Rates (RR) - Assessment of duration of response"></FilterOption><FilterOption id="37159" count="13" label="Breast tumor - Assessment of Laboratory/Diagnostic Measures"></FilterOption><FilterOption id="2703" count="13" label="Coronary artery disease - Assessment of Vascular Indices or Parameters - Assessment of target lesion revascularization (TLR)"></FilterOption><FilterOption id="8639" count="13" label="Lung tumor - Assessment of Safety and Tolerability"></FilterOption><FilterOption id="6951" count="13" label="Melanoma - Assessment of Response Rates (RR) - Assessment of duration of response"></FilterOption><FilterOption id="7373" count="13" label="Multiple myeloma - Assessment of Response Rates (RR) - Assessment of Complete Response"></FilterOption><FilterOption id="42921" count="13" label="Other gastrointestinal disease - Assessment of Safety and Tolerability"></FilterOption><FilterOption id="10839" count="13" label="Ovary tumor - Assessment of Response Rates (RR) - Assessment of overall/objective response rate(ORR)"></FilterOption><FilterOption id="7045" count="13" label="Prostate tumor - Assessment of Overall Survival (OS)"></FilterOption><FilterOption id="15907" count="13" label="Ulcerative colitis - Ulcerative Colitis Assessed by Activity Indices - Assessment by Mayo clinic score (MCS)/ disease activity index (DAI)"></FilterOption><FilterOption id="11722" count="12" label="Bladder cancer - Assessment of Progression Free Survival (PFS)"></FilterOption><FilterOption id="9310" count="12" label="Breast tumor - Imaging/Radiological Assessments"></FilterOption><FilterOption id="8151" count="12" label="Colorectal tumor - Assessment of Overall Survival (OS)"></FilterOption><FilterOption id="2623" count="12" label="Coronary artery disease - Assessment of Mortality/Death Rates - Assessment of all cause mortality"></FilterOption><FilterOption id="10830" count="12" label="Ovary tumor - Assessment of Progression Free Survival (PFS)"></FilterOption><FilterOption id="15212" count="12" label="Solid tumor - Assessment of Response Rates (RR) - Assessment of objective response rate (ORR)"></FilterOption><FilterOption id="12156" count="12" label="Stomach tumor - Assessment of Response Rates (RR) - Assessment of objective/overall response rate (ORR)"></FilterOption><FilterOption id="8764" count="11" label="Breast tumor - Patient Reported Outcomes/Quality of Life Assessments - Assessment by EORTC QLQ-C30"></FilterOption><FilterOption id="6863" count="11" label="Hepatitis C virus infection - Assessment of Viral Load/Viral Kinetics"></FilterOption><FilterOption id="7891" count="11" label="Leukemia - Assessment of Progression Free Survival (PFS)"></FilterOption><FilterOption id="7916" count="11" label="Leukemia - Assessment of Response Rates (RR) - Assessment of hematologic/bone marrow response"></FilterOption><FilterOption id="6972" count="11" label="Melanoma - Imaging/Radiological Assessments - Assessment by Response Evaluation Criteria in Solid Tumors (RECIST) Criteria"></FilterOption><FilterOption id="43670" count="11" label="Other gastrointestinal disease - Assessment of adverse events"></FilterOption><FilterOption id="7088" count="11" label="Prostate tumor - Assessment of Disease Progression"></FilterOption><FilterOption id="15218" count="11" label="Solid tumor - Assessment of Response Rates (RR) - Assessment of duration of tumor response"></FilterOption><FilterOption id="11773" count="10" label="Bladder cancer - Assessment of Safety and Tolerability - Assessment of adverse events/serious adverse events"></FilterOption><FilterOption id="10187" count="10" label="Parkinsons disease - Assessment of Disability Measured by Unified Parkinson’s Disease Rating Scale (UPDRS) - Assessment of UPDRS Part III scale/score"></FilterOption><FilterOption id="11730" count="9" label="Bladder cancer - Assessment of Response Rates (RR) - Assessment of Complete Response"></FilterOption><FilterOption id="11729" count="9" label="Bladder cancer - Assessment of Response Rates (RR) - Assessment of Partial Response (PR)"></FilterOption><FilterOption id="8745" count="9" label="Breast tumor - Assessment of Disease Progression - Assessment of Time to Tumor Progression (TTP)"></FilterOption></Filter><Filter label="Biomarker" name="trialBiomarkerNames" total="100"><FilterOption id="1211" count="100" label="Alanine transaminase"></FilterOption><FilterOption id="3" count="85" label="HER2"></FilterOption><FilterOption id="213" count="82" label="Creatinine"></FilterOption><FilterOption id="2527" count="81" label="Aspartate aminotransferase"></FilterOption><FilterOption id="2054" count="73" label="Blood platelets"></FilterOption><FilterOption id="1236" count="70" label="Hemoglobin"></FilterOption><FilterOption id="12058" count="70" label="Total body mass"></FilterOption><FilterOption id="1857" count="62" label="T-cell surface glycoprotein CD4"></FilterOption><FilterOption id="1925" count="61" label="Neutrophils"></FilterOption><FilterOption id="5" count="53" label="Estrogen receptor"></FilterOption><FilterOption id="2387" count="52" label="Bilirubin"></FilterOption><FilterOption id="46" count="51" label="C-reactive protein"></FilterOption><FilterOption id="824" count="51" label="Programmed cell death 1 ligand 1"></FilterOption><FilterOption id="1880" count="47" label="T-Helper Lymphocytes"></FilterOption><FilterOption id="1904" count="45" label="Heart rate"></FilterOption><FilterOption id="2586" count="40" label="Blood pressure"></FilterOption><FilterOption id="125" count="40" label="Leukocyte count"></FilterOption><FilterOption id="3447" count="40" label="T-cell surface glycoprotein CD8 alpha chain"></FilterOption><FilterOption id="6" count="39" label="Progesterone receptor"></FilterOption><FilterOption id="1735" count="38" label="Glucose"></FilterOption><FilterOption id="118" count="37" label="Albumin"></FilterOption><FilterOption id="28899" count="37" label="Alkaline phosphatase"></FilterOption><FilterOption id="44218" count="37" label="Human immunodeficiency virus RNA"></FilterOption><FilterOption id="176" count="37" label="Interleukin-6"></FilterOption><FilterOption id="133" count="36" label="Total cholesterol"></FilterOption><FilterOption id="152" count="35" label="Low-density lipoprotein cholesterol"></FilterOption><FilterOption id="217" count="34" label="Triglycerides"></FilterOption><FilterOption id="7895" count="32" label="Estimated glomerular filtration rate"></FilterOption><FilterOption id="4806" count="32" label="Lymphocytes"></FilterOption><FilterOption id="8" count="31" label="Epidermal growth factor receptor"></FilterOption><FilterOption id="147" count="31" label="Six-minute walk distance"></FilterOption><FilterOption id="46505" count="30" label="Cytotoxic T-Lymphocytes"></FilterOption><FilterOption id="153" count="29" label="High-density lipoprotein cholesterol"></FilterOption><FilterOption id="38" count="29" label="Prostate-specific antigen"></FilterOption><FilterOption id="330" count="29" label="Systolic blood pressure"></FilterOption><FilterOption id="82" count="28" label="B-Raf proto-oncogene serine/threonine-protein kinase"></FilterOption><FilterOption id="14767" count="28" label="Lipids"></FilterOption><FilterOption id="113" count="27" label="Body Mass Index"></FilterOption><FilterOption id="36136" count="27" label="Cytokines"></FilterOption><FilterOption id="8458" count="27" label="gamma-Glutamyltransferase"></FilterOption><FilterOption id="106" count="26" label="N-terminal Pro Brain Natriuretic Peptide"></FilterOption><FilterOption id="1945" count="25" label="Left ventricular ejection fraction"></FilterOption><FilterOption id="46506" count="25" label="T-Lymphocytes"></FilterOption><FilterOption id="8024" count="24" label="Creatine kinase"></FilterOption><FilterOption id="332" count="24" label="Diastolic blood pressure"></FilterOption><FilterOption id="44216" count="21" label="Body temperature"></FilterOption><FilterOption id="4522" count="21" label="Erythrocytes"></FilterOption><FilterOption id="2662" count="21" label="Sodium"></FilterOption><FilterOption id="5700" count="19" label="ALK receptor"></FilterOption><FilterOption id="1731" count="19" label="B-lymphocyte antigen CD20"></FilterOption><FilterOption id="2417" count="19" label="Calcium"></FilterOption><FilterOption id="148" count="19" label="QT interval"></FilterOption><FilterOption id="7" count="18" label="Antigen KI-67"></FilterOption><FilterOption id="3374" count="18" label="Bone mineral density"></FilterOption><FilterOption id="252" count="18" label="Interferon gamma"></FilterOption><FilterOption id="2098" count="18" label="Potassium"></FilterOption><FilterOption id="274" count="18" label="Tumor necrosis factor"></FilterOption><FilterOption id="6663" count="17" label="B-lymphocytes"></FilterOption><FilterOption id="165" count="17" label="Beta-2-microglobulin"></FilterOption><FilterOption id="10684" count="17" label="Blood cells"></FilterOption><FilterOption id="289" count="17" label="Hemoglobin A, glycosylated"></FilterOption><FilterOption id="154" count="17" label="Lactate dehydrogenase"></FilterOption><FilterOption id="22" count="16" label="Breast cancer type 1 susceptibility protein"></FilterOption><FilterOption id="1912" count="16" label="Forced Vital Capacity"></FilterOption><FilterOption id="1289" count="16" label="Tumor mass"></FilterOption><FilterOption id="41" count="15" label="Breast cancer type 2 susceptibility protein"></FilterOption><FilterOption id="2713" count="15" label="Forced expiratory volume"></FilterOption><FilterOption id="749" count="15" label="Free light chains"></FilterOption><FilterOption id="71" count="14" label="CA-125 antigen"></FilterOption><FilterOption id="9" count="14" label="Cellular tumor antigen p53"></FilterOption><FilterOption id="7033" count="14" label="Lipase"></FilterOption><FilterOption id="13158" count="14" label="Myeloma protein"></FilterOption><FilterOption id="3098" count="13" label="Calprotectin"></FilterOption><FilterOption id="92" count="13" label="Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha isoform"></FilterOption><FilterOption id="17697" count="12" label="Body height"></FilterOption><FilterOption id="2254" count="12" label="HLA-DR Antigens"></FilterOption><FilterOption id="808" count="12" label="Insulin"></FilterOption><FilterOption id="175" count="12" label="Interleukin-10"></FilterOption><FilterOption id="11117" count="12" label="Plasma cells"></FilterOption><FilterOption id="11857" count="12" label="Transaminases"></FilterOption><FilterOption id="12516" count="12" label="Urinary protein"></FilterOption><FilterOption id="769" count="11" label="ADP-ribosyl cyclase 1"></FilterOption><FilterOption id="126" count="11" label="BCR-ABL1 fusion protein"></FilterOption><FilterOption id="64" count="11" label="Circulating Tumor Cells"></FilterOption><FilterOption id="10306" count="11" label="Ejection fraction"></FilterOption><FilterOption id="2412" count="11" label="Immunoglobulin M"></FilterOption><FilterOption id="900" count="11" label="Microtubule associated protein tau"></FilterOption><FilterOption id="2613" count="11" label="Norepinephrine"></FilterOption><FilterOption id="2411" count="11" label="Pulmonary vascular resistance"></FilterOption><FilterOption id="122" count="11" label="Renin"></FilterOption><FilterOption id="46244" count="10" label="Circulating tumor DNA"></FilterOption><FilterOption id="3451" count="10" label="Immunoglobulin G"></FilterOption><FilterOption id="8097" count="10" label="Monocytes"></FilterOption><FilterOption id="10833" count="10" label="Myomesin-2"></FilterOption><FilterOption id="2139" count="10" label="Pulmonary arterial pressure"></FilterOption><FilterOption id="6993" count="9" label="Alpha-amylase 1"></FilterOption><FilterOption id="11114" count="9" label="Brain"></FilterOption><FilterOption id="5393" count="9" label="Chromosome locus 17p"></FilterOption><FilterOption id="52" count="9" label="GTPase KRas"></FilterOption><FilterOption id="1221" count="9" label="Hematocrit"></FilterOption></Filter><Filter label="Trial Terms Endpoint" name="trialTermsEndpoint" total="5"><FilterOption id="SIEEFC" count="1120" label="Efficacy"></FilterOption><FilterOption id="SIESFT" count="1062" label="Safety"></FilterOption><FilterOption id="SIEPCK" count="430" label="Pharmacokinetics"></FilterOption><FilterOption id="SIEPCD" count="230" label="Pharmacodynamics"></FilterOption><FilterOption id="SIEBAV" count="4" label="Bioavailability"></FilterOption></Filter><Filter label="Trial Interventions Primary In Regimen Name Display" name="trialInterventionsPrimaryInRegimenNameDisplay" total="100"><FilterOption id="3803" count="36" label="paclitaxel"></FilterOption><FilterOption id="44383" count="33" label="carboplatin"></FilterOption><FilterOption id="3199" count="31" label="gemcitabine"></FilterOption><FilterOption id="72699" count="30" label="atezolizumab"></FilterOption><FilterOption id="6736" count="29" label="rituximab"></FilterOption><FilterOption id="8047" count="23" label="bevacizumab"></FilterOption><FilterOption id="2953" count="20" label="docetaxel"></FilterOption><FilterOption id="6386" count="20" label="trastuzumab"></FilterOption><FilterOption id="15954" count="18" label="bortezomib"></FilterOption><FilterOption id="27572" count="18" label="lenalidomide"></FilterOption><FilterOption id="3072" count="16" label="etoposide phosphate"></FilterOption><FilterOption id="3792" count="16" label="oxaliplatin"></FilterOption><FilterOption id="7310" count="16" label="ritonavir"></FilterOption><FilterOption id="12205" count="14" label="capecitabine"></FilterOption><FilterOption id="70667" count="14" label="pembrolizumab"></FilterOption><FilterOption id="28532" count="14" label="pertuzumab"></FilterOption><FilterOption id="2784" count="13" label="letrozole"></FilterOption><FilterOption id="54804" count="12" label="nivolumab"></FilterOption><FilterOption id="3313" count="11" label="fulvestrant"></FilterOption><FilterOption id="47000" count="10" label="bendamustine"></FilterOption><FilterOption id="56544" count="10" label="cobimetinib"></FilterOption><FilterOption id="13022" count="9" label="epirubicin"></FilterOption><FilterOption id="6156" count="9" label="fludarabine"></FilterOption><FilterOption id="55237" count="9" label="ibrutinib"></FilterOption><FilterOption id="14681" count="9" label="lopinavir + ritonavir"></FilterOption><FilterOption id="29016" count="9" label="paclitaxel (albumin-bound nanoparticle, intravenous), Celgene"></FilterOption><FilterOption id="5369" count="9" label="ribavirin"></FilterOption><FilterOption id="54601" count="8" label="carfilzomib"></FilterOption><FilterOption id="32981" count="8" label="darunavir"></FilterOption><FilterOption id="3081" count="8" label="exemestane"></FilterOption><FilterOption id="3474" count="8" label="lamivudine"></FilterOption><FilterOption id="11519" count="8" label="mitoxantrone"></FilterOption><FilterOption id="54488" count="8" label="raltegravir"></FilterOption><FilterOption id="37370" count="7" label="azacitidine"></FilterOption><FilterOption id="53200" count="7" label="daratumumab"></FilterOption><FilterOption id="36630" count="7" label="ipilimumab"></FilterOption><FilterOption id="53227" count="7" label="obinutuzumab"></FilterOption><FilterOption id="3536" count="7" label="pemetrexed disodium"></FilterOption><FilterOption id="14493" count="7" label="tenofovir disoproxil fumarate"></FilterOption><FilterOption id="54469" count="7" label="vemurafenib"></FilterOption><FilterOption id="12150" count="7" label="vincristine sulfate (liposomal injection), Spectrum Pharmaceuticals"></FilterOption><FilterOption id="10309" count="6" label="abiraterone"></FilterOption><FilterOption id="15254" count="6" label="atazanavir"></FilterOption><FilterOption id="10388" count="6" label="cetuximab"></FilterOption><FilterOption id="4728" count="6" label="emtricitabine"></FilterOption><FilterOption id="11961" count="6" label="erlotinib"></FilterOption><FilterOption id="45841" count="6" label="lenvatinib mesylate"></FilterOption><FilterOption id="10271" count="6" label="palbociclib"></FilterOption><FilterOption id="12646" count="6" label="panitumumab"></FilterOption><FilterOption id="23625" count="6" label="peginterferon alfa-2a"></FilterOption><FilterOption id="44314" count="6" label="tamoxifen"></FilterOption><FilterOption id="6242" count="5" label="abacavir"></FilterOption><FilterOption id="3321" count="5" label="anastrozole"></FilterOption><FilterOption id="83065" count="5" label="avelumab"></FilterOption><FilterOption id="5999" count="5" label="ciclosporin, Novartis"></FilterOption><FilterOption id="59062" count="5" label="dolutegravir"></FilterOption><FilterOption id="81193" count="5" label="durvalumab"></FilterOption><FilterOption id="2871" count="5" label="irinotecan"></FilterOption><FilterOption id="37613" count="5" label="maraviroc"></FilterOption><FilterOption id="27696" count="5" label="pomalidomide"></FilterOption><FilterOption id="55305" count="4" label="binimetinib"></FilterOption><FilterOption id="2836" count="4" label="clopidogrel"></FilterOption><FilterOption id="10172" count="4" label="efavirenz"></FilterOption><FilterOption id="73843" count="4" label="encorafenib"></FilterOption><FilterOption id="53981" count="4" label="enzalutamide"></FilterOption><FilterOption id="13340" count="4" label="everolimus"></FilterOption><FilterOption id="3130" count="4" label="filgrastim"></FilterOption><FilterOption id="48319" count="4" label="idelalisib"></FilterOption><FilterOption id="66051" count="4" label="ipatasertib dihydrochloride"></FilterOption><FilterOption id="4510" count="4" label="tacrolimus"></FilterOption><FilterOption id="49219" count="4" label="tenofovir disoproxil fumarate + emtricitabine (fixed dose), Gilead Sciences"></FilterOption><FilterOption id="70678" count="4" label="xentuzumab"></FilterOption><FilterOption id="39172" count="3" label="brentuximab vedotin"></FilterOption><FilterOption id="13239" count="3" label="decitabine"></FilterOption><FilterOption id="7934" count="3" label="doxorubicin (liposomal, STEALTH), Alza"></FilterOption><FilterOption id="4563" count="3" label="doxorubicin (liposome formulation), Cephalon"></FilterOption><FilterOption id="48099" count="3" label="farletuzumab"></FilterOption><FilterOption id="11460" count="3" label="imatinib"></FilterOption><FilterOption id="3669" count="3" label="mycophenolate mofetil"></FilterOption><FilterOption id="61287" count="3" label="niraparib"></FilterOption><FilterOption id="16063" count="3" label="olaparib"></FilterOption><FilterOption id="4200" count="3" label="sirolimus"></FilterOption><FilterOption id="70199" count="3" label="taselisib"></FilterOption><FilterOption id="45562" count="3" label="tremelimumab"></FilterOption><FilterOption id="70895" count="3" label="venetoclax"></FilterOption><FilterOption id="6408" count="3" label="vinorelbine"></FilterOption><FilterOption id="99926" count="2" label="18F-GTP1"></FilterOption><FilterOption id="72538" count="2" label="abemaciclib"></FilterOption><FilterOption id="24885" count="2" label="albinterferon alfa-2b"></FilterOption><FilterOption id="69066" count="2" label="alectinib"></FilterOption><FilterOption id="2716" count="2" label="alemtuzumab"></FilterOption><FilterOption id="7867" count="2" label="amprenavir"></FilterOption><FilterOption id="66828" count="2" label="bemcentinib"></FilterOption><FilterOption id="50935" count="2" label="cabozantinib S-malate"></FilterOption><FilterOption id="44384" count="2" label="ceftriaxone"></FilterOption><FilterOption id="64231" count="2" label="copanlisib hydrochloride"></FilterOption><FilterOption id="9049" count="2" label="cytarabine (sustained release, DepoFoam), Pacira/Sigma-Tau/Pfizer/Napp Pharmaceutical"></FilterOption><FilterOption id="13486" count="2" label="entecavir"></FilterOption><FilterOption id="55085" count="2" label="filanesib"></FilterOption><FilterOption id="5202" count="2" label="gemtuzumab ozogamicin"></FilterOption></Filter><Filter label="Trial Document Source" name="trialDocumentSource" total="5"><FilterOption id="OTHER" count="424" label="Other Publications"></FilterOption><FilterOption id="PR" count="414" label="Press Releases"></FilterOption><FilterOption id="SERIAL" count="372" label="Serial Publications"></FilterOption><FilterOption id="CORPORATE" count="113" label="Corporate Publications"></FilterOption><FilterOption id="CONFERENCE" count="79" label="Conference Reports"></FilterOption></Filter><Filter label="Trial Interventions Primary Alone Name Display" name="trialInterventionsPrimaryAloneNameDisplay" total="100"><FilterOption id="72699" count="13" label="atezolizumab"></FilterOption><FilterOption id="27572" count="12" label="lenalidomide"></FilterOption><FilterOption id="52854" count="8" label="macitentan"></FilterOption><FilterOption id="14681" count="7" label="lopinavir + ritonavir"></FilterOption><FilterOption id="70667" count="7" label="pembrolizumab"></FilterOption><FilterOption id="45499" count="7" label="tofacitinib citrate (oral, inflammation), Pfizer"></FilterOption><FilterOption id="8047" count="6" label="bevacizumab"></FilterOption><FilterOption id="57369" count="6" label="etrolizumab"></FilterOption><FilterOption id="55237" count="6" label="ibrutinib"></FilterOption><FilterOption id="6736" count="6" label="rituximab"></FilterOption><FilterOption id="14163" count="5" label="adalimumab"></FilterOption><FilterOption id="83065" count="5" label="avelumab"></FilterOption><FilterOption id="3700" count="5" label="nevirapine"></FilterOption><FilterOption id="50963" count="5" label="obeticholic acid (primary biliary cholangitis), Intercept/AOP Orphan"></FilterOption><FilterOption id="54488" count="5" label="raltegravir"></FilterOption><FilterOption id="36669" count="5" label="trastuzumab emtansine"></FilterOption><FilterOption id="69066" count="4" label="alectinib"></FilterOption><FilterOption id="30379" count="4" label="bosutinib"></FilterOption><FilterOption id="24343" count="4" label="dabigatran etexilate"></FilterOption><FilterOption id="53981" count="4" label="enzalutamide"></FilterOption><FilterOption id="11961" count="4" label="erlotinib"></FilterOption><FilterOption id="6850" count="4" label="infliximab"></FilterOption><FilterOption id="37613" count="4" label="maraviroc"></FilterOption><FilterOption id="54804" count="4" label="nivolumab"></FilterOption><FilterOption id="16063" count="4" label="olaparib"></FilterOption><FilterOption id="43738" count="4" label="pazopanib"></FilterOption><FilterOption id="88619" count="4" label="sofosbuvir + velpatasvir (fixed dose combination, HCV), Gilead"></FilterOption><FilterOption id="12973" count="4" label="sunitinib"></FilterOption><FilterOption id="75324" count="4" label="tenofovir alafenamide + emtricitabine + cobicistat + elvitegravir (FDC, HIV), Gilead/ Japan Tobacco"></FilterOption><FilterOption id="42858" count="4" label="ustekinumab"></FilterOption><FilterOption id="7781" count="3" label="aripiprazole"></FilterOption><FilterOption id="100097" count="3" label="bictegravir + emtricitabine + tenofovir alafenamide (HIV-1 infection), Gilead"></FilterOption><FilterOption id="72743" count="3" label="birtamimab"></FilterOption><FilterOption id="15954" count="3" label="bortezomib"></FilterOption><FilterOption id="5871" count="3" label="bosentan"></FilterOption><FilterOption id="8955" count="3" label="carvedilol"></FilterOption><FilterOption id="62277" count="3" label="emtricitabine + tenofovir disoproxil fumarate + elvitegravir + cobicistat (single tablet regimen, HIV/AIDS), Gilead Sciences"></FilterOption><FilterOption id="89500" count="3" label="esketamine (intranasal), Janssen Research &amp; Development"></FilterOption><FilterOption id="4567" count="3" label="etanercept"></FilterOption><FilterOption id="13340" count="3" label="everolimus"></FilterOption><FilterOption id="53840" count="3" label="gantenerumab"></FilterOption><FilterOption id="3199" count="3" label="gemcitabine"></FilterOption><FilterOption id="42857" count="3" label="golimumab"></FilterOption><FilterOption id="56776" count="3" label="SHP-647"></FilterOption><FilterOption id="4529" count="3" label="temozolomide"></FilterOption><FilterOption id="50038" count="3" label="tenofovir disoproxil fumarate + emtricitabine + efavirenz, Gilead/BMS/Merck &amp; Co"></FilterOption><FilterOption id="50961" count="2" label="abobotulinumtoxinA"></FilterOption><FilterOption id="84728" count="2" label="abrocitinib"></FilterOption><FilterOption id="64893" count="2" label="acetylsalicylic acid + simvastatin + ramipril (oral, cardiovascular disease), Ferrer Internacional"></FilterOption><FilterOption id="6306" count="2" label="aldesleukin"></FilterOption><FilterOption id="6893" count="2" label="alteplase"></FilterOption><FilterOption id="44374" count="2" label="amiodarone"></FilterOption><FilterOption id="15254" count="2" label="atazanavir"></FilterOption><FilterOption id="39209" count="2" label="axitinib"></FilterOption><FilterOption id="37370" count="2" label="azacitidine"></FilterOption><FilterOption id="94069" count="2" label="BAY-1213790"></FilterOption><FilterOption id="31831" count="2" label="belimumab"></FilterOption><FilterOption id="34140" count="2" label="blinatumomab"></FilterOption><FilterOption id="105633" count="2" label="bumetanide (autism), Servier/ Neurochlore"></FilterOption><FilterOption id="5929" count="2" label="bupropion (oral sustained release), GlaxoSmithKline"></FilterOption><FilterOption id="55798" count="2" label="crizotinib"></FilterOption><FilterOption id="63587" count="2" label="Cx-611"></FilterOption><FilterOption id="9049" count="2" label="cytarabine (sustained release, DepoFoam), Pacira/Sigma-Tau/Pfizer/Napp Pharmaceutical"></FilterOption><FilterOption id="63586" count="2" label="darvadstrocel"></FilterOption><FilterOption id="54116" count="2" label="disitertide"></FilterOption><FilterOption id="2953" count="2" label="docetaxel"></FilterOption><FilterOption id="81193" count="2" label="durvalumab"></FilterOption><FilterOption id="15593" count="2" label="eculizumab"></FilterOption><FilterOption id="51255" count="2" label="edoxaban"></FilterOption><FilterOption id="10172" count="2" label="efavirenz"></FilterOption><FilterOption id="55066" count="2" label="elafibranor"></FilterOption><FilterOption id="58762" count="2" label="empagliflozin"></FilterOption><FilterOption id="16156" count="2" label="emricasan (oral, islet transplant rejection/liver disease), Novartis"></FilterOption><FilterOption id="4728" count="2" label="emtricitabine"></FilterOption><FilterOption id="13486" count="2" label="entecavir"></FilterOption><FilterOption id="60512" count="2" label="erdafitinib"></FilterOption><FilterOption id="87805" count="2" label="faricimab"></FilterOption><FilterOption id="78759" count="2" label="infliximab biosimilar, Celltrion/Nippon Kayaku/Hospira/Orion/EGIS Gyogyszergyar"></FilterOption><FilterOption id="67653" count="2" label="inotersen"></FilterOption><FilterOption id="2714" count="2" label="inotuzumab ozogamicin"></FilterOption><FilterOption id="36630" count="2" label="ipilimumab"></FilterOption><FilterOption id="55488" count="2" label="lanabecestat"></FilterOption><FilterOption id="9313" count="2" label="lanreotide"></FilterOption><FilterOption id="52798" count="2" label="lebrikizumab"></FilterOption><FilterOption id="62073" count="2" label="mongersen"></FilterOption><FilterOption id="60575" count="2" label="murepavadin"></FilterOption><FilterOption id="50341" count="2" label="neratinib"></FilterOption><FilterOption id="3705" count="2" label="nicotine"></FilterOption><FilterOption id="51160" count="2" label="nintedanib"></FilterOption><FilterOption id="48638" count="2" label="ocrelizumab"></FilterOption><FilterOption id="3738" count="2" label="olanzapine"></FilterOption><FilterOption id="2534" count="2" label="omalizumab"></FilterOption><FilterOption id="3803" count="2" label="paclitaxel"></FilterOption><FilterOption id="10271" count="2" label="palbociclib"></FilterOption><FilterOption id="54422" count="2" label="QPI-1002"></FilterOption><FilterOption id="63895" count="2" label="ralinepag"></FilterOption><FilterOption id="4199" count="2" label="ranolazine"></FilterOption><FilterOption id="32677" count="2" label="rivaroxaban"></FilterOption><FilterOption id="81852" count="2" label="selonsertib"></FilterOption><FilterOption id="7707" count="2" label="seocalcitol"></FilterOption></Filter><Filter label="Trial Interventions Control In Regimen Name Display" name="trialInterventionsControlInRegimenNameDisplay" total="100"><FilterOption id="44383" count="27" label="carboplatin"></FilterOption><FilterOption id="3199" count="21" label="gemcitabine"></FilterOption><FilterOption id="3803" count="21" label="paclitaxel"></FilterOption><FilterOption id="2953" count="16" label="docetaxel"></FilterOption><FilterOption id="6386" count="14" label="trastuzumab"></FilterOption><FilterOption id="12205" count="12" label="capecitabine"></FilterOption><FilterOption id="6736" count="12" label="rituximab"></FilterOption><FilterOption id="7310" count="9" label="ritonavir"></FilterOption><FilterOption id="49219" count="9" label="tenofovir disoproxil fumarate + emtricitabine (fixed dose), Gilead Sciences"></FilterOption><FilterOption id="8047" count="8" label="bevacizumab"></FilterOption><FilterOption id="15954" count="7" label="bortezomib"></FilterOption><FilterOption id="3072" count="7" label="etoposide phosphate"></FilterOption><FilterOption id="3536" count="7" label="pemetrexed disodium"></FilterOption><FilterOption id="32981" count="6" label="darunavir"></FilterOption><FilterOption id="13022" count="6" label="epirubicin"></FilterOption><FilterOption id="14681" count="6" label="lopinavir + ritonavir"></FilterOption><FilterOption id="3792" count="6" label="oxaliplatin"></FilterOption><FilterOption id="10309" count="5" label="abiraterone"></FilterOption><FilterOption id="27572" count="5" label="lenalidomide"></FilterOption><FilterOption id="28532" count="5" label="pertuzumab"></FilterOption><FilterOption id="15254" count="4" label="atazanavir"></FilterOption><FilterOption id="47000" count="4" label="bendamustine"></FilterOption><FilterOption id="7934" count="4" label="doxorubicin (liposomal, STEALTH), Alza"></FilterOption><FilterOption id="48181" count="4" label="lamivudine + abacavir, GlaxoSmithKline"></FilterOption><FilterOption id="33591" count="4" label="lapatinib"></FilterOption><FilterOption id="29016" count="4" label="paclitaxel (albumin-bound nanoparticle, intravenous), Celgene"></FilterOption><FilterOption id="10172" count="3" label="efavirenz"></FilterOption><FilterOption id="6156" count="3" label="fludarabine"></FilterOption><FilterOption id="11519" count="3" label="mitoxantrone"></FilterOption><FilterOption id="53227" count="3" label="obinutuzumab"></FilterOption><FilterOption id="23625" count="3" label="peginterferon alfa-2a"></FilterOption><FilterOption id="54488" count="3" label="raltegravir"></FilterOption><FilterOption id="5369" count="3" label="ribavirin"></FilterOption><FilterOption id="14493" count="3" label="tenofovir disoproxil fumarate"></FilterOption><FilterOption id="8050" count="3" label="thalidomide, Celgene"></FilterOption><FilterOption id="12150" count="3" label="vincristine sulfate (liposomal injection), Spectrum Pharmaceuticals"></FilterOption><FilterOption id="6408" count="3" label="vinorelbine"></FilterOption><FilterOption id="72699" count="2" label="atezolizumab"></FilterOption><FilterOption id="37370" count="2" label="azacitidine"></FilterOption><FilterOption id="54601" count="2" label="carfilzomib"></FilterOption><FilterOption id="2836" count="2" label="clopidogrel"></FilterOption><FilterOption id="62275" count="2" label="cobicistat"></FilterOption><FilterOption id="72148" count="2" label="darunavir + cobicistat (fixed dose, HIV infection), Janssen R&amp;D/ Gilead"></FilterOption><FilterOption id="59062" count="2" label="dolutegravir"></FilterOption><FilterOption id="51371" count="2" label="elvitegravir"></FilterOption><FilterOption id="4728" count="2" label="emtricitabine"></FilterOption><FilterOption id="30682" count="2" label="etravirine"></FilterOption><FilterOption id="13340" count="2" label="everolimus"></FilterOption><FilterOption id="3081" count="2" label="exemestane"></FilterOption><FilterOption id="24471" count="2" label="fosamprenavir"></FilterOption><FilterOption id="3474" count="2" label="lamivudine"></FilterOption><FilterOption id="3700" count="2" label="nevirapine"></FilterOption><FilterOption id="4196" count="2" label="ramipril"></FilterOption><FilterOption id="52857" count="2" label="rilpivirine hydrochloride"></FilterOption><FilterOption id="4259" count="2" label="saquinavir"></FilterOption><FilterOption id="44313" count="2" label="simvastatin"></FilterOption><FilterOption id="15130" count="2" label="vinflunine"></FilterOption><FilterOption id="44375" count="2" label="warfarin"></FilterOption><FilterOption id="6242" count="1" label="abacavir"></FilterOption><FilterOption id="14163" count="1" label="adalimumab"></FilterOption><FilterOption id="7867" count="1" label="amprenavir"></FilterOption><FilterOption id="3321" count="1" label="anastrozole"></FilterOption><FilterOption id="74263" count="1" label="atazanavir sulfate + cobicistat (fixed-dose combination, HIV infection), Bristol-Myers Squibb"></FilterOption><FilterOption id="16915" count="1" label="calcium levofolinate"></FilterOption><FilterOption id="12544" count="1" label="caspofungin"></FilterOption><FilterOption id="44384" count="1" label="ceftriaxone"></FilterOption><FilterOption id="5999" count="1" label="ciclosporin, Novartis"></FilterOption><FilterOption id="44370" count="1" label="clindamycin"></FilterOption><FilterOption id="9049" count="1" label="cytarabine (sustained release, DepoFoam), Pacira/Sigma-Tau/Pfizer/Napp Pharmaceutical"></FilterOption><FilterOption id="13239" count="1" label="decitabine"></FilterOption><FilterOption id="2935" count="1" label="didanosine"></FilterOption><FilterOption id="4563" count="1" label="doxorubicin (liposome formulation), Cephalon"></FilterOption><FilterOption id="13486" count="1" label="entecavir"></FilterOption><FilterOption id="53981" count="1" label="enzalutamide"></FilterOption><FilterOption id="28773" count="1" label="eribulin mesylate"></FilterOption><FilterOption id="3130" count="1" label="filgrastim"></FilterOption><FilterOption id="44292" count="1" label="fluconazole"></FilterOption><FilterOption id="3195" count="1" label="ganciclovir (oral), Roche Bioscience"></FilterOption><FilterOption id="36630" count="1" label="ipilimumab"></FilterOption><FilterOption id="2871" count="1" label="irinotecan"></FilterOption><FilterOption id="65757" count="1" label="JNJ-3989"></FilterOption><FilterOption id="100866" count="1" label="JNJ-56136379"></FilterOption><FilterOption id="26574" count="1" label="lamivudine + abacavir + zidovudine, GSK"></FilterOption><FilterOption id="16696" count="1" label="lamivudine + zidovudine, GlaxoSmithKline"></FilterOption><FilterOption id="3488" count="1" label="leflunomide"></FilterOption><FilterOption id="2784" count="1" label="letrozole"></FilterOption><FilterOption id="37613" count="1" label="maraviroc"></FilterOption><FilterOption id="61287" count="1" label="niraparib"></FilterOption><FilterOption id="54804" count="1" label="nivolumab"></FilterOption><FilterOption id="52139" count="1" label="ofloxacin"></FilterOption><FilterOption id="21374" count="1" label="pegfilgrastim"></FilterOption><FilterOption id="4481" count="1" label="stavudine"></FilterOption><FilterOption id="12973" count="1" label="sunitinib"></FilterOption><FilterOption id="44314" count="1" label="tamoxifen"></FilterOption><FilterOption id="4529" count="1" label="temozolomide"></FilterOption><FilterOption id="40532" count="1" label="tenofovir alafenamide fumarate"></FilterOption><FilterOption id="36332" count="1" label="ticagrelor"></FilterOption><FilterOption id="4577" count="1" label="topotecan"></FilterOption><FilterOption id="25182" count="1" label="valganciclovir"></FilterOption><FilterOption id="44401" count="1" label="vancomycin"></FilterOption></Filter><Filter label="Trial Category" name="trialCategory" total="16"><FilterOption id="4" count="854" label="Small molecule"></FilterOption><FilterOption id="3" count="443" label="Biological"></FilterOption><FilterOption id="8" count="107" label="Medical device"></FilterOption><FilterOption id="9" count="60" label="Medical procedure"></FilterOption><FilterOption id="5" count="33" label="Vaccine"></FilterOption><FilterOption id="16" count="32" label="Behavioral intervention"></FilterOption><FilterOption id="15" count="28" label="Radiation therapy"></FilterOption><FilterOption id="6" count="21" label="Cell therapy"></FilterOption><FilterOption id="7" count="19" label="Gene therapy"></FilterOption><FilterOption id="11" count="18" label="Dietary supplement"></FilterOption><FilterOption id="18" count="12" label="Pathophysiology"></FilterOption><FilterOption id="14" count="10" label="Diagnostic"></FilterOption><FilterOption id="17" count="9" label="Biomarker identification"></FilterOption><FilterOption id="19" count="2" label="Surgical procedure"></FilterOption><FilterOption id="10" count="1" label="Borderline product"></FilterOption><FilterOption id="13" count="1" label="Hospital solutions"></FilterOption></Filter><Filter label="Trial Outcome Available" name="trialOutcomesAvailable" total="2"><FilterOption id="NO" count="678" label="No"></FilterOption><FilterOption id="YES" count="559" label="Yes"></FilterOption></Filter><Filter label="Trial Actions Primary Interventions Primary" name="trialActionsPrimaryInterventionsPrimary" total="100"><FilterOption id="14007" count="57" label="Programmed cell death ligand 1 inhibitor"></FilterOption><FilterOption id="5085" count="45" label="B-lymphocyte antigen CD20 inhibitor"></FilterOption><FilterOption id="67136" count="45" label="Programmed cell death protein 1 inhibitor"></FilterOption><FilterOption id="740" count="43" label="Epidermal growth factor receptor antagonist"></FilterOption><FilterOption id="3756" count="38" label="Erbb2 tyrosine kinase receptor inhibitor"></FilterOption><FilterOption id="1832" count="38" label="Nucleoside reverse transcriptase inhibitor"></FilterOption><FilterOption id="3808" count="34" label="Kit tyrosine kinase inhibitor"></FilterOption><FilterOption id="142" count="33" label="Topoisomerase II inhibitor"></FilterOption><FilterOption id="1016" count="32" label="HIV-1 reverse transcriptase inhibitor"></FilterOption><FilterOption id="4917" count="31" label="Proteasome inhibitor"></FilterOption><FilterOption id="3848" count="31" label="VEGF-2 receptor antagonist"></FilterOption><FilterOption id="138" count="30" label="DNA polymerase inhibitor"></FilterOption><FilterOption id="3846" count="30" label="VEGF-1 receptor antagonist"></FilterOption><FilterOption id="204" count="29" label="HIV protease inhibitor"></FilterOption><FilterOption id="7588" count="29" label="HIV-1 integrase inhibitor"></FilterOption><FilterOption id="3850" count="29" label="VEGF-3 receptor antagonist"></FilterOption><FilterOption id="768" count="27" label="HIV-1 protease inhibitor"></FilterOption><FilterOption id="12521" count="25" label="VEGF ligand inhibitor"></FilterOption><FilterOption id="3806" count="23" label="Flt3 tyrosine kinase inhibitor"></FilterOption><FilterOption id="48492" count="23" label="PDGF receptor beta antagonist"></FilterOption><FilterOption id="372" count="23" label="Thymidylate synthase inhibitor"></FilterOption><FilterOption id="948" count="22" label="PDGF receptor antagonist"></FilterOption><FilterOption id="76469" count="21" label="26S proteasome complex inhibitor"></FilterOption><FilterOption id="76" count="21" label="Aromatase inhibitor"></FilterOption><FilterOption id="10240" count="20" label="mTOR inhibitor"></FilterOption><FilterOption id="4548" count="20" label="Raf B protein kinase inhibitor"></FilterOption><FilterOption id="3682" count="19" label="FGF1 receptor antagonist"></FilterOption><FilterOption id="3688" count="19" label="FGF3 receptor antagonist"></FilterOption><FilterOption id="48489" count="19" label="PDGF receptor alpha antagonist"></FilterOption><FilterOption id="7424" count="18" label="Cytochrome P450 3A4 inhibitor"></FilterOption><FilterOption id="286" count="18" label="Estrogen receptor antagonist"></FilterOption><FilterOption id="38283" count="17" label="Poly ADP ribose polymerase 1 inhibitor"></FilterOption><FilterOption id="38286" count="17" label="Poly ADP ribose polymerase 2 inhibitor"></FilterOption><FilterOption id="3816" count="17" label="RET tyrosine kinase receptor family inhibitor"></FilterOption><FilterOption id="1722" count="17" label="VEGF receptor antagonist"></FilterOption><FilterOption id="3754" count="16" label="EGFR family tyrosine kinase receptor inhibitor"></FilterOption><FilterOption id="4762" count="16" label="MEK-1 protein kinase inhibitor"></FilterOption><FilterOption id="4764" count="16" label="MEK-2 protein kinase inhibitor"></FilterOption><FilterOption id="1833" count="16" label="Non-nucleoside reverse transcriptase inhibitor"></FilterOption><FilterOption id="4760" count="15" label="MEK protein kinase inhibitor"></FilterOption><FilterOption id="4314" count="14" label="Cyclin-dependent kinase-4 inhibitor"></FilterOption><FilterOption id="4318" count="14" label="Cyclin-dependent kinase-6 inhibitor"></FilterOption><FilterOption id="770" count="14" label="Endothelin ET-A receptor antagonist"></FilterOption><FilterOption id="3685" count="14" label="FGF2 receptor antagonist"></FilterOption><FilterOption id="3592" count="13" label="Btk tyrosine kinase inhibitor"></FilterOption><FilterOption id="5482" count="13" label="Cytotoxic T-lymphocyte protein-4 inhibitor"></FilterOption><FilterOption id="3154" count="12" label="CSF-1 antagonist"></FilterOption><FilterOption id="3562" count="12" label="Jak1 tyrosine kinase inhibitor"></FilterOption><FilterOption id="385" count="12" label="Protein tyrosine kinase inhibitor"></FilterOption><FilterOption id="3576" count="12" label="Src tyrosine kinase inhibitor"></FilterOption><FilterOption id="541" count="12" label="Tubulin receptor antagonist"></FilterOption><FilterOption id="60" count="11" label="Androgen receptor antagonist"></FilterOption><FilterOption id="4010" count="11" label="Calcineurin inhibitor"></FilterOption><FilterOption id="771" count="11" label="Endothelin ET-B receptor antagonist"></FilterOption><FilterOption id="214" count="11" label="Interferon alpha 2 ligand"></FilterOption><FilterOption id="13571" count="10" label="Bcr protein inhibitor"></FilterOption><FilterOption id="6512" count="10" label="DNA methyltransferase inhibitor"></FilterOption><FilterOption id="675" count="10" label="Hepatocyte growth factor receptor antagonist"></FilterOption><FilterOption id="3584" count="10" label="Lck tyrosine kinase inhibitor"></FilterOption><FilterOption id="2506" count="10" label="PARP modulator"></FilterOption><FilterOption id="3818" count="10" label="Ret tyrosine kinase receptor inhibitor"></FilterOption><FilterOption id="3524" count="9" label="Abl tyrosine kinase inhibitor"></FilterOption><FilterOption id="5136" count="9" label="ADP ribosyl cyclase-1 inhibitor"></FilterOption><FilterOption id="3736" count="9" label="Anaplastic lymphoma kinase receptor inhibitor"></FilterOption><FilterOption id="3107" count="9" label="CCR5 chemokine antagonist"></FilterOption><FilterOption id="5027" count="9" label="CD4 agonist"></FilterOption><FilterOption id="82444" count="9" label="DNA helicase inhibitor"></FilterOption><FilterOption id="51708" count="9" label="DNA polymerase alpha inhibitor"></FilterOption><FilterOption id="6830" count="9" label="DNA primase inhibitor"></FilterOption><FilterOption id="120" count="9" label="Factor Xa antagonist"></FilterOption><FilterOption id="168" count="9" label="FGF receptor antagonist"></FilterOption><FilterOption id="11219" count="9" label="HIV-1 gp120 protein inhibitor"></FilterOption><FilterOption id="3560" count="9" label="JAK tyrosine kinase inhibitor"></FilterOption><FilterOption id="3566" count="9" label="Jak3 tyrosine kinase inhibitor"></FilterOption><FilterOption id="76090" count="9" label="mTOR complex 1 inhibitor"></FilterOption><FilterOption id="347" count="9" label="RNA polymerase inhibitor"></FilterOption><FilterOption id="381" count="9" label="TNF alpha ligand inhibitor"></FilterOption><FilterOption id="721" count="9" label="TNF binding agent"></FilterOption><FilterOption id="1513" count="9" label="Topoisomerase II modulator"></FilterOption><FilterOption id="3851" count="8" label="ALK tyrosine kinase receptor family inhibitor"></FilterOption><FilterOption id="621" count="8" label="Amyloid protein deposition inhibitor"></FilterOption><FilterOption id="7418" count="8" label="Cytochrome P450 3 inhibitor"></FilterOption><FilterOption id="135" count="8" label="DHFR inhibitor"></FilterOption><FilterOption id="431" count="8" label="DNA gyrase inhibitor"></FilterOption><FilterOption id="144" count="8" label="Dopamine receptor agonist"></FilterOption><FilterOption id="3755" count="8" label="Erbb2 tyrosine kinase receptor modulator"></FilterOption><FilterOption id="3760" count="8" label="Erbb4 tyrosine kinase receptor inhibitor"></FilterOption><FilterOption id="3691" count="8" label="FGF4 receptor antagonist"></FilterOption><FilterOption id="71851" count="8" label="HIV GAG POL polyprotein inhibitor"></FilterOption><FilterOption id="12395" count="8" label="HIV GAG protein inhibitor"></FilterOption><FilterOption id="205" count="8" label="HMG CoA reductase inhibitor"></FilterOption><FilterOption id="2950" count="8" label="Integrin alpha-4/beta-7 antagonist"></FilterOption><FilterOption id="2507" count="8" label="PARP inhibitor"></FilterOption><FilterOption id="327" count="8" label="PGI2 agonist"></FilterOption><FilterOption id="38289" count="8" label="Poly ADP ribose polymerase 3 inhibitor"></FilterOption><FilterOption id="19467" count="8" label="Retinoblastoma associated protein modulator"></FilterOption><FilterOption id="346" count="8" label="Ribonucleotide reductase inhibitor"></FilterOption><FilterOption id="141" count="8" label="Topoisomerase I inhibitor"></FilterOption><FilterOption id="814" count="8" label="Tubulin modulator"></FilterOption><FilterOption id="58716" count="8" label="Ubiquitin inhibitor"></FilterOption></Filter><Filter label="Trial Company Collaborator" name="trialCompaniesCollaborator" total="100"><FilterOption id="18767" count="19" label="Pfizer Inc"></FilterOption><FilterOption id="19446" count="19" label="Roche Holding AG"></FilterOption><FilterOption id="1039423" count="18" label="Hospital Clinic of Barcelona"></FilterOption><FilterOption id="1017818" count="17" label="Instituto de Salud Carlos III"></FilterOption><FilterOption id="20300" count="16" label="Takeda Pharmaceutical Co Ltd"></FilterOption><FilterOption id="15331" count="15" label="Celgene Corp"></FilterOption><FilterOption id="28355" count="12" label="GlaxoSmithKline plc"></FilterOption><FilterOption id="14109" count="11" label="Amgen Inc"></FilterOption><FilterOption id="14190" count="11" label="AstraZeneca plc"></FilterOption><FilterOption id="15065" count="11" label="Bristol-Myers Squibb Co"></FilterOption><FilterOption id="1065900" count="10" label="Apices Soluciones, S.L."></FilterOption><FilterOption id="1059823" count="10" label="Merck Sharp &amp; Dohme Corp"></FilterOption><FilterOption id="23137" count="10" label="Novartis AG"></FilterOption><FilterOption id="17810" count="9" label="Eli Lilly &amp; Co"></FilterOption><FilterOption id="19453" count="9" label="Genentech Inc"></FilterOption><FilterOption id="1039086" count="9" label="Germans Trias i Pujol Hospital"></FilterOption><FilterOption id="1017771" count="9" label="Institut d'Investigacions Biomediques August Pi I Sunyer"></FilterOption><FilterOption id="1013295" count="8" label="Astellas Pharma Inc"></FilterOption><FilterOption id="26178" count="8" label="F Hoffmann-La Roche AG"></FilterOption><FilterOption id="1067538" count="8" label="Janssen Research &amp; Development LLC"></FilterOption><FilterOption id="13601" count="7" label="Abbott Laboratories"></FilterOption><FilterOption id="19620" count="6" label="Eisai Inc"></FilterOption><FilterOption id="1059977" count="6" label="European Commission"></FilterOption><FilterOption id="1053612" count="6" label="Fundacion Clinic per a la Recerca Biomédica"></FilterOption><FilterOption id="18077" count="6" label="Merck &amp; Co Inc"></FilterOption><FilterOption id="1097931" count="5" label="Andalusian Initiative for Advanced Therapies"></FilterOption><FilterOption id="25902" count="5" label="Array BioPharma Inc"></FilterOption><FilterOption id="14455" count="5" label="Bayer AG"></FilterOption><FilterOption id="1045910" count="5" label="Hospital Clinico San Carlos"></FilterOption><FilterOption id="17416" count="5" label="Janssen LP"></FilterOption><FilterOption id="17401" count="5" label="Janssen-Cilag SA"></FilterOption><FilterOption id="20519" count="5" label="National Cancer Institute"></FilterOption><FilterOption id="1067340" count="5" label="Pivotal SL"></FilterOption><FilterOption id="25554" count="5" label="Seattle Genetics Inc"></FilterOption><FilterOption id="1061163" count="4" label="Abbott Vascular"></FilterOption><FilterOption id="1072507" count="4" label="AbbVie Inc"></FilterOption><FilterOption id="1042255" count="4" label="Breast International Group"></FilterOption><FilterOption id="1041980" count="4" label="Charite University"></FilterOption><FilterOption id="1017506" count="4" label="Daiichi Sankyo Co Ltd"></FilterOption><FilterOption id="22676" count="4" label="Exelixis Inc"></FilterOption><FilterOption id="1039087" count="4" label="Fundacio Lluita Contra La Sida"></FilterOption><FilterOption id="28959" count="4" label="Hannover Medical School"></FilterOption><FilterOption id="1040862" count="4" label="Hospital General Universitario Gregorio Marañon"></FilterOption><FilterOption id="1003065" count="4" label="Hospital Vall D'Hebron"></FilterOption><FilterOption id="18438" count="4" label="Medical Research Council"></FilterOption><FilterOption id="18101" count="4" label="Merck KGaA"></FilterOption><FilterOption id="1074428" count="4" label="Ministerio de Economia y Competitividad"></FilterOption><FilterOption id="1053488" count="4" label="NCIC Clinical Trials Group"></FilterOption><FilterOption id="1116693" count="4" label="Productos Roche, S.A. de C.V."></FilterOption><FilterOption id="1009547" count="4" label="Sanofi SA"></FilterOption><FilterOption id="1114403" count="4" label="TFS Trial Form Support"></FilterOption><FilterOption id="21279" count="4" label="Universite Catholique de Louvain"></FilterOption><FilterOption id="19864" count="3" label="Adir &amp; Co"></FilterOption><FilterOption id="1038808" count="3" label="Azienda Ospedaliera di Padova"></FilterOption><FilterOption id="1052569" count="3" label="B Braun Surgical Sa"></FilterOption><FilterOption id="1103224" count="3" label="Centro Hospitalar do Porto"></FilterOption><FilterOption id="15414" count="3" label="Chugai Pharmaceutical Co Ltd"></FilterOption><FilterOption id="1091345" count="3" label="Complejo Hospitalario de Navarra"></FilterOption><FilterOption id="1069026" count="3" label="Effice Servicios Para la Investigacion"></FilterOption><FilterOption id="1062976" count="3" label="Europath Biosciences Sl"></FilterOption><FilterOption id="1084506" count="3" label="European Network of Gynaecological Oncological Trial Groups"></FilterOption><FilterOption id="1063203" count="3" label="Fondazione IRCCS Ca' Granda-Ospedale Maggiore Policlinico"></FilterOption><FilterOption id="1073758" count="3" label="Fondo de Investigacion Sanitaria"></FilterOption><FilterOption id="13738" count="3" label="Fresenius SE &amp; Co KGaA"></FilterOption><FilterOption id="1045896" count="3" label="Fundacion Para La Investigacion Hospital La Fe"></FilterOption><FilterOption id="1017513" count="3" label="Fundació Clínic Per A La Recerca Biomèdica"></FilterOption><FilterOption id="1033112" count="3" label="Hospital Universitario 12 de Octubre"></FilterOption><FilterOption id="1006639" count="3" label="Hospital Universitario Ramon y Cajal"></FilterOption><FilterOption id="1072647" count="3" label="Institut de Recherches Internationales Servier (France)"></FilterOption><FilterOption id="1056690" count="3" label="Institut Investigació Biomèdica Bellvitge"></FilterOption><FilterOption id="1101929" count="3" label="IQVIA Holdings Inc"></FilterOption><FilterOption id="17392" count="3" label="Janssen-Cilag Ltd"></FilterOption><FilterOption id="21110" count="3" label="Karolinska Institutet"></FilterOption><FilterOption id="1075878" count="3" label="Klinikum der Universität Köln"></FilterOption><FilterOption id="22137" count="3" label="Ludwig-Maximilians University of Munich"></FilterOption><FilterOption id="1175391" count="3" label="Medivation LLC"></FilterOption><FilterOption id="21404" count="3" label="MorphoSys AG"></FilterOption><FilterOption id="19087" count="3" label="Pierre Fabre SA"></FilterOption><FilterOption id="1114888" count="3" label="Quartz Bio SA"></FilterOption><FilterOption id="1119200" count="3" label="Sanofi-Aventis Research and Development"></FilterOption><FilterOption id="1058089" count="3" label="Servicio Andaluz De Salud"></FilterOption><FilterOption id="1096345" count="3" label="Servicio Cántabro De Salud"></FilterOption><FilterOption id="21991" count="3" label="Takeda Oncology"></FilterOption><FilterOption id="1054559" count="3" label="TESARO Inc"></FilterOption><FilterOption id="1119462" count="3" label="The Cyprus Foundation For Muscular Dystrophy Research"></FilterOption><FilterOption id="1104050" count="3" label="UCB Biopharma SPRL"></FilterOption><FilterOption id="20625" count="3" label="Universita degli Studi di Milano"></FilterOption><FilterOption id="1003992" count="3" label="Universitat de Barcelona"></FilterOption><FilterOption id="1042041" count="3" label="University Hospital, Brest"></FilterOption><FilterOption id="24222" count="3" label="University of Geneva"></FilterOption><FilterOption id="25460" count="3" label="University of Granada"></FilterOption><FilterOption id="DOL1000156" count="3" label="University of Szeged"></FilterOption><FilterOption id="21082" count="3" label="Walter and Eliza Hall Institute of Medical Research"></FilterOption><FilterOption id="1150199" count="2" label="A2F-Associates Limited"></FilterOption><FilterOption id="1012474" count="2" label="AC Immune SA"></FilterOption><FilterOption id="1117605" count="2" label="Adknoma Health Research"></FilterOption><FilterOption id="1150200" count="2" label="alphabioresearch"></FilterOption><FilterOption id="23948" count="2" label="Assistance Publique Hopitaux de Paris"></FilterOption><FilterOption id="1037956" count="2" label="Astellas Pharma Global Development Inc"></FilterOption><FilterOption id="1045129" count="2" label="Australasian Leukaemia and Lymphoma Group"></FilterOption></Filter><Filter label="Trial Actions Secondary Interventions Control" name="trialActionsSecondaryInterventionsControl" total="94"><FilterOption id="1545" count="171" label="Anticancer"></FilterOption><FilterOption id="767" count="73" label="Cell cycle inhibitor"></FilterOption><FilterOption id="1569" count="55" label="Anticancer antimetabolite"></FilterOption><FilterOption id="55685" count="54" label="Anticancer monoclonal antibody"></FilterOption><FilterOption id="140" count="51" label="DNA synthesis inhibitor"></FilterOption><FilterOption id="991" count="47" label="Antiviral"></FilterOption><FilterOption id="2953" count="45" label="Anti-inflammatory"></FilterOption><FilterOption id="50" count="43" label="Anticancer alkylating agent"></FilterOption><FilterOption id="1589" count="41" label="Apoptosis stimulator"></FilterOption><FilterOption id="62255" count="38" label="Anticancer protein kinase inhibitor"></FilterOption><FilterOption id="2575" count="31" label="Microtubule inhibitor"></FilterOption><FilterOption id="2576" count="31" label="Microtubule stabilizer"></FilterOption><FilterOption id="61" count="28" label="Angiogenesis inhibitor"></FilterOption><FilterOption id="2660" count="27" label="Vasoprotectant"></FilterOption><FilterOption id="7293" count="21" label="Synergist"></FilterOption><FilterOption id="750" count="15" label="DNA intercalator"></FilterOption><FilterOption id="1596" count="13" label="Immunomodulator"></FilterOption><FilterOption id="747" count="12" label="HIV replication inhibitor"></FilterOption><FilterOption id="393" count="10" label="Immunostimulant"></FilterOption><FilterOption id="7761" count="10" label="T-lymphocyte stimulator"></FilterOption><FilterOption id="396" count="9" label="Immunosuppressant"></FilterOption><FilterOption id="62254" count="8" label="Anticancer hormone antagonist"></FilterOption><FilterOption id="382" count="8" label="TNF alpha synthesis inhibitor"></FilterOption><FilterOption id="2657" count="7" label="Antihypertensive"></FilterOption><FilterOption id="805" count="7" label="Folate modulator"></FilterOption><FilterOption id="1594" count="6" label="Antibacterial"></FilterOption><FilterOption id="937" count="5" label="Androgen synthesis inhibitor"></FilterOption><FilterOption id="659" count="5" label="Coagulation inhibitor"></FilterOption><FilterOption id="32411" count="5" label="Hepatitis B virus replication inhibitor"></FilterOption><FilterOption id="2946" count="4" label="Analgesic"></FilterOption><FilterOption id="1748" count="4" label="Fungicide"></FilterOption><FilterOption id="399" count="4" label="Hypoglycemic agent"></FilterOption><FilterOption id="312" count="4" label="Platelet aggregation inhibitor"></FilterOption><FilterOption id="439" count="4" label="RNA synthesis inhibitor"></FilterOption><FilterOption id="15184" count="4" label="Systemic antipsoriatic product"></FilterOption><FilterOption id="1532" count="4" label="Viral replication inhibitor"></FilterOption><FilterOption id="70" count="3" label="Anticonvulsant agent"></FilterOption><FilterOption id="71" count="3" label="Antihypercholesterolemic agent"></FilterOption><FilterOption id="2947" count="3" label="Antiparkinsonian"></FilterOption><FilterOption id="563" count="3" label="Microtubule modulator"></FilterOption><FilterOption id="15148" count="3" label="Ocular antineovascularisation agent"></FilterOption><FilterOption id="5704" count="2" label="B-lymphocyte adhesion inhibitor"></FilterOption><FilterOption id="5710" count="2" label="B-lymphocyte migration inhibitor"></FilterOption><FilterOption id="104" count="2" label="Bacterial cell wall synthesis inhibitor"></FilterOption><FilterOption id="1538" count="2" label="Bacterial protein synthesis inhibitor"></FilterOption><FilterOption id="2659" count="2" label="Cardioprotectant"></FilterOption><FilterOption id="5580" count="2" label="Chemotaxis inhibitor"></FilterOption><FilterOption id="7211" count="2" label="CNS diagnostic agent"></FilterOption><FilterOption id="11593" count="2" label="DNA repair inhibitor"></FilterOption><FilterOption id="664" count="2" label="Fibrosuppressant"></FilterOption><FilterOption id="610" count="2" label="Hematopoietic stimulator"></FilterOption><FilterOption id="38211" count="2" label="Human insulin fast acting product"></FilterOption><FilterOption id="211" count="2" label="Inotropic agent"></FilterOption><FilterOption id="1129" count="2" label="Non-steroid hormone receptor antagonist"></FilterOption><FilterOption id="5555" count="2" label="PET contrast agent"></FilterOption><FilterOption id="5720" count="2" label="Radiodiagnostic"></FilterOption><FilterOption id="1479" count="2" label="RNA synthesis modulator"></FilterOption><FilterOption id="26035" count="2" label="siRNA agent"></FilterOption><FilterOption id="15187" count="2" label="Systemic dermatological antibacterial product"></FilterOption><FilterOption id="15178" count="2" label="Systemic dermatological antifungal product"></FilterOption><FilterOption id="388" count="2" label="Vasodilator"></FilterOption><FilterOption id="882" count="1" label="5-HETE modulator"></FilterOption><FilterOption id="449" count="1" label="Antiarrhythmic agent"></FilterOption><FilterOption id="2941" count="1" label="Antidepressant"></FilterOption><FilterOption id="15135" count="1" label="Antiglaucoma agent"></FilterOption><FilterOption id="955" count="1" label="Antimicrobial permeability enhancer"></FilterOption><FilterOption id="2638" count="1" label="Antiparasitic"></FilterOption><FilterOption id="2942" count="1" label="Anxiolytic"></FilterOption><FilterOption id="38206" count="1" label="Biguanide antidiabetic product"></FilterOption><FilterOption id="863" count="1" label="Bile acid modulator"></FilterOption><FilterOption id="743" count="1" label="Bile acid transport inhibitor"></FilterOption><FilterOption id="646" count="1" label="Bronchodilator"></FilterOption><FilterOption id="1260" count="1" label="Calcium metabolism modulator"></FilterOption><FilterOption id="1537" count="1" label="Cephalosporin"></FilterOption><FilterOption id="2833" count="1" label="CMV replication inhibitor"></FilterOption><FilterOption id="2939" count="1" label="CNS modulator"></FilterOption><FilterOption id="124" count="1" label="Collagen synthesis inhibitor"></FilterOption><FilterOption id="137" count="1" label="Diuretic agent"></FilterOption><FilterOption id="839" count="1" label="Ergosterol modulator"></FilterOption><FilterOption id="7251" count="1" label="Female contraceptive"></FilterOption><FilterOption id="686" count="1" label="Folic acid analog"></FilterOption><FilterOption id="1668" count="1" label="General anesthetic"></FilterOption><FilterOption id="3980" count="1" label="HIV fusion inhibitor"></FilterOption><FilterOption id="539" count="1" label="Immunotoxin"></FilterOption><FilterOption id="3246" count="1" label="Insulin release stimulator"></FilterOption><FilterOption id="1540" count="1" label="Macrolide antibiotic"></FilterOption><FilterOption id="695" count="1" label="Metastasis inhibitor"></FilterOption><FilterOption id="1615" count="1" label="Neuroprotectant"></FilterOption><FilterOption id="285" count="1" label="Norepinephrine uptake inhibitor"></FilterOption><FilterOption id="15128" count="1" label="Ophthalmological agent"></FilterOption><FilterOption id="472" count="1" label="Phosphate lowering agent"></FilterOption><FilterOption id="463" count="1" label="Ribosome binding agent"></FilterOption><FilterOption id="5717" count="1" label="Sensitizer"></FilterOption><FilterOption id="38205" count="1" label="Sulphonylurea antidiabetic product"></FilterOption></Filter><Filter label="Biomarker Type" name="trialBiomarkerTypes" total="7"><FilterOption id="37" count="649" label="Proteomic"></FilterOption><FilterOption id="38" count="634" label="Genomic"></FilterOption><FilterOption id="31" count="261" label="Physiological"></FilterOption><FilterOption id="32" count="255" label="Biochemical"></FilterOption><FilterOption id="75" count="233" label="Cellular"></FilterOption><FilterOption id="40" count="93" label="Structural (imaging)"></FilterOption><FilterOption id="39" count="92" label="Anthropomorphic"></FilterOption></Filter><Filter label="Biomarker Role" name="trialBiomarkerRoles" total="4"><FilterOption id="695863716" count="633" label="Therapeutic effect marker"></FilterOption><FilterOption id="1571666123" count="348" label="Disease marker"></FilterOption><FilterOption id="730490367" count="170" label="Toxic effect marker"></FilterOption><FilterOption id="3242045531" count="7" label="Not determined"></FilterOption></Filter><Filter label="Interventions" name="trialInterventions" total="100"><FilterOption id="72699" count="39" label="atezolizumab"></FilterOption><FilterOption id="3803" count="37" label="paclitaxel"></FilterOption><FilterOption id="44383" count="33" label="carboplatin"></FilterOption><FilterOption id="6736" count="32" label="rituximab"></FilterOption><FilterOption id="3199" count="31" label="gemcitabine"></FilterOption><FilterOption id="27572" count="28" label="lenalidomide"></FilterOption><FilterOption id="8047" count="25" label="bevacizumab"></FilterOption><FilterOption id="6386" count="22" label="trastuzumab"></FilterOption><FilterOption id="15954" count="21" label="bortezomib"></FilterOption><FilterOption id="2953" count="21" label="docetaxel"></FilterOption><FilterOption id="70667" count="20" label="pembrolizumab"></FilterOption><FilterOption id="7310" count="18" label="ritonavir"></FilterOption><FilterOption id="3072" count="17" label="etoposide phosphate"></FilterOption><FilterOption id="3792" count="16" label="oxaliplatin"></FilterOption><FilterOption id="12205" count="15" label="capecitabine"></FilterOption><FilterOption id="14681" count="15" label="lopinavir + ritonavir"></FilterOption><FilterOption id="2784" count="14" label="letrozole"></FilterOption><FilterOption id="54804" count="14" label="nivolumab"></FilterOption><FilterOption id="28532" count="14" label="pertuzumab"></FilterOption><FilterOption id="54488" count="14" label="raltegravir"></FilterOption><FilterOption id="3313" count="11" label="fulvestrant"></FilterOption><FilterOption id="55237" count="11" label="ibrutinib"></FilterOption><FilterOption id="29016" count="11" label="paclitaxel (albumin-bound nanoparticle, intravenous), Celgene"></FilterOption><FilterOption id="83065" count="10" label="avelumab"></FilterOption><FilterOption id="47000" count="10" label="bendamustine"></FilterOption><FilterOption id="56544" count="10" label="cobimetinib"></FilterOption><FilterOption id="11961" count="10" label="erlotinib"></FilterOption><FilterOption id="5369" count="10" label="ribavirin"></FilterOption><FilterOption id="37370" count="9" label="azacitidine"></FilterOption><FilterOption id="32981" count="9" label="darunavir"></FilterOption><FilterOption id="13022" count="9" label="epirubicin"></FilterOption><FilterOption id="3081" count="9" label="exemestane"></FilterOption><FilterOption id="6156" count="9" label="fludarabine"></FilterOption><FilterOption id="36630" count="9" label="ipilimumab"></FilterOption><FilterOption id="3474" count="9" label="lamivudine"></FilterOption><FilterOption id="37613" count="9" label="maraviroc"></FilterOption><FilterOption id="11519" count="9" label="mitoxantrone"></FilterOption><FilterOption id="14493" count="9" label="tenofovir disoproxil fumarate"></FilterOption><FilterOption id="54469" count="9" label="vemurafenib"></FilterOption><FilterOption id="15254" count="8" label="atazanavir"></FilterOption><FilterOption id="54601" count="8" label="carfilzomib"></FilterOption><FilterOption id="4728" count="8" label="emtricitabine"></FilterOption><FilterOption id="52854" count="8" label="macitentan"></FilterOption><FilterOption id="10271" count="8" label="palbociclib"></FilterOption><FilterOption id="45499" count="8" label="tofacitinib citrate (oral, inflammation), Pfizer"></FilterOption><FilterOption id="53200" count="7" label="daratumumab"></FilterOption><FilterOption id="53981" count="7" label="enzalutamide"></FilterOption><FilterOption id="13340" count="7" label="everolimus"></FilterOption><FilterOption id="53227" count="7" label="obinutuzumab"></FilterOption><FilterOption id="16063" count="7" label="olaparib"></FilterOption><FilterOption id="23625" count="7" label="peginterferon alfa-2a"></FilterOption><FilterOption id="3536" count="7" label="pemetrexed disodium"></FilterOption><FilterOption id="27696" count="7" label="pomalidomide"></FilterOption><FilterOption id="44314" count="7" label="tamoxifen"></FilterOption><FilterOption id="4529" count="7" label="temozolomide"></FilterOption><FilterOption id="49219" count="7" label="tenofovir disoproxil fumarate + emtricitabine (fixed dose), Gilead Sciences"></FilterOption><FilterOption id="36669" count="7" label="trastuzumab emtansine"></FilterOption><FilterOption id="12150" count="7" label="vincristine sulfate (liposomal injection), Spectrum Pharmaceuticals"></FilterOption><FilterOption id="6242" count="6" label="abacavir"></FilterOption><FilterOption id="10309" count="6" label="abiraterone"></FilterOption><FilterOption id="14163" count="6" label="adalimumab"></FilterOption><FilterOption id="3321" count="6" label="anastrozole"></FilterOption><FilterOption id="10388" count="6" label="cetuximab"></FilterOption><FilterOption id="59062" count="6" label="dolutegravir"></FilterOption><FilterOption id="10172" count="6" label="efavirenz"></FilterOption><FilterOption id="57369" count="6" label="etrolizumab"></FilterOption><FilterOption id="45841" count="6" label="lenvatinib mesylate"></FilterOption><FilterOption id="50341" count="6" label="neratinib"></FilterOption><FilterOption id="50963" count="6" label="obeticholic acid (primary biliary cholangitis), Intercept/AOP Orphan"></FilterOption><FilterOption id="12646" count="6" label="panitumumab"></FilterOption><FilterOption id="69066" count="5" label="alectinib"></FilterOption><FilterOption id="55305" count="5" label="binimetinib"></FilterOption><FilterOption id="5999" count="5" label="ciclosporin, Novartis"></FilterOption><FilterOption id="24343" count="5" label="dabigatran etexilate"></FilterOption><FilterOption id="81193" count="5" label="durvalumab"></FilterOption><FilterOption id="3130" count="5" label="filgrastim"></FilterOption><FilterOption id="3700" count="5" label="nevirapine"></FilterOption><FilterOption id="61287" count="5" label="niraparib"></FilterOption><FilterOption id="43738" count="5" label="pazopanib"></FilterOption><FilterOption id="12973" count="5" label="sunitinib"></FilterOption><FilterOption id="30379" count="4" label="bosutinib"></FilterOption><FilterOption id="2836" count="4" label="clopidogrel"></FilterOption><FilterOption id="9049" count="4" label="cytarabine (sustained release, DepoFoam), Pacira/Sigma-Tau/Pfizer/Napp Pharmaceutical"></FilterOption><FilterOption id="73843" count="4" label="encorafenib"></FilterOption><FilterOption id="13486" count="4" label="entecavir"></FilterOption><FilterOption id="48319" count="4" label="idelalisib"></FilterOption><FilterOption id="6850" count="4" label="infliximab"></FilterOption><FilterOption id="66051" count="4" label="ipatasertib dihydrochloride"></FilterOption><FilterOption id="2871" count="4" label="irinotecan"></FilterOption><FilterOption id="16696" count="4" label="lamivudine + zidovudine, GlaxoSmithKline"></FilterOption><FilterOption id="4200" count="4" label="sirolimus"></FilterOption><FilterOption id="88619" count="4" label="sofosbuvir + velpatasvir (fixed dose combination, HCV), Gilead"></FilterOption><FilterOption id="29831" count="4" label="sorafenib"></FilterOption><FilterOption id="4510" count="4" label="tacrolimus"></FilterOption><FilterOption id="75324" count="4" label="tenofovir alafenamide + emtricitabine + cobicistat + elvitegravir (FDC, HIV), Gilead/ Japan Tobacco"></FilterOption><FilterOption id="42858" count="4" label="ustekinumab"></FilterOption><FilterOption id="70678" count="4" label="xentuzumab"></FilterOption><FilterOption id="72538" count="3" label="abemaciclib"></FilterOption><FilterOption id="6306" count="3" label="aldesleukin"></FilterOption><FilterOption id="72743" count="3" label="birtamimab"></FilterOption></Filter><Filter label="Endpoint Index Primary" name="trialEndpointIndexPrimary" total="100"><FilterOption id="8713" count="26" label="Breast tumor - Assessment of Progression Free Survival (PFS)"></FilterOption><FilterOption id="8489" count="23" label="Lung tumor - Assessment of Progression Free Survival (PFS)"></FilterOption><FilterOption id="9213" count="22" label="HIV infection - Assessment of Viral Load - Assessment of HIV RNA levels"></FilterOption><FilterOption id="7908" count="21" label="Leukemia - Assessment of Response Rates (RR) - Assessment of Complete Response"></FilterOption><FilterOption id="9247" count="20" label="HIV infection - Assessment of Safety and Tolerability - Assessment of adverse events/serious adverse events"></FilterOption><FilterOption id="7547" count="19" label="Lymphoma - Assessment of Progression Free Survival (PFS)"></FilterOption><FilterOption id="8721" count="18" label="Breast tumor - Assessment of Response Rates (RR) - Assessment of Complete Response"></FilterOption><FilterOption id="9153" count="18" label="Lung tumor - Imaging/Radiological Assessments - Assessment by Response Evaluation Criteria in Solid Tumors (RECIST) Criteria"></FilterOption><FilterOption id="8140" count="17" label="Leukemia - Protocol Specified Other Endpoints - Assessment of Clinical Efficacy"></FilterOption><FilterOption id="7563" count="15" label="Lymphoma - Assessment of Response Rates (RR) - Assessment of Complete Response"></FilterOption><FilterOption id="7360" count="15" label="Multiple myeloma - Assessment of Progression Free Survival (PFS)"></FilterOption><FilterOption id="8719" count="14" label="Breast tumor - Assessment of Response Rates (RR) - Assessment of Overall/Objective Response Rate (ORR)"></FilterOption><FilterOption id="7367" count="14" label="Multiple myeloma - Assessment of Response Rates (RR) - Assessment of Overall/Objective Response Rate (ORR)"></FilterOption><FilterOption id="10830" count="14" label="Ovary tumor - Assessment of Progression Free Survival (PFS)"></FilterOption><FilterOption id="8714" count="13" label="Breast tumor - Assessment of Disease Free Survival (DFS)"></FilterOption><FilterOption id="9215" count="13" label="HIV infection - Assessment of CD4 Cell Responses - Assessment of CD4 cell count/percentage"></FilterOption><FilterOption id="9218" count="13" label="HIV infection - Assessment of Immune Response"></FilterOption><FilterOption id="7909" count="12" label="Leukemia - Assessment of Response Rates (RR) - Assessment of Overall/Objective Response Rate (ORR)"></FilterOption><FilterOption id="7906" count="12" label="Leukemia - Assessment of Response Rates (RR)"></FilterOption><FilterOption id="8744" count="11" label="Breast tumor - Assessment of Disease Progression"></FilterOption><FilterOption id="8720" count="11" label="Breast tumor - Assessment of Response Rates (RR) - Assessment of Partial Response (PR)"></FilterOption><FilterOption id="2622" count="11" label="Coronary artery disease - Assessment of Mortality/Death Rates - Cardiovascular mortality"></FilterOption><FilterOption id="3736" count="11" label="Hepatitis C virus infection - Assessment of Sustained Virologic Response (SVR)"></FilterOption><FilterOption id="7879" count="11" label="Leukemia - Assessment of Overall Survival (OS)"></FilterOption><FilterOption id="8078" count="11" label="Leukemia - Assessment of adverse events"></FilterOption><FilterOption id="8505" count="11" label="Lung tumor - Assessment of Objective Response - Assessment of objective response rate(ORR)"></FilterOption><FilterOption id="42921" count="11" label="Other gastrointestinal disease - Assessment of Safety and Tolerability"></FilterOption><FilterOption id="7049" count="11" label="Prostate tumor - Assessment of Progression Free Survival (PFS)"></FilterOption><FilterOption id="8998" count="10" label="Breast tumor - Assessment of adverse events"></FilterOption><FilterOption id="2492" count="10" label="Coronary artery disease - Assessment of Cardiovascular Events - Acute/New Myocardial infarction (MI)/MI (Q-wave and non-Q wave)"></FilterOption><FilterOption id="8523" count="10" label="Lung tumor - Assessment of Disease Progression"></FilterOption><FilterOption id="6924" count="10" label="Melanoma - Assessment of Progression Free Survival (PFS)"></FilterOption><FilterOption id="10545" count="10" label="Renal cell carcinoma - Assessment of Progression Free Survival (PFS)"></FilterOption><FilterOption id="15287" count="10" label="Solid tumor - Assessment of adverse events"></FilterOption><FilterOption id="8759" count="9" label="Breast tumor - Patient Reported Outcomes/Quality of Life Assessments"></FilterOption><FilterOption id="9272" count="9" label="HIV infection - Assessment of Mortality/Death Rates"></FilterOption><FilterOption id="9212" count="9" label="HIV infection - Assessment of Viral Load"></FilterOption><FilterOption id="9242" count="9" label="HIV infection - Assessment of lipid profiles"></FilterOption><FilterOption id="7891" count="9" label="Leukemia - Assessment of Progression Free Survival (PFS)"></FilterOption><FilterOption id="6940" count="9" label="Melanoma - Assessment of Response Rates (RR) - Assessment of overall/objective response rate"></FilterOption><FilterOption id="6972" count="9" label="Melanoma - Imaging/Radiological Assessments - Assessment by Response Evaluation Criteria in Solid Tumors (RECIST) Criteria"></FilterOption><FilterOption id="7372" count="9" label="Multiple myeloma - Assessment of Response Rates (RR) - Assessment of Partial Response (PR)"></FilterOption><FilterOption id="25660" count="9" label="Pulmonary artery hypertension - Assessment of Six Minute Walk Test"></FilterOption><FilterOption id="15293" count="9" label="Solid tumor - Assessment of Safety and Tolerability - Assessment of dose limiting toxicity"></FilterOption><FilterOption id="15907" count="9" label="Ulcerative colitis - Ulcerative Colitis Assessed by Activity Indices - Assessment by Mayo clinic score (MCS)/ disease activity index (DAI)"></FilterOption><FilterOption id="11773" count="8" label="Bladder cancer - Assessment of Safety and Tolerability - Assessment of adverse events/serious adverse events"></FilterOption><FilterOption id="8163" count="8" label="Colorectal tumor - Assessment of Progression Free Survival (PFS)"></FilterOption><FilterOption id="6863" count="8" label="Hepatitis C virus infection - Assessment of Viral Load/Viral Kinetics"></FilterOption><FilterOption id="7916" count="8" label="Leukemia - Assessment of Response Rates (RR) - Assessment of hematologic/bone marrow response"></FilterOption><FilterOption id="9155" count="8" label="Lung tumor - Assessment of Safety and Tolerability - Assessment of dose limiting toxicity"></FilterOption><FilterOption id="15285" count="8" label="Solid tumor - Assessment of Safety and Tolerability"></FilterOption><FilterOption id="17356" count="7" label="Anemia - Assessment of adverse events"></FilterOption><FilterOption id="9510" count="7" label="Atrial fibrillation - Assessment of Hemorrhagic Complications - Assessment of major bleeding events"></FilterOption><FilterOption id="11949" count="7" label="Bladder cancer - Assessment of Safety and Tolerability - Assessment of dose limiting toxicity"></FilterOption><FilterOption id="8754" count="7" label="Breast tumor - Assessment of Mortality/Death Rates"></FilterOption><FilterOption id="8996" count="7" label="Breast tumor - Assessment of Safety and Tolerability"></FilterOption><FilterOption id="9310" count="7" label="Breast tumor - Imaging/Radiological Assessments"></FilterOption><FilterOption id="9238" count="7" label="HIV infection - Assessment of Laboratory/Diagnostic Measures"></FilterOption><FilterOption id="9246" count="7" label="HIV infection - Assessment of Safety and Tolerability"></FilterOption><FilterOption id="9255" count="7" label="HIV infection - Assessment of Therapy Related Outcomes - Assessment of treatment discontinuation"></FilterOption><FilterOption id="8109" count="7" label="Leukemia - Assessment of Mortality/Death Rates"></FilterOption><FilterOption id="7907" count="7" label="Leukemia - Assessment of Response Rates (RR) - Assessment of Partial Response (PR)"></FilterOption><FilterOption id="7914" count="7" label="Leukemia - Assessment of Response Rates (RR) - Assessment of cytogenetic response"></FilterOption><FilterOption id="8481" count="7" label="Lung tumor - Assessment of Overall Survival (OS)"></FilterOption><FilterOption id="9415" count="7" label="Lymphoma - Assessment of Disease Progression"></FilterOption><FilterOption id="7680" count="7" label="Lymphoma - Assessment of adverse events"></FilterOption><FilterOption id="7374" count="7" label="Multiple myeloma - Assessment of Therapy Related Outcomes"></FilterOption><FilterOption id="43670" count="7" label="Other gastrointestinal disease - Assessment of adverse events"></FilterOption><FilterOption id="10224" count="7" label="Parkinsons disease - Assessment of Parkinson's Disease ON-OFF States - Assessment of OFF state of Parkinson's disease"></FilterOption><FilterOption id="7045" count="7" label="Prostate tumor - Assessment of Overall Survival (OS)"></FilterOption><FilterOption id="15212" count="7" label="Solid tumor - Assessment of Response Rates (RR) - Assessment of objective response rate (ORR)"></FilterOption><FilterOption id="26827" count="7" label="Solid tumor - Imaging/Radiological Assessments - Assessment by Response Evaluation Criteria in Solid Tumors (RECIST) Criteria"></FilterOption><FilterOption id="2332" count="6" label="Alzheimers disease - Assessment of Dementia - Clinical dementia rating sum of boxes (CDR-SOB)"></FilterOption><FilterOption id="11778" count="6" label="Bladder cancer - Assessment of Mortality/Death Rates"></FilterOption><FilterOption id="11786" count="6" label="Bladder cancer - Assessment of Therapy Related Outcomes - Assessment of imaging/diagnostic tests"></FilterOption><FilterOption id="2619" count="6" label="Coronary artery disease - Assessment of Cardiovascular Events - Assessment of major adverse cardiac events (MACEs)"></FilterOption><FilterOption id="12048" count="6" label="Hepatobiliary system tumor - Assessment of Overall Survival (OS)"></FilterOption><FilterOption id="9174" count="6" label="HIV infection - Assessment of AIDS Defining Events(CDC Criteria)"></FilterOption><FilterOption id="7898" count="6" label="Leukemia - Assessment of Survival - Assessment of event free survival (EFS)"></FilterOption><FilterOption id="8514" count="6" label="Lung tumor - Assessment of Response Rates (RR) - Assessment of Complete Response"></FilterOption><FilterOption id="8513" count="6" label="Lung tumor - Assessment of Response Rates (RR) - Assessment of Partial Response (PR)"></FilterOption><FilterOption id="8640" count="6" label="Lung tumor - Assessment of Safety and Tolerability - Adverse events as graded by CTCAE/CTC"></FilterOption><FilterOption id="7569" count="6" label="Lymphoma - Assessment of Response Rates (RR) - Assessment of Overall/Objective Response Rate (ORR)"></FilterOption><FilterOption id="7373" count="6" label="Multiple myeloma - Assessment of Response Rates (RR) - Assessment of Complete Response"></FilterOption><FilterOption id="7188" count="6" label="Prostate tumor - Assessment of Laboratory/Diagnostic Measures - Assessments by radiography/imaging"></FilterOption><FilterOption id="7211" count="6" label="Prostate tumor - Assessment of Mortality/Death Rates"></FilterOption><FilterOption id="10664" count="6" label="Renal cell carcinoma - Assessment of Safety and Tolerability - Assessment of dose limiting toxicity"></FilterOption><FilterOption id="12148" count="6" label="Stomach tumor - Assessment of Overall Survival (OS)"></FilterOption><FilterOption id="15936" count="6" label="Ulcerative colitis - Assessment of Safety and Tolerability - Assessment of adverse events/serious adverse events"></FilterOption><FilterOption id="2981" count="5" label="Acute coronary syndrome - Assessment of Mortality/Death Rates - Cardiovascular mortality"></FilterOption><FilterOption id="9504" count="5" label="Atrial fibrillation - Assessment of Cerebrovascular Events - Assessment of ischemic stroke"></FilterOption><FilterOption id="9519" count="5" label="Atrial fibrillation - Assessment of Thrombotic/Thromboembolic Events - Assessment of systemic thromboembolism"></FilterOption><FilterOption id="11793" count="5" label="Bladder cancer - Assessment of Disease Progression"></FilterOption><FilterOption id="11717" count="5" label="Bladder cancer - Assessment of Overall Survival (OS)"></FilterOption><FilterOption id="8730" count="5" label="Breast tumor - Assessment of Response Rates (RR) - Assessment of histo-pathologic response"></FilterOption><FilterOption id="2703" count="5" label="Coronary artery disease - Assessment of Vascular Indices or Parameters - Assessment of target lesion revascularization (TLR)"></FilterOption><FilterOption id="6339" count="5" label="Crohns disease - Crohn's Disease Activity Assessed by Indices/Scores - Crohn's disease activity index (CDAI) score"></FilterOption><FilterOption id="8077" count="5" label="Leukemia - Assessment of Safety and Tolerability"></FilterOption><FilterOption id="6952" count="5" label="Melanoma - Assessment of Disease Progression"></FilterOption><FilterOption id="46305" count="5" label="Other gastrointestinal disease - Assessment of Liver Functions - Alkaline phosphatase levels"></FilterOption></Filter><Filter label="Sponsors/Collaborators" name="trialCompanies" total="100"><FilterOption id="19446" count="118" label="Roche Holding AG"></FilterOption><FilterOption id="1039423" count="115" label="Hospital Clinic of Barcelona"></FilterOption><FilterOption id="26178" count="87" label="F Hoffmann-La Roche AG"></FilterOption><FilterOption id="18767" count="80" label="Pfizer Inc"></FilterOption><FilterOption id="15331" count="50" label="Celgene Corp"></FilterOption><FilterOption id="1038736" count="46" label="PETHEMA Foundation"></FilterOption><FilterOption id="16450" count="38" label="Gilead Sciences Inc"></FilterOption><FilterOption id="14881" count="31" label="Boehringer Ingelheim International GmbH"></FilterOption><FilterOption id="19453" count="29" label="Genentech Inc"></FilterOption><FilterOption id="1067538" count="28" label="Janssen Research &amp; Development LLC"></FilterOption><FilterOption id="1059823" count="28" label="Merck Sharp &amp; Dohme Corp"></FilterOption><FilterOption id="15414" count="27" label="Chugai Pharmaceutical Co Ltd"></FilterOption><FilterOption id="15065" count="20" label="Bristol-Myers Squibb Co"></FilterOption><FilterOption id="1053612" count="20" label="Fundacion Clinic per a la Recerca Biomédica"></FilterOption><FilterOption id="20300" count="20" label="Takeda Pharmaceutical Co Ltd"></FilterOption><FilterOption id="1017818" count="19" label="Instituto de Salud Carlos III"></FilterOption><FilterOption id="14455" count="18" label="Bayer AG"></FilterOption><FilterOption id="1039086" count="17" label="Germans Trias i Pujol Hospital"></FilterOption><FilterOption id="1042061" count="17" label="Spanish Breast Cancer Research Group"></FilterOption><FilterOption id="27847" count="16" label="Boston Scientific Corp"></FilterOption><FilterOption id="17810" count="16" label="Eli Lilly &amp; Co"></FilterOption><FilterOption id="1091809" count="16" label="Janssen-Cilag International NV (BE)"></FilterOption><FilterOption id="14109" count="14" label="Amgen Inc"></FilterOption><FilterOption id="14190" count="14" label="AstraZeneca plc"></FilterOption><FilterOption id="22546" count="14" label="Boehringer Ingelheim GmbH"></FilterOption><FilterOption id="23780" count="13" label="Actelion Ltd"></FilterOption><FilterOption id="1017771" count="13" label="Institut d'Investigacions Biomediques August Pi I Sunyer"></FilterOption><FilterOption id="1042371" count="13" label="Spanish Oncology Genito-Urinary Group"></FilterOption><FilterOption id="21991" count="13" label="Takeda Oncology"></FilterOption><FilterOption id="1017513" count="12" label="Fundació Clínic Per A La Recerca Biomèdica"></FilterOption><FilterOption id="28355" count="12" label="GlaxoSmithKline plc"></FilterOption><FilterOption id="1043659" count="12" label="Grupo Espanol Multidisciplinario del Cancer Digestivo"></FilterOption><FilterOption id="23137" count="12" label="Novartis AG"></FilterOption><FilterOption id="13601" count="11" label="Abbott Laboratories"></FilterOption><FilterOption id="1013295" count="11" label="Astellas Pharma Inc"></FilterOption><FilterOption id="1065900" count="10" label="Apices Soluciones, S.L."></FilterOption><FilterOption id="19620" count="10" label="Eisai Inc"></FilterOption><FilterOption id="1052299" count="10" label="Fundación Pública Andaluza Para La Gestión De La Investigación En Salud De Sevilla"></FilterOption><FilterOption id="1103352" count="9" label="Boehringer Ingelheim Espana Sa"></FilterOption><FilterOption id="1020322" count="9" label="Daiichi Sankyo Inc"></FilterOption><FilterOption id="23119" count="9" label="European Organisation for Research and Treatment of Cancer (EORTC)"></FilterOption><FilterOption id="1051470" count="9" label="Fundacio Clinic Per A La Recerca Biomedica"></FilterOption><FilterOption id="1042252" count="9" label="Grupo Espanol de Linfomas y Transplante Autologo de Medula Osea"></FilterOption><FilterOption id="1003065" count="9" label="Hospital Vall D'Hebron"></FilterOption><FilterOption id="28611" count="8" label="Actelion Pharmaceuticals Ltd"></FilterOption><FilterOption id="25902" count="8" label="Array BioPharma Inc"></FilterOption><FilterOption id="22554" count="8" label="Boehringer Ingelheim BV"></FilterOption><FilterOption id="22586" count="8" label="Boehringer Ingelheim Corp"></FilterOption><FilterOption id="22563" count="8" label="Boehringer Ingelheim Ltd"></FilterOption><FilterOption id="17259" count="8" label="Ipsen"></FilterOption><FilterOption id="18077" count="8" label="Merck &amp; Co Inc"></FilterOption><FilterOption id="18101" count="8" label="Merck KGaA"></FilterOption><FilterOption id="1122528" count="8" label="SCS Boehringer Ingelheim Comm.V"></FilterOption><FilterOption id="25554" count="8" label="Seattle Genetics Inc"></FilterOption><FilterOption id="22598" count="8" label="Unilfarma Lda"></FilterOption><FilterOption id="22549" count="7" label="Boehringer Ingelheim Austria GmbH"></FilterOption><FilterOption id="1040940" count="7" label="Hospital Universitari de Bellvitge"></FilterOption><FilterOption id="20519" count="7" label="National Cancer Institute"></FilterOption><FilterOption id="22560" count="6" label="Boehringer Ingelheim Italia SpA"></FilterOption><FilterOption id="1059977" count="6" label="European Commission"></FilterOption><FilterOption id="1045910" count="6" label="Hospital Clinico San Carlos"></FilterOption><FilterOption id="1072647" count="6" label="Institut de Recherches Internationales Servier (France)"></FilterOption><FilterOption id="1009440" count="6" label="Intercept Pharmaceuticals Inc"></FilterOption><FilterOption id="15938" count="6" label="Millennium Pharmaceuticals Ltd"></FilterOption><FilterOption id="1097931" count="5" label="Andalusian Initiative for Advanced Therapies"></FilterOption><FilterOption id="1063251" count="5" label="BeiGene Co Ltd"></FilterOption><FilterOption id="1005244" count="5" label="Biogen Inc"></FilterOption><FilterOption id="22555" count="5" label="Boehringer Ingelheim Ellas AE"></FilterOption><FilterOption id="22556" count="5" label="Boehringer Ingelheim France SARL"></FilterOption><FilterOption id="1056497" count="5" label="CETLAM Group"></FilterOption><FilterOption id="1035512" count="5" label="EMD Serono Inc"></FilterOption><FilterOption id="1046331" count="5" label="Fundacion SEIMC-GESIDA"></FilterOption><FilterOption id="1046875" count="5" label="Grupo Espanol de Estudio, Tratamiento y Otras Estrategias Experimentales en Tumores Solidos"></FilterOption><FilterOption id="1040862" count="5" label="Hospital General Universitario Gregorio Marañon"></FilterOption><FilterOption id="17401" count="5" label="Janssen-Cilag SA"></FilterOption><FilterOption id="1053488" count="5" label="NCIC Clinical Trials Group"></FilterOption><FilterOption id="19063" count="5" label="Pharmacyclics Inc"></FilterOption><FilterOption id="1067340" count="5" label="Pivotal SL"></FilterOption><FilterOption id="1091820" count="5" label="Roche China Co Ltd"></FilterOption><FilterOption id="1090417" count="5" label="Roche Singapore Pte Ltd"></FilterOption><FilterOption id="1009547" count="5" label="Sanofi SA"></FilterOption><FilterOption id="1045513" count="5" label="Spanish Lung Cancer Group"></FilterOption><FilterOption id="1073757" count="5" label="Spanish Society of Cardiology"></FilterOption><FilterOption id="22545" count="4" label="Boehringer Ingelheim AB"></FilterOption><FilterOption id="1122527" count="4" label="Boehringer Ingelheim Finland Ky"></FilterOption><FilterOption id="1042255" count="4" label="Breast International Group"></FilterOption><FilterOption id="1067616" count="4" label="Clinica Universidad de Navarra"></FilterOption><FilterOption id="1017506" count="4" label="Daiichi Sankyo Co Ltd"></FilterOption><FilterOption id="22676" count="4" label="Exelixis Inc"></FilterOption><FilterOption id="16118" count="4" label="Ferrer Internacional SA"></FilterOption><FilterOption id="1073758" count="4" label="Fondo de Investigacion Sanitaria"></FilterOption><FilterOption id="1079783" count="4" label="FUNDACIÓ INSTITUT DE RECERCA DE L'HOSPITAL DE LA SANTA CREU I SANT PAU"></FilterOption><FilterOption id="1056260" count="4" label="Grupo Espanol de Investigacion en Cancer de Ovario"></FilterOption><FilterOption id="1069025" count="4" label="Grupo Espanol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa"></FilterOption><FilterOption id="28959" count="4" label="Hannover Medical School"></FilterOption><FilterOption id="1006639" count="4" label="Hospital Universitario Ramon y Cajal"></FilterOption><FilterOption id="1056690" count="4" label="Institut Investigació Biomèdica Bellvitge"></FilterOption><FilterOption id="17392" count="4" label="Janssen-Cilag Ltd"></FilterOption><FilterOption id="1084801" count="4" label="Medica Scientia Innovation Research"></FilterOption><FilterOption id="18438" count="4" label="Medical Research Council"></FilterOption></Filter><Filter label="Last Changed Date By Day" name="trialDateChangeLastByDay" total="100"><FilterOption count="36" label="2019-01-24"></FilterOption><FilterOption count="24" label="2018-10-14"></FilterOption><FilterOption count="24" label="2019-01-25"></FilterOption><FilterOption count="24" label="2019-01-26"></FilterOption><FilterOption count="23" label="2019-07-02"></FilterOption><FilterOption count="22" label="2019-06-27"></FilterOption><FilterOption count="21" label="2019-06-19"></FilterOption><FilterOption count="20" label="2018-10-13"></FilterOption><FilterOption count="20" label="2018-10-15"></FilterOption><FilterOption count="20" label="2019-07-03"></FilterOption><FilterOption count="19" label="2019-06-20"></FilterOption><FilterOption count="18" label="2019-06-21"></FilterOption><FilterOption count="17" label="2019-06-14"></FilterOption><FilterOption count="16" label="2019-03-07"></FilterOption><FilterOption count="16" label="2019-06-28"></FilterOption><FilterOption count="15" label="2018-10-12"></FilterOption><FilterOption count="15" label="2019-06-26"></FilterOption><FilterOption count="15" label="2019-07-01"></FilterOption><FilterOption count="14" label="2019-06-07"></FilterOption><FilterOption count="13" label="2019-06-25"></FilterOption><FilterOption count="12" label="2019-05-17"></FilterOption><FilterOption count="12" label="2019-06-13"></FilterOption><FilterOption count="10" label="2013-12-02"></FilterOption><FilterOption count="10" label="2019-05-23"></FilterOption><FilterOption count="9" label="2019-06-06"></FilterOption><FilterOption count="9" label="2019-06-12"></FilterOption><FilterOption count="8" label="2019-05-07"></FilterOption><FilterOption count="8" label="2019-05-24"></FilterOption><FilterOption count="8" label="2019-05-27"></FilterOption><FilterOption count="8" label="2019-06-10"></FilterOption><FilterOption count="8" label="2019-06-11"></FilterOption><FilterOption count="8" label="2019-06-22"></FilterOption><FilterOption count="8" label="2019-06-24"></FilterOption><FilterOption count="7" label="2018-07-07"></FilterOption><FilterOption count="7" label="2018-10-16"></FilterOption><FilterOption count="7" label="2018-12-12"></FilterOption><FilterOption count="7" label="2019-04-22"></FilterOption><FilterOption count="6" label="2013-09-13"></FilterOption><FilterOption count="6" label="2018-06-23"></FilterOption><FilterOption count="6" label="2018-12-13"></FilterOption><FilterOption count="6" label="2018-12-14"></FilterOption><FilterOption count="6" label="2019-02-08"></FilterOption><FilterOption count="6" label="2019-04-15"></FilterOption><FilterOption count="6" label="2019-04-23"></FilterOption><FilterOption count="5" label="2018-05-26"></FilterOption><FilterOption count="5" label="2019-01-09"></FilterOption><FilterOption count="5" label="2019-02-04"></FilterOption><FilterOption count="5" label="2019-02-20"></FilterOption><FilterOption count="5" label="2019-03-20"></FilterOption><FilterOption count="5" label="2019-03-21"></FilterOption><FilterOption count="5" label="2019-04-05"></FilterOption><FilterOption count="5" label="2019-04-12"></FilterOption><FilterOption count="5" label="2019-05-10"></FilterOption><FilterOption count="5" label="2019-05-13"></FilterOption><FilterOption count="5" label="2019-05-31"></FilterOption><FilterOption count="5" label="2019-06-04"></FilterOption><FilterOption count="5" label="2019-06-08"></FilterOption><FilterOption count="5" label="2019-06-17"></FilterOption><FilterOption count="4" label="2018-07-14"></FilterOption><FilterOption count="4" label="2018-12-18"></FilterOption><FilterOption count="4" label="2019-01-28"></FilterOption><FilterOption count="4" label="2019-02-22"></FilterOption><FilterOption count="4" label="2019-03-01"></FilterOption><FilterOption count="4" label="2019-03-15"></FilterOption><FilterOption count="4" label="2019-04-10"></FilterOption><FilterOption count="4" label="2019-05-08"></FilterOption><FilterOption count="4" label="2019-05-09"></FilterOption><FilterOption count="4" label="2019-05-22"></FilterOption><FilterOption count="4" label="2019-06-03"></FilterOption><FilterOption count="4" label="2019-06-05"></FilterOption><FilterOption count="4" label="2019-06-18"></FilterOption><FilterOption count="4" label="2019-06-29"></FilterOption><FilterOption count="3" label="2013-09-14"></FilterOption><FilterOption count="3" label="2018-01-24"></FilterOption><FilterOption count="3" label="2018-03-01"></FilterOption><FilterOption count="3" label="2018-04-28"></FilterOption><FilterOption count="3" label="2018-05-19"></FilterOption><FilterOption count="3" label="2018-11-19"></FilterOption><FilterOption count="3" label="2018-11-20"></FilterOption><FilterOption count="3" label="2018-11-28"></FilterOption><FilterOption count="3" label="2018-12-03"></FilterOption><FilterOption count="3" label="2018-12-05"></FilterOption><FilterOption count="3" label="2019-01-04"></FilterOption><FilterOption count="3" label="2019-02-06"></FilterOption><FilterOption count="3" label="2019-02-07"></FilterOption><FilterOption count="3" label="2019-02-11"></FilterOption><FilterOption count="3" label="2019-03-05"></FilterOption><FilterOption count="3" label="2019-03-18"></FilterOption><FilterOption count="3" label="2019-03-19"></FilterOption><FilterOption count="3" label="2019-03-22"></FilterOption><FilterOption count="3" label="2019-04-01"></FilterOption><FilterOption count="3" label="2019-04-02"></FilterOption><FilterOption count="3" label="2019-04-03"></FilterOption><FilterOption count="3" label="2019-04-24"></FilterOption><FilterOption count="3" label="2019-05-30"></FilterOption><FilterOption count="3" label="2019-06-15"></FilterOption><FilterOption count="2" label="2013-02-12"></FilterOption><FilterOption count="2" label="2014-03-25"></FilterOption><FilterOption count="2" label="2015-09-21"></FilterOption><FilterOption count="2" label="2016-12-06"></FilterOption></Filter><Filter label="Trial Date End By Month" name="trialDateEndByMonth" total="100"><FilterOption count="25" label="201912"></FilterOption><FilterOption count="20" label="202012"></FilterOption><FilterOption count="18" label="202112"></FilterOption><FilterOption count="14" label="202006"></FilterOption><FilterOption count="14" label="202007"></FilterOption><FilterOption count="13" label="201612"></FilterOption><FilterOption count="13" label="201712"></FilterOption><FilterOption count="13" label="201909"></FilterOption><FilterOption count="13" label="201910"></FilterOption><FilterOption count="13" label="202003"></FilterOption><FilterOption count="13" label="202109"></FilterOption><FilterOption count="12" label="201812"></FilterOption><FilterOption count="12" label="201901"></FilterOption><FilterOption count="12" label="202005"></FilterOption><FilterOption count="12" label="202103"></FilterOption><FilterOption count="12" label="202106"></FilterOption><FilterOption count="11" label="201112"></FilterOption><FilterOption count="11" label="201409"></FilterOption><FilterOption count="11" label="201801"></FilterOption><FilterOption count="11" label="201805"></FilterOption><FilterOption count="11" label="201806"></FilterOption><FilterOption count="11" label="201808"></FilterOption><FilterOption count="11" label="201810"></FilterOption><FilterOption count="10" label="201710"></FilterOption><FilterOption count="10" label="201903"></FilterOption><FilterOption count="10" label="201911"></FilterOption><FilterOption count="9" label="201704"></FilterOption><FilterOption count="9" label="201908"></FilterOption><FilterOption count="9" label="202001"></FilterOption><FilterOption count="9" label="202009"></FilterOption><FilterOption count="9" label="202107"></FilterOption><FilterOption count="9" label="202209"></FilterOption><FilterOption count="8" label="201307"></FilterOption><FilterOption count="8" label="201312"></FilterOption><FilterOption count="8" label="201401"></FilterOption><FilterOption count="8" label="201405"></FilterOption><FilterOption count="8" label="201604"></FilterOption><FilterOption count="8" label="201607"></FilterOption><FilterOption count="8" label="201709"></FilterOption><FilterOption count="8" label="201803"></FilterOption><FilterOption count="8" label="201807"></FilterOption><FilterOption count="8" label="201811"></FilterOption><FilterOption count="8" label="201907"></FilterOption><FilterOption count="8" label="202011"></FilterOption><FilterOption count="8" label="202206"></FilterOption><FilterOption count="7" label="201012"></FilterOption><FilterOption count="7" label="201106"></FilterOption><FilterOption count="7" label="201412"></FilterOption><FilterOption count="7" label="201512"></FilterOption><FilterOption count="7" label="201605"></FilterOption><FilterOption count="7" label="201609"></FilterOption><FilterOption count="7" label="201905"></FilterOption><FilterOption count="7" label="201906"></FilterOption><FilterOption count="7" label="202004"></FilterOption><FilterOption count="7" label="202202"></FilterOption><FilterOption count="7" label="202204"></FilterOption><FilterOption count="7" label="202205"></FilterOption><FilterOption count="6" label="201203"></FilterOption><FilterOption count="6" label="201302"></FilterOption><FilterOption count="6" label="201411"></FilterOption><FilterOption count="6" label="201504"></FilterOption><FilterOption count="6" label="201505"></FilterOption><FilterOption count="6" label="201506"></FilterOption><FilterOption count="6" label="201601"></FilterOption><FilterOption count="6" label="201702"></FilterOption><FilterOption count="6" label="201706"></FilterOption><FilterOption count="6" label="201711"></FilterOption><FilterOption count="6" label="201804"></FilterOption><FilterOption count="6" label="201809"></FilterOption><FilterOption count="6" label="201904"></FilterOption><FilterOption count="6" label="202008"></FilterOption><FilterOption count="6" label="202010"></FilterOption><FilterOption count="6" label="202102"></FilterOption><FilterOption count="6" label="202105"></FilterOption><FilterOption count="6" label="202212"></FilterOption><FilterOption count="6" label="202303"></FilterOption><FilterOption count="6" label="202307"></FilterOption><FilterOption count="5" label="200812"></FilterOption><FilterOption count="5" label="201006"></FilterOption><FilterOption count="5" label="201205"></FilterOption><FilterOption count="5" label="201207"></FilterOption><FilterOption count="5" label="201212"></FilterOption><FilterOption count="5" label="201310"></FilterOption><FilterOption count="5" label="201410"></FilterOption><FilterOption count="5" label="201508"></FilterOption><FilterOption count="5" label="201603"></FilterOption><FilterOption count="5" label="201610"></FilterOption><FilterOption count="5" label="201611"></FilterOption><FilterOption count="5" label="201701"></FilterOption><FilterOption count="5" label="201705"></FilterOption><FilterOption count="5" label="201707"></FilterOption><FilterOption count="5" label="202002"></FilterOption><FilterOption count="5" label="202101"></FilterOption><FilterOption count="5" label="202110"></FilterOption><FilterOption count="5" label="202201"></FilterOption><FilterOption count="5" label="202203"></FilterOption><FilterOption count="5" label="202304"></FilterOption><FilterOption count="5" label="202404"></FilterOption><FilterOption count="5" label="202412"></FilterOption><FilterOption count="4" label="200712"></FilterOption></Filter><Filter label="Trial Date Start By Month" name="trialDateStartByMonth" total="100"><FilterOption count="16" label="201706"></FilterOption><FilterOption count="16" label="201711"></FilterOption><FilterOption count="16" label="201806"></FilterOption><FilterOption count="15" label="201606"></FilterOption><FilterOption count="15" label="201707"></FilterOption><FilterOption count="14" label="201001"></FilterOption><FilterOption count="14" label="201411"></FilterOption><FilterOption count="14" label="201701"></FilterOption><FilterOption count="14" label="201805"></FilterOption><FilterOption count="13" label="201212"></FilterOption><FilterOption count="13" label="201810"></FilterOption><FilterOption count="12" label="201210"></FilterOption><FilterOption count="12" label="201504"></FilterOption><FilterOption count="12" label="201512"></FilterOption><FilterOption count="12" label="201710"></FilterOption><FilterOption count="12" label="201801"></FilterOption><FilterOption count="12" label="201811"></FilterOption><FilterOption count="12" label="201812"></FilterOption><FilterOption count="11" label="200711"></FilterOption><FilterOption count="11" label="201110"></FilterOption><FilterOption count="11" label="201407"></FilterOption><FilterOption count="11" label="201506"></FilterOption><FilterOption count="11" label="201604"></FilterOption><FilterOption count="11" label="201703"></FilterOption><FilterOption count="11" label="201704"></FilterOption><FilterOption count="11" label="201705"></FilterOption><FilterOption count="11" label="201803"></FilterOption><FilterOption count="10" label="201009"></FilterOption><FilterOption count="10" label="201103"></FilterOption><FilterOption count="10" label="201204"></FilterOption><FilterOption count="10" label="201301"></FilterOption><FilterOption count="10" label="201402"></FilterOption><FilterOption count="10" label="201405"></FilterOption><FilterOption count="10" label="201501"></FilterOption><FilterOption count="10" label="201503"></FilterOption><FilterOption count="10" label="201607"></FilterOption><FilterOption count="10" label="201611"></FilterOption><FilterOption count="10" label="201709"></FilterOption><FilterOption count="10" label="201807"></FilterOption><FilterOption count="10" label="201902"></FilterOption><FilterOption count="9" label="201011"></FilterOption><FilterOption count="9" label="201107"></FilterOption><FilterOption count="9" label="201303"></FilterOption><FilterOption count="9" label="201309"></FilterOption><FilterOption count="9" label="201412"></FilterOption><FilterOption count="9" label="201603"></FilterOption><FilterOption count="9" label="201605"></FilterOption><FilterOption count="9" label="201612"></FilterOption><FilterOption count="9" label="201712"></FilterOption><FilterOption count="9" label="201804"></FilterOption><FilterOption count="8" label="200610"></FilterOption><FilterOption count="8" label="201006"></FilterOption><FilterOption count="8" label="201101"></FilterOption><FilterOption count="8" label="201102"></FilterOption><FilterOption count="8" label="201111"></FilterOption><FilterOption count="8" label="201310"></FilterOption><FilterOption count="8" label="201404"></FilterOption><FilterOption count="8" label="201808"></FilterOption><FilterOption count="8" label="201901"></FilterOption><FilterOption count="8" label="201904"></FilterOption><FilterOption count="8" label="201905"></FilterOption><FilterOption count="7" label="200808"></FilterOption><FilterOption count="7" label="200812"></FilterOption><FilterOption count="7" label="200904"></FilterOption><FilterOption count="7" label="201007"></FilterOption><FilterOption count="7" label="201109"></FilterOption><FilterOption count="7" label="201201"></FilterOption><FilterOption count="7" label="201206"></FilterOption><FilterOption count="7" label="201208"></FilterOption><FilterOption count="7" label="201305"></FilterOption><FilterOption count="7" label="201306"></FilterOption><FilterOption count="7" label="201307"></FilterOption><FilterOption count="7" label="201403"></FilterOption><FilterOption count="7" label="201502"></FilterOption><FilterOption count="7" label="201602"></FilterOption><FilterOption count="7" label="201610"></FilterOption><FilterOption count="7" label="201702"></FilterOption><FilterOption count="7" label="201809"></FilterOption><FilterOption count="7" label="201903"></FilterOption><FilterOption count="7" label="201906"></FilterOption><FilterOption count="6" label="200601"></FilterOption><FilterOption count="6" label="200807"></FilterOption><FilterOption count="6" label="200902"></FilterOption><FilterOption count="6" label="200907"></FilterOption><FilterOption count="6" label="200911"></FilterOption><FilterOption count="6" label="201003"></FilterOption><FilterOption count="6" label="201105"></FilterOption><FilterOption count="6" label="201207"></FilterOption><FilterOption count="6" label="201211"></FilterOption><FilterOption count="6" label="201312"></FilterOption><FilterOption count="6" label="201406"></FilterOption><FilterOption count="6" label="201507"></FilterOption><FilterOption count="6" label="201509"></FilterOption><FilterOption count="6" label="201511"></FilterOption><FilterOption count="6" label="201609"></FilterOption><FilterOption count="5" label="200301"></FilterOption><FilterOption count="5" label="200509"></FilterOption><FilterOption count="5" label="200603"></FilterOption><FilterOption count="5" label="200706"></FilterOption><FilterOption count="5" label="200712"></FilterOption></Filter><Filter label="Trial Phase" name="trialPhase" total="14"><FilterOption id="C3" count="422" label="Phase 3 Clinical"></FilterOption><FilterOption id="C2" count="296" label="Phase 2 Clinical"></FilterOption><FilterOption id="C4" count="167" label="Phase 4 Clinical"></FilterOption><FilterOption id="PNA" count="114" label="Phase Not Applicable"></FilterOption><FilterOption id="C12" count="58" label="Phase 1/Phase 2 Clinical"></FilterOption><FilterOption id="C1" count="38" label="Phase 1 Clinical"></FilterOption><FilterOption id="C2B" count="31" label="Phase 2b Clinical"></FilterOption><FilterOption id="C23" count="27" label="Phase 2/Phase 3 Clinical"></FilterOption><FilterOption id="C3B" count="25" label="Phase 3b Clinical"></FilterOption><FilterOption id="NS" count="23" label="Phase not specified"></FilterOption><FilterOption id="C2A" count="16" label="Phase 2a Clinical"></FilterOption><FilterOption id="C1B" count="15" label="Phase 1b Clinical"></FilterOption><FilterOption id="C0" count="4" label="Phase 0 Clinical"></FilterOption><FilterOption id="C1A" count="1" label="Phase 1a Clinical"></FilterOption></Filter><Filter label="Inclusion Criteria Index" name="trialInclusionCriteriaIndex" total="100"><FilterOption id="4879" count="67" label="Breast tumor - Subjects with Protocol Specified Performance Status - Subjects with ECOG/WHO/Zubrod score performance status of 0"></FilterOption><FilterOption id="4880" count="67" label="Breast tumor - Subjects with Protocol Specified Performance Status - Subjects with ECOG/WHO/Zubrod score performance status of 1"></FilterOption><FilterOption id="5418" count="56" label="HIV infection - Subjects with HIV Infection - Subjects with HIV-1 infection"></FilterOption><FilterOption id="4840" count="49" label="Breast tumor - Subjects with Advanced/Metastatic Cancer"></FilterOption><FilterOption id="3976" count="48" label="Lung tumor - Subjects with Protocol Specified Performance Status - Subjects with ECOG/WHO/Zubrod score performance status of 0"></FilterOption><FilterOption id="3977" count="48" label="Lung tumor - Subjects with Protocol Specified Performance Status - Subjects with ECOG/WHO/Zubrod score performance status of 1"></FilterOption><FilterOption id="5317" count="47" label="HIV infection - Subjects with Protocol Specified HIV Viral Load"></FilterOption><FilterOption id="5086" count="46" label="Leukemia - Subjects with Protocol Specified Performance Status - Subjects with ECOG/WHO/Zubrod score performance status of 0"></FilterOption><FilterOption id="3537" count="46" label="Lymphoma - Subjects with Protocol Specified Performance Status - Subjects with ECOG/WHO/Zubrod score performance status of 0"></FilterOption><FilterOption id="3538" count="46" label="Lymphoma - Subjects with Protocol Specified Performance Status - Subjects with ECOG/WHO/Zubrod score performance status of 1"></FilterOption><FilterOption id="5087" count="45" label="Leukemia - Subjects with Protocol Specified Performance Status - Subjects with ECOG/WHO/Zubrod score performance status of 1"></FilterOption><FilterOption id="22417" count="40" label="Breast tumor - Subjects with Locally Advanced Cancer/Tumor"></FilterOption><FilterOption id="5088" count="40" label="Leukemia - Subjects with Protocol Specified Performance Status - Subjects with ECOG/WHO/Zubrod score performance status of 2"></FilterOption><FilterOption id="3539" count="39" label="Lymphoma - Subjects with Protocol Specified Performance Status - Subjects with ECOG/WHO/Zubrod score performance status of 2"></FilterOption><FilterOption id="4814" count="38" label="Breast tumor - Subjects with HER-2 Negative Breast Cancer"></FilterOption><FilterOption id="3957" count="38" label="Lung tumor - Subjects Confirmed of Lung Cancer by Specific Modes - Subjects with cytologically/histologically confirmed diagnosis of lung cancer"></FilterOption><FilterOption id="3900" count="38" label="Lung tumor - Subjects with Non Small Cell Lung Cancer (NSCLC)"></FilterOption><FilterOption id="4691" count="38" label="Multiple myeloma - Subjects with Protocol Specified Performance Status - Subjects with ECOG/WHO/Zubrod score performance status of 0"></FilterOption><FilterOption id="4692" count="38" label="Multiple myeloma - Subjects with Protocol Specified Performance Status - Subjects with ECOG/WHO/Zubrod score performance status of 1"></FilterOption><FilterOption id="4813" count="35" label="Breast tumor - Subjects with HER-2 Positive Breast Cancer"></FilterOption><FilterOption id="4928" count="34" label="Breast tumor - Subjects with Protocol Specified Compliance Status - Subjects able to comply with the study protocol procedures/ requirements"></FilterOption><FilterOption id="4981" count="34" label="Leukemia - Subjects with Acute Myeloid Leukemia (AML)"></FilterOption><FilterOption id="3548" count="34" label="Lymphoma - Subjects Diagnosed Based on Histo-Pathological Examination"></FilterOption><FilterOption id="5322" count="33" label="HIV infection - Subjects with Protocol Specified CD4+ T Cell Counts"></FilterOption><FilterOption id="3936" count="33" label="Lung tumor - Subjects with Protocol Specified Stages of Lung Cancer(TNM staging) - Subjects with stage IV lung cancer"></FilterOption><FilterOption id="4808" count="32" label="Breast tumor - Subjects with Hormone Receptor Positive Breast Cancer - Estrogen receptor positive (ER+) breast cancer"></FilterOption><FilterOption id="5074" count="30" label="Leukemia - Subjects with Protocol Specified Renal Function - Subjects with normal/acceptable renal function"></FilterOption><FilterOption id="22381" count="30" label="Lung tumor - Protocol Specified Other Inclusion Criteria - Protocol specified inclusion criteria for females"></FilterOption><FilterOption id="5073" count="29" label="Leukemia - Subjects with Normal/Acceptable Organ Function - Subjects with normal/adequate liver function"></FilterOption><FilterOption id="3940" count="29" label="Lung tumor - Subjects with Advanced/Metastatic Cancer"></FilterOption><FilterOption id="4693" count="29" label="Multiple myeloma - Subjects with Protocol Specified Performance Status - Subjects with ECOG/WHO/Zubrod score performance status of 2"></FilterOption><FilterOption id="4857" count="27" label="Breast tumor - Subjects with Measurable Disease - Subjects with measurable disease as per RECIST criteria"></FilterOption><FilterOption id="4973" count="27" label="Leukemia - Subjects with Acute Leukemia Unspecified Type"></FilterOption><FilterOption id="4817" count="26" label="Breast tumor - Postmenopausal Breast Cancer Women"></FilterOption><FilterOption id="4864" count="26" label="Breast tumor - Subjects with Normal/Acceptable Organ Function - Subjects with acceptable hematological test values"></FilterOption><FilterOption id="22405" count="26" label="Leukemia - Treatment Naive Subjects"></FilterOption><FilterOption id="4024" count="26" label="Lung tumor - Subjects with Normal/Acceptable Organ Function - Subjects with normal/acceptable liver function"></FilterOption><FilterOption id="4169" count="26" label="Melanoma - Subjects with Protocol Specified Performance Status - Subjects with ECOG/WHO/Zubrod score performance status of 0"></FilterOption><FilterOption id="4170" count="26" label="Melanoma - Subjects with Protocol Specified Performance Status - Subjects with ECOG/WHO/Zubrod score performance status of 1"></FilterOption><FilterOption id="4628" count="26" label="Multiple myeloma - Subjects with Measurable Disease - Subjects with measurable serum M-protein"></FilterOption><FilterOption id="7091" count="26" label="Prostate tumor - Subjects with Advanced/Metastatic Cancer"></FilterOption><FilterOption id="4922" count="25" label="Breast tumor - Subjects with Progressive/Treatment Refractory Disease"></FilterOption><FilterOption id="4955" count="25" label="Breast tumor - Subjects with Protocol Specified Participation Status - Subjects willing/able to provide informed consent/assent"></FilterOption><FilterOption id="3447" count="25" label="Lymphoma - Subjects with B Cell Non Hodgkin's Lymphoma - Subjects with diffuse large B cell lymphoma"></FilterOption><FilterOption id="3642" count="25" label="Lymphoma - Subjects with Normal/Acceptable Organ Function - Subjects with normal/acceptable hematological functions"></FilterOption><FilterOption id="4672" count="25" label="Multiple myeloma - Subjects with Normal/Acceptable Organ Function - Subjects with acceptable hematological status"></FilterOption><FilterOption id="4675" count="25" label="Multiple myeloma - Subjects with Normal/Acceptable Organ Function - Subjects with normal/acceptable liver function"></FilterOption><FilterOption id="4767" count="25" label="Multiple myeloma - Subjects with Relapsed/Recurrent Disease"></FilterOption><FilterOption id="32953" count="25" label="Other gastrointestinal disease - Protocol Specified Other Inclusion Criteria"></FilterOption><FilterOption id="4041" count="24" label="Lung tumor - Subjects with Normal/Acceptable Organ Function - Subjects with normal/acceptable hematological functions"></FilterOption><FilterOption id="4074" count="24" label="Lung tumor - Subjects with Protocol Specified Compliance Status - Subjects able to comply with the study protocol procedures/ requirements"></FilterOption><FilterOption id="4032" count="24" label="Lung tumor - Subjects with Protocol Specified Renal Function - Subjects with normal/acceptable renal function"></FilterOption><FilterOption id="4139" count="24" label="Melanoma - Subjects with Stage IV Melanoma"></FilterOption><FilterOption id="4676" count="24" label="Multiple myeloma - Subjects with Protocol Specified Renal Function - Subjects with normal/acceptable renal function"></FilterOption><FilterOption id="4894" count="23" label="Breast tumor - Subjects with History of Anti Cancer Therapy - Subjects with history of anti-cancer chemotherapy"></FilterOption><FilterOption id="3914" count="23" label="Lung tumor - Subjects with Measurable Disease - Subjects with measurable disease as per RECIST criteria"></FilterOption><FilterOption id="4106" count="23" label="Lung tumor - Subjects with Protocol Specified Reproductive Status - Men with adequate contraception"></FilterOption><FilterOption id="4162" count="23" label="Melanoma - Subjects with Diagnosis of Melanoma - Subjects with histological diagnosis of melanoma"></FilterOption><FilterOption id="7465" count="22" label="Bladder cancer - Subjects with Protocol Specified Performance Status - Subjects with ECOG/WHO/Zubrod score performance status of 1"></FilterOption><FilterOption id="22416" count="22" label="Breast tumor - Subjects with Unresectable Breast Cancer"></FilterOption><FilterOption id="3622" count="22" label="Lymphoma - Subjects with Normal/Acceptable Organ Function - Subjects with normal/acceptable liver function"></FilterOption><FilterOption id="4756" count="22" label="Multiple myeloma - Subjects with Progressive/Treatment Refractory Disease"></FilterOption><FilterOption id="13096" count="22" label="Solid tumor - Subjects with Advanced/Metastatic Cancer"></FilterOption><FilterOption id="7441" count="21" label="Bladder cancer - Subjects with Advanced/Metastatic Cancer"></FilterOption><FilterOption id="7464" count="21" label="Bladder cancer - Subjects with Protocol Specified Performance Status - Subjects with ECOG/WHO/Zubrod score performance status of 0"></FilterOption><FilterOption id="4877" count="21" label="Breast tumor - Subjects with Protocol Specified Life Expectancy"></FilterOption><FilterOption id="4957" count="21" label="Breast tumor - Subjects with Protocol Specified Reproductive Status - Subjects with adequate contraception"></FilterOption><FilterOption id="4483" count="21" label="Colorectal tumor - Subjects with Advanced/Metastatic Cancer"></FilterOption><FilterOption id="4527" count="21" label="Colorectal tumor - Subjects with Protocol Specified Performance Status - Subjects with ECOG/WHO/Zubrod score performance status of 0"></FilterOption><FilterOption id="4528" count="21" label="Colorectal tumor - Subjects with Protocol Specified Performance Status - Subjects with ECOG/WHO/Zubrod score performance status of 1"></FilterOption><FilterOption id="5344" count="21" label="HIV infection - Subjects on Prior/Concurrent Antiretroviral Therapy"></FilterOption><FilterOption id="5164" count="21" label="Leukemia - Subjects with Progressive/Treatment Refractory Disease"></FilterOption><FilterOption id="4630" count="21" label="Multiple myeloma - Subjects with Measurable Disease - Subjects with measurable serum/urine light chain"></FilterOption><FilterOption id="22418" count="20" label="Breast tumor - Subjects with Early Breast Cancer"></FilterOption><FilterOption id="4809" count="20" label="Breast tumor - Subjects with Hormone Receptor Positive Breast Cancer - Progesterone receptor positive (PR+) breast cancer"></FilterOption><FilterOption id="4866" count="20" label="Breast tumor - Subjects with Protocol Specified Renal Function - Subjects with normal/acceptable renal function"></FilterOption><FilterOption id="4985" count="20" label="Leukemia - Subjects with Acute Lymphocytic Leukemia (ALL)"></FilterOption><FilterOption id="3448" count="20" label="Lymphoma - Subjects with B Cell Non Hodgkin's Lymphoma - Subjects with follicular lymphoma"></FilterOption><FilterOption id="4198" count="20" label="Melanoma - Subjects with Normal/Acceptable Organ Function - Subjects with normal/acceptable hematological functions"></FilterOption><FilterOption id="33170" count="19" label="Breast tumor - Protocol Specified Other Inclusion Criteria - Subjects with a cytological diagnostic and/or pathology of breast cancer"></FilterOption><FilterOption id="4865" count="19" label="Breast tumor - Subjects with Normal/Acceptable Organ Function - Subjects with normal/acceptable liver function"></FilterOption><FilterOption id="4923" count="19" label="Breast tumor - Subjects with Relapsed/Recurrent Disease"></FilterOption><FilterOption id="7485" count="18" label="Bladder cancer - Subjects with Normal/Acceptable Organ Function - Subjects with normal/acceptable hematological functions"></FilterOption><FilterOption id="4856" count="18" label="Breast tumor - Subjects with Measurable Disease"></FilterOption><FilterOption id="4509" count="18" label="Colorectal tumor - Subjects with Histologically Confirmed Colorectal Cancer"></FilterOption><FilterOption id="4569" count="18" label="Colorectal tumor - Subjects with Normal/Acceptable Organ Function - Subjects with normal/acceptable hematopoetic/marrow function"></FilterOption><FilterOption id="5331" count="18" label="HIV infection - Subjects with Normal/Acceptable Laboratory Criteria - Subjects with normal/acceptable liver function tests"></FilterOption><FilterOption id="3477" count="18" label="Lymphoma - Subjects with Specific Grade of Lymphoma - Subjects with aggressive (high grade) lymphoma"></FilterOption><FilterOption id="3475" count="18" label="Lymphoma - Subjects with Specific Grade of Lymphoma - Subjects with indolent (slow-growing, low grade) lymphoma"></FilterOption><FilterOption id="7445" count="17" label="Bladder cancer - Subjects with Stage IV Bladder Cancer"></FilterOption><FilterOption id="4815" count="17" label="Breast tumor - Subjects with Triple Negative Breast Cancer"></FilterOption><FilterOption id="3935" count="17" label="Lung tumor - Subjects with Protocol Specified Stages of Lung Cancer(TNM staging) - Subjects with stage IIIB lung cancer"></FilterOption><FilterOption id="4208" count="17" label="Melanoma - Subjects with Feasibility for Specific Treatment Modalities - Subjects with surgically non-resectable melanoma"></FilterOption><FilterOption id="3715" count="17" label="Prostate tumor - Subjects with Histologically/Cytologically Confirmed Prostate Cancer - Subjects with adenocarcinoma of prostate"></FilterOption><FilterOption id="13129" count="17" label="Solid tumor - Subjects with Treatment Refractory Disease"></FilterOption><FilterOption id="4564" count="16" label="Colorectal tumor - Subjects with Normal/Acceptable Organ Function - Subjects with normal/acceptable liver function"></FilterOption><FilterOption id="5278" count="16" label="HIV infection - Subjects with HIV Infection"></FilterOption><FilterOption id="5332" count="16" label="HIV infection - Subjects with Normal/Acceptable Laboratory Criteria - Subjects with normal/acceptable renal function tests"></FilterOption><FilterOption id="5329" count="16" label="HIV infection - Subjects with Normal/Acceptable Organ Function - Subjects with normal/acceptable hematological functions"></FilterOption><FilterOption id="3971" count="16" label="Lung tumor - Subjects with Protocol Specified Life Expectancy - Subjects with life expectancy of three months or more"></FilterOption></Filter><Filter label="Trial Interventions Control Alone Name Display" name="trialInterventionsControlAloneNameDisplay" total="100"><FilterOption id="2953" count="7" label="docetaxel"></FilterOption><FilterOption id="37370" count="6" label="azacitidine"></FilterOption><FilterOption id="3313" count="6" label="fulvestrant"></FilterOption><FilterOption id="3803" count="6" label="paclitaxel"></FilterOption><FilterOption id="12205" count="4" label="capecitabine"></FilterOption><FilterOption id="3199" count="4" label="gemcitabine"></FilterOption><FilterOption id="2784" count="4" label="letrozole"></FilterOption><FilterOption id="12973" count="4" label="sunitinib"></FilterOption><FilterOption id="13239" count="3" label="decitabine"></FilterOption><FilterOption id="53981" count="3" label="enzalutamide"></FilterOption><FilterOption id="70667" count="3" label="pembrolizumab"></FilterOption><FilterOption id="14493" count="3" label="tenofovir disoproxil fumarate"></FilterOption><FilterOption id="99926" count="2" label="18F-GTP1"></FilterOption><FilterOption id="53547" count="2" label="aflibercept (intravitreal, wet AMD, macular edema, diabetic retinopathy), Regeneron/Bayer"></FilterOption><FilterOption id="55798" count="2" label="crizotinib"></FilterOption><FilterOption id="53200" count="2" label="daratumumab"></FilterOption><FilterOption id="7934" count="2" label="doxorubicin (liposomal, STEALTH), Alza"></FilterOption><FilterOption id="62277" count="2" label="emtricitabine + tenofovir disoproxil fumarate + elvitegravir + cobicistat (single tablet regimen, HIV/AIDS), Gilead Sciences"></FilterOption><FilterOption id="13928" count="2" label="enoxaparin sodium"></FilterOption><FilterOption id="55237" count="2" label="ibrutinib"></FilterOption><FilterOption id="6850" count="2" label="infliximab"></FilterOption><FilterOption id="2871" count="2" label="irinotecan"></FilterOption><FilterOption id="5267" count="2" label="leuprorelin acetate"></FilterOption><FilterOption id="14681" count="2" label="lopinavir + ritonavir"></FilterOption><FilterOption id="3669" count="2" label="mycophenolate mofetil"></FilterOption><FilterOption id="54804" count="2" label="nivolumab"></FilterOption><FilterOption id="29831" count="2" label="sorafenib"></FilterOption><FilterOption id="4529" count="2" label="temozolomide"></FilterOption><FilterOption id="4577" count="2" label="topotecan"></FilterOption><FilterOption id="6408" count="2" label="vinorelbine"></FilterOption><FilterOption id="2503" count="1" label="amphotericin B (liposomal iv, visceral leishmaniasis), Drugs for Neglected Diseases initiative"></FilterOption><FilterOption id="3321" count="1" label="anastrozole"></FilterOption><FilterOption id="52967" count="1" label="apixaban"></FilterOption><FilterOption id="50484" count="1" label="apomorphine hydrochloride (Parkinson's disease), Britannia"></FilterOption><FilterOption id="72699" count="1" label="atezolizumab"></FilterOption><FilterOption id="16905" count="1" label="atomoxetine"></FilterOption><FilterOption id="11141" count="1" label="basiliximab"></FilterOption><FilterOption id="8047" count="1" label="bevacizumab"></FilterOption><FilterOption id="100071" count="1" label="BMS-986177"></FilterOption><FilterOption id="50935" count="1" label="cabozantinib S-malate"></FilterOption><FilterOption id="63194" count="1" label="carbidopa + levodopa (Parkinsons disease, immediate/extended release), Impax"></FilterOption><FilterOption id="44388" count="1" label="carbidopa + levodopa"></FilterOption><FilterOption id="44383" count="1" label="carboplatin"></FilterOption><FilterOption id="95204" count="1" label="cemiplimab"></FilterOption><FilterOption id="2836" count="1" label="clopidogrel"></FilterOption><FilterOption id="2911" count="1" label="daptomycin"></FilterOption><FilterOption id="72148" count="1" label="darunavir + cobicistat (fixed dose, HIV infection), Janssen R&amp;D/ Gilead"></FilterOption><FilterOption id="72153" count="1" label="darunavir + tenofovir alafenamide + emtricitabine + cobicistat (single tablet regimen, HIV-1),Janssen R&amp;D"></FilterOption><FilterOption id="10172" count="1" label="efavirenz"></FilterOption><FilterOption id="4728" count="1" label="emtricitabine"></FilterOption><FilterOption id="13486" count="1" label="entecavir"></FilterOption><FilterOption id="14603" count="1" label="eplerenone"></FilterOption><FilterOption id="67892" count="1" label="epoetin alfa (Procrit/Eprex), Johnson &amp; Johnson"></FilterOption><FilterOption id="28773" count="1" label="eribulin mesylate"></FilterOption><FilterOption id="13340" count="1" label="everolimus"></FilterOption><FilterOption id="3081" count="1" label="exemestane"></FilterOption><FilterOption id="44292" count="1" label="fluconazole"></FilterOption><FilterOption id="8832" count="1" label="glimepiride"></FilterOption><FilterOption id="8888" count="1" label="hydroxycarbamide (sickle cell anemia, thrombocythemia, polycythemia), BMS"></FilterOption><FilterOption id="44397" count="1" label="hylan G-F 20"></FilterOption><FilterOption id="62922" count="1" label="IFX-1"></FilterOption><FilterOption id="11460" count="1" label="imatinib"></FilterOption><FilterOption id="10411" count="1" label="insulin aspart"></FilterOption><FilterOption id="3353" count="1" label="insulin lispro"></FilterOption><FilterOption id="3360" count="1" label="interferon beta-1a, Biogen"></FilterOption><FilterOption id="36630" count="1" label="ipilimumab"></FilterOption><FilterOption id="9819" count="1" label="lanthanum carbonate"></FilterOption><FilterOption id="9443" count="1" label="levosimendan"></FilterOption><FilterOption id="6050" count="1" label="metformin hydrochloride"></FilterOption><FilterOption id="44303" count="1" label="midazolam hydrochloride"></FilterOption><FilterOption id="10634" count="1" label="milrinone"></FilterOption><FilterOption id="61287" count="1" label="niraparib"></FilterOption><FilterOption id="42299" count="1" label="ofatumumab"></FilterOption><FilterOption id="13460" count="1" label="oseltamivir"></FilterOption><FilterOption id="8747" count="1" label="palivizumab"></FilterOption><FilterOption id="67037" count="1" label="patisiran"></FilterOption><FilterOption id="7871" count="1" label="pirfenidone"></FilterOption><FilterOption id="22395" count="1" label="ranibizumab"></FilterOption><FilterOption id="9702" count="1" label="recombinant interferon beta-1a, Merck Serono"></FilterOption><FilterOption id="54624" count="1" label="regorafenib"></FilterOption><FilterOption id="7310" count="1" label="ritonavir"></FilterOption><FilterOption id="54662" count="1" label="ruxolitinib (oral, myeloproliferative disorders), Incyte/Novartis"></FilterOption><FilterOption id="44312" count="1" label="salmeterol"></FilterOption><FilterOption id="8713" count="1" label="sildenafil citrate"></FilterOption><FilterOption id="44313" count="1" label="simvastatin"></FilterOption><FilterOption id="44314" count="1" label="tamoxifen"></FilterOption><FilterOption id="49219" count="1" label="tenofovir disoproxil fumarate + emtricitabine (fixed dose), Gilead Sciences"></FilterOption><FilterOption id="50038" count="1" label="tenofovir disoproxil fumarate + emtricitabine + efavirenz, Gilead/BMS/Merck &amp; Co"></FilterOption><FilterOption id="8050" count="1" label="thalidomide, Celgene"></FilterOption><FilterOption id="44315" count="1" label="timolol"></FilterOption><FilterOption id="6386" count="1" label="trastuzumab"></FilterOption><FilterOption id="36669" count="1" label="trastuzumab emtansine"></FilterOption><FilterOption id="23239" count="1" label="ulipristal"></FilterOption><FilterOption id="61574" count="1" label="umirolimus stent (BioMatrix, restenosis), Biosensors"></FilterOption><FilterOption id="13338" count="1" label="ursodeoxycholic acid"></FilterOption><FilterOption id="2773" count="1" label="valsartan"></FilterOption><FilterOption id="44401" count="1" label="vancomycin"></FilterOption><FilterOption id="54469" count="1" label="vemurafenib"></FilterOption><FilterOption id="15130" count="1" label="vinflunine"></FilterOption><FilterOption id="44375" count="1" label="warfarin"></FilterOption></Filter><Filter label="Trial Actions Primary Interventions Control" name="trialActionsPrimaryInterventionsControl" total="100"><FilterOption id="372" count="23" label="Thymidylate synthase inhibitor"></FilterOption><FilterOption id="142" count="19" label="Topoisomerase II inhibitor"></FilterOption><FilterOption id="1016" count="18" label="HIV-1 reverse transcriptase inhibitor"></FilterOption><FilterOption id="3756" count="17" label="Erbb2 tyrosine kinase receptor inhibitor"></FilterOption><FilterOption id="5085" count="16" label="B-lymphocyte antigen CD20 inhibitor"></FilterOption><FilterOption id="1832" count="16" label="Nucleoside reverse transcriptase inhibitor"></FilterOption><FilterOption id="204" count="15" label="HIV protease inhibitor"></FilterOption><FilterOption id="138" count="14" label="DNA polymerase inhibitor"></FilterOption><FilterOption id="768" count="12" label="HIV-1 protease inhibitor"></FilterOption><FilterOption id="7424" count="10" label="Cytochrome P450 3A4 inhibitor"></FilterOption><FilterOption id="3808" count="10" label="Kit tyrosine kinase inhibitor"></FilterOption><FilterOption id="3846" count="10" label="VEGF-1 receptor antagonist"></FilterOption><FilterOption id="3848" count="10" label="VEGF-2 receptor antagonist"></FilterOption><FilterOption id="76" count="9" label="Aromatase inhibitor"></FilterOption><FilterOption id="740" count="9" label="Epidermal growth factor receptor antagonist"></FilterOption><FilterOption id="4917" count="9" label="Proteasome inhibitor"></FilterOption><FilterOption id="3816" count="9" label="RET tyrosine kinase receptor family inhibitor"></FilterOption><FilterOption id="3850" count="9" label="VEGF-3 receptor antagonist"></FilterOption><FilterOption id="6512" count="8" label="DNA methyltransferase inhibitor"></FilterOption><FilterOption id="286" count="8" label="Estrogen receptor antagonist"></FilterOption><FilterOption id="3806" count="8" label="Flt3 tyrosine kinase inhibitor"></FilterOption><FilterOption id="374" count="8" label="Transferase inhibitor"></FilterOption><FilterOption id="12521" count="8" label="VEGF ligand inhibitor"></FilterOption><FilterOption id="76469" count="7" label="26S proteasome complex inhibitor"></FilterOption><FilterOption id="135" count="7" label="DHFR inhibitor"></FilterOption><FilterOption id="181" count="7" label="GAR transformylase inhibitor"></FilterOption><FilterOption id="48492" count="7" label="PDGF receptor beta antagonist"></FilterOption><FilterOption id="7418" count="6" label="Cytochrome P450 3 inhibitor"></FilterOption><FilterOption id="82444" count="6" label="DNA helicase inhibitor"></FilterOption><FilterOption id="7588" count="6" label="HIV-1 integrase inhibitor"></FilterOption><FilterOption id="67136" count="6" label="Programmed cell death protein 1 inhibitor"></FilterOption><FilterOption id="141" count="6" label="Topoisomerase I inhibitor"></FilterOption><FilterOption id="814" count="6" label="Tubulin modulator"></FilterOption><FilterOption id="3154" count="5" label="CSF-1 antagonist"></FilterOption><FilterOption id="7472" count="5" label="Cytochrome P450 17 inhibitor"></FilterOption><FilterOption id="1833" count="5" label="Non-nucleoside reverse transcriptase inhibitor"></FilterOption><FilterOption id="48489" count="5" label="PDGF receptor alpha antagonist"></FilterOption><FilterOption id="60" count="4" label="Androgen receptor antagonist"></FilterOption><FilterOption id="7423" count="4" label="Cytochrome P450 3A4 stimulator"></FilterOption><FilterOption id="6515" count="4" label="Cytosine DNA methyltransferase inhibitor"></FilterOption><FilterOption id="18889" count="4" label="DNA binding protein inhibitor"></FilterOption><FilterOption id="71851" count="4" label="HIV GAG POL polyprotein inhibitor"></FilterOption><FilterOption id="12395" count="4" label="HIV GAG protein inhibitor"></FilterOption><FilterOption id="1671" count="4" label="HIV integrase inhibitor"></FilterOption><FilterOption id="10240" count="4" label="mTOR inhibitor"></FilterOption><FilterOption id="2506" count="4" label="PARP modulator"></FilterOption><FilterOption id="948" count="4" label="PDGF receptor antagonist"></FilterOption><FilterOption id="35354" count="4" label="Prostate specific antigen modulator"></FilterOption><FilterOption id="4548" count="4" label="Raf B protein kinase inhibitor"></FilterOption><FilterOption id="346" count="4" label="Ribonucleotide reductase inhibitor"></FilterOption><FilterOption id="78089" count="4" label="Translocation associated protein inhibitor"></FilterOption><FilterOption id="1722" count="4" label="VEGF receptor antagonist"></FilterOption><FilterOption id="51708" count="3" label="DNA polymerase alpha inhibitor"></FilterOption><FilterOption id="6830" count="3" label="DNA primase inhibitor"></FilterOption><FilterOption id="111" count="3" label="Factor IIa antagonist"></FilterOption><FilterOption id="113" count="3" label="Factor IX antagonist"></FilterOption><FilterOption id="114" count="3" label="Factor VII antagonist"></FilterOption><FilterOption id="119" count="3" label="Factor X antagonist"></FilterOption><FilterOption id="675" count="3" label="Hepatocyte growth factor receptor antagonist"></FilterOption><FilterOption id="205" count="3" label="HMG CoA reductase inhibitor"></FilterOption><FilterOption id="214" count="3" label="Interferon alpha 2 ligand"></FilterOption><FilterOption id="3796" count="3" label="MET tyrosine kinase receptor family inhibitor"></FilterOption><FilterOption id="76090" count="3" label="mTOR complex 1 inhibitor"></FilterOption><FilterOption id="4913" count="3" label="P2Y12 purinoceptor antagonist"></FilterOption><FilterOption id="14007" count="3" label="Programmed cell death ligand 1 inhibitor"></FilterOption><FilterOption id="4550" count="3" label="Raf 1 protein kinase inhibitor"></FilterOption><FilterOption id="381" count="3" label="TNF alpha ligand inhibitor"></FilterOption><FilterOption id="721" count="3" label="TNF binding agent"></FilterOption><FilterOption id="1513" count="3" label="Topoisomerase II modulator"></FilterOption><FilterOption id="10583" count="3" label="Vitamin K epoxide reductase inhibitor"></FilterOption><FilterOption id="18" count="2" label="ACE inhibitor"></FilterOption><FilterOption id="5136" count="2" label="ADP ribosyl cyclase-1 inhibitor"></FilterOption><FilterOption id="3851" count="2" label="ALK tyrosine kinase receptor family inhibitor"></FilterOption><FilterOption id="3736" count="2" label="Anaplastic lymphoma kinase receptor inhibitor"></FilterOption><FilterOption id="77" count="2" label="Aspartic protease inhibitor"></FilterOption><FilterOption id="3592" count="2" label="Btk tyrosine kinase inhibitor"></FilterOption><FilterOption id="5482" count="2" label="Cytotoxic T-lymphocyte protein-4 inhibitor"></FilterOption><FilterOption id="5554" count="2" label="Dopa decarboxylase inhibitor"></FilterOption><FilterOption id="144" count="2" label="Dopamine receptor agonist"></FilterOption><FilterOption id="48389" count="2" label="Echinoderm microtubule like protein 4 inhibitor"></FilterOption><FilterOption id="1092" count="2" label="GNRH receptor agonist"></FilterOption><FilterOption id="629" count="2" label="Inosine monophosphate dehydrogenase inhibitor"></FilterOption><FilterOption id="23014" count="2" label="Insulin ligand"></FilterOption><FilterOption id="400" count="2" label="Insulin receptor agonist"></FilterOption><FilterOption id="481" count="2" label="Interferon beta ligand"></FilterOption><FilterOption id="777" count="2" label="Lanosterol-14 demethylase inhibitor"></FilterOption><FilterOption id="1741" count="2" label="Low molecular weight heparin"></FilterOption><FilterOption id="57003" count="2" label="Peptidoglycan recognition protein inhibitor"></FilterOption><FilterOption id="15904" count="2" label="Placenta growth factor ligand inhibitor"></FilterOption><FilterOption id="38283" count="2" label="Poly ADP ribose polymerase 1 inhibitor"></FilterOption><FilterOption id="38286" count="2" label="Poly ADP ribose polymerase 2 inhibitor"></FilterOption><FilterOption id="11778" count="2" label="PurH purine biosynthesis protein inhibitor"></FilterOption><FilterOption id="4542" count="2" label="Raf protein kinase inhibitor"></FilterOption><FilterOption id="345" count="2" label="Reverse transcriptase inhibitor"></FilterOption><FilterOption id="551" count="2" label="RNA DNA polymerase inhibitor"></FilterOption><FilterOption id="3826" count="2" label="Ros1 tyrosine kinase receptor inhibitor"></FilterOption><FilterOption id="2422" count="2" label="Tau protein modulator"></FilterOption><FilterOption id="3834" count="2" label="Tek tyrosine kinase receptor inhibitor"></FilterOption><FilterOption id="58716" count="2" label="Ubiquitin inhibitor"></FilterOption><FilterOption id="1689" count="2" label="VEGF-A ligand inhibitor"></FilterOption></Filter><Filter label="Trial Indications Adverse" name="trialIndicationsAdverse" total="100"><FilterOption id="102" count="145" label="Diarrhea"></FilterOption><FilterOption id="226" count="133" label="Nausea"></FilterOption><FilterOption id="1991" count="125" label="Neutropenia"></FilterOption><FilterOption id="829" count="124" label="Fatigue"></FilterOption><FilterOption id="17" count="110" label="Anemia"></FilterOption><FilterOption id="324" count="98" label="Thrombocytopenia"></FilterOption><FilterOption id="110" count="79" label="Emesis"></FilterOption><FilterOption id="148" count="65" label="Headache"></FilterOption><FilterOption id="404" count="58" label="Constipation"></FilterOption><FilterOption id="3038" count="53" label="Appetite loss"></FilterOption><FilterOption id="3020" count="53" label="Skin rash"></FilterOption><FilterOption id="1833" count="52" label="Fever"></FilterOption><FilterOption id="360" count="50" label="Pneumonia"></FilterOption><FilterOption id="746" count="46" label="Infectious disease"></FilterOption><FilterOption id="3795" count="43" label="Febrile neutropenia"></FilterOption><FilterOption id="3062" count="41" label="Death"></FilterOption><FilterOption id="680" count="40" label="Leukopenia"></FilterOption><FilterOption id="178" count="37" label="Hypertension"></FilterOption><FilterOption id="259" count="37" label="Peripheral neuropathy"></FilterOption><FilterOption id="2439" count="34" label="Arthralgia"></FilterOption><FilterOption id="82" count="34" label="Cough"></FilterOption><FilterOption id="402" count="30" label="Edema"></FilterOption><FilterOption id="3472" count="29" label="Abdominal pain"></FilterOption><FilterOption id="2400" count="29" label="Dyspnea"></FilterOption><FilterOption id="516" count="29" label="Upper respiratory tract infection"></FilterOption><FilterOption id="2274" count="27" label="Rhinopharyngitis"></FilterOption><FilterOption id="3221" count="25" label="Back pain"></FilterOption><FilterOption id="13" count="22" label="Alopecia"></FilterOption><FilterOption id="181" count="22" label="Hypokalemia"></FilterOption><FilterOption id="3454" count="20" label="Dizziness"></FilterOption><FilterOption id="1821" count="20" label="Hyperglycemia"></FilterOption><FilterOption id="279" count="20" label="Pruritus"></FilterOption><FilterOption id="552" count="19" label="Bleeding"></FilterOption><FilterOption id="1078" count="19" label="Lung embolism"></FilterOption><FilterOption id="1039" count="19" label="Myalgia"></FilterOption><FilterOption id="750" count="18" label="Insomnia"></FilterOption><FilterOption id="1992" count="18" label="Lymphocytopenia"></FilterOption><FilterOption id="20" count="18" label="Pain"></FilterOption><FilterOption id="1009" count="17" label="Urinary tract infection"></FilterOption><FilterOption id="129" count="16" label="Gastrointestinal disease"></FilterOption><FilterOption id="574" count="15" label="Deep vein thrombosis"></FilterOption><FilterOption id="1016" count="14" label="Stomatitis"></FilterOption><FilterOption id="2576" count="13" label="Dysgeusia"></FilterOption><FilterOption id="114" count="12" label="Sepsis"></FilterOption><FilterOption id="50" count="11" label="Bronchitis"></FilterOption><FilterOption id="3050" count="11" label="Chill"></FilterOption><FilterOption id="408" count="10" label="Hypotension"></FilterOption><FilterOption id="224" count="10" label="Myocardial infarction"></FilterOption><FilterOption id="1072" count="9" label="Colitis"></FilterOption><FilterOption id="2955" count="9" label="Weight loss"></FilterOption><FilterOption id="1280" count="8" label="Hypophosphatemia"></FilterOption><FilterOption id="1263" count="8" label="Mucositis"></FilterOption><FilterOption id="2440" count="8" label="Musculoskeletal pain"></FilterOption><FilterOption id="93" count="7" label="Depression"></FilterOption><FilterOption id="182" count="7" label="Hypothyroidism"></FilterOption><FilterOption id="201" count="7" label="Liver disease"></FilterOption><FilterOption id="358" count="7" label="Muscle spasm"></FilterOption><FilterOption id="69" count="7" label="Renal failure"></FilterOption><FilterOption id="307" count="7" label="Squamous cell carcinoma"></FilterOption><FilterOption id="325" count="7" label="Thromboembolism"></FilterOption><FilterOption id="55" count="6" label="Cardiac failure"></FilterOption><FilterOption id="1835" count="6" label="Epistaxis"></FilterOption><FilterOption id="2024" count="6" label="Erythema"></FilterOption><FilterOption id="154" count="6" label="Hepatitis"></FilterOption><FilterOption id="2529" count="6" label="Hot flashes"></FilterOption><FilterOption id="172" count="6" label="Hyperbilirubinemia"></FilterOption><FilterOption id="191" count="6" label="Influenza virus infection"></FilterOption><FilterOption id="678" count="6" label="Neuropathy"></FilterOption><FilterOption id="2948" count="6" label="Tumor lysis syndrome"></FilterOption><FilterOption id="1063" count="6" label="Xerostomia"></FilterOption><FilterOption id="6832" count="5" label="Acral erythema"></FilterOption><FilterOption id="2184" count="5" label="Gastrointestinal bleeding"></FilterOption><FilterOption id="626" count="5" label="Heart disease"></FilterOption><FilterOption id="505" count="5" label="Hypersensitivity"></FilterOption><FilterOption id="277" count="5" label="Proteinuria"></FilterOption><FilterOption id="286" count="5" label="Renal disease"></FilterOption><FilterOption id="25" count="4" label="Anxiety disorder"></FilterOption><FilterOption id="57" count="4" label="Cardiovascular disease"></FilterOption><FilterOption id="2525" count="4" label="Cellulitis"></FilterOption><FilterOption id="95" count="4" label="Dermatological disease"></FilterOption><FilterOption id="3073" count="4" label="Drowsiness"></FilterOption><FilterOption id="432" count="4" label="Dyspepsia"></FilterOption><FilterOption id="1632" count="4" label="Intracranial hemorrhage"></FilterOption><FilterOption id="511" count="4" label="Lower respiratory tract infection"></FilterOption><FilterOption id="668" count="4" label="Muscle weakness"></FilterOption><FilterOption id="509" count="4" label="Respiratory tract infection"></FilterOption><FilterOption id="816" count="4" label="Septic shock"></FilterOption><FilterOption id="1076" count="4" label="Thrombosis"></FilterOption><FilterOption id="2434" count="4" label="Vertigo"></FilterOption><FilterOption id="1731" count="3" label="Acute myelogenous leukemia"></FilterOption><FilterOption id="1542" count="3" label="Atrial fibrillation"></FilterOption><FilterOption id="3826" count="3" label="Bone marrow depression"></FilterOption><FilterOption id="412" count="3" label="Bradycardia"></FilterOption><FilterOption id="1308" count="3" label="Candida infection"></FilterOption><FilterOption id="3414" count="3" label="Cerebral hemorrhage"></FilterOption><FilterOption id="1559" count="3" label="Congestive heart failure"></FilterOption><FilterOption id="89" count="3" label="Cytomegalovirus infection"></FilterOption><FilterOption id="3063" count="3" label="Delirium"></FilterOption><FilterOption id="2749" count="3" label="Hematoma"></FilterOption><FilterOption id="2291" count="3" label="Hematuria"></FilterOption></Filter></Filters><NormalizedQuery>Hospital AND Clínic AND i AND Provincial AND de AND Barcelona</NormalizedQuery><SearchResults><Trial Id="367216"><Indications><Indication>Vascular fistula</Indication></Indications><CompaniesSponsor><Company>Hospital Clinic of Barcelona</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2019-01-24T00:00:00Z</DateChangeLast><DateEnd>2014-11-30T00:00:00Z</DateEnd><DateStart>2012-11-01T00:00:00Z</DateStart><Identifiers><Identifier>HOSPITAL CLINIC INVESTIGATIONAL COMMITTEE REGISTRATION: 2013/8042 (HOSPITAL CLINIC, BARCELONA, SPAIN</Identifier><Identifier>ISRCTN15802482</Identifier></Identifiers><InterventionsControlDisplay><Intervention>Usual lifestyle alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>exercise program alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>82</PatientCountEnrollment><Phase>Phase Not Applicable</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The aim of this study was to determine whether a postoperative exercise program could really increase arteriovenous fistula (AVF) maturation at 1 month, and was to determine if exercises after AVF creation could or could not be recommended. The invsetigator hypothesized that a postoperative exercise program would increase arteriovenous fistula maturation after its surgical creation.</Teaser><TrialCategories><Category>Behavioral intervention</Category><Category>Medical procedure</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Single Blind</Term><Term>Active Control</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>End stage renal disease - Assessment of Cardiac Function - Assessment of vascular structure/function</EndpointIndex><EndpointIndex>End stage renal disease - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>End stage renal disease - Assessment of Physical Examination</EndpointIndex><EndpointIndex>End stage renal disease - Clinical Assessments</EndpointIndex><EndpointIndex>End stage renal disease - Imaging/Radiological Assessments</EndpointIndex></EndpointIndex><TitleDisplay>Effect of a postoperative exercise program on arteriovenous fistula maturation</TitleDisplay><PatientSegmentTerms><PatientSegment>End stage renal disease - Subjects Received/Scheduled for Other Therapies - Subjects received/scheduled for hemodialysis</PatientSegment><PatientSegment>End stage renal disease - Subjects by disease severity - Subjects with stage 5 chronic kidney disease/end stage renal disease(ESRD)</PatientSegment><PatientSegment>End stage renal disease - Subjects with Dialysis Dependant Chronic Kidney Disease(DD-CKD)</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Blood flow</BiomarkerName></BiomarkerNames><PrimaryCompletionDate></PrimaryCompletionDate><TrialDuration>25 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Dr Fontsere</Name></ContactNames></Trial><Trial Id="267627"><Indications><Indication>Acute liver failure</Indication><Indication>Chronic liver failure</Indication><Indication>Liver cirrhosis</Indication></Indications><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Intravenous formulation</Technology><Technology>Stem cell therapy</Technology></Technologies><CompaniesCollaborator><Company>Clinica Universidad de Navarra</Company></CompaniesCollaborator><CompaniesSponsor><Company>Hospital Clinic of Barcelona</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2017-07-25T00:00:00Z</DateChangeLast><DateEnd>2020-02-29T00:00:00Z</DateEnd><DateStart>2016-02-29T00:00:00Z</DateStart><Identifiers><Identifier>2012-003900-11</Identifier><Identifier>Liveradvance</Identifier><Identifier>NCT02857010</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>mesenchymal stem cell therapy (liver failure), Hospital Clinic of Barcelona/Clinica Universidad de Navarra alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>30</PatientCountEnrollment><Phase>Phase 1 Clinical</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>The aim of this double-blind, placebo randomized, controlled trial is to investigate the effects of allogenic bone marrow derived mesenchymal stem cells (MSCs) transplantation on liver and other organ functions and systemic inflammation in patients with acute-on-chronic liver failure (ACLF). Expected results: therapy with MSCs could have beneficial effects on the evolution of patients with ACLF (modulation of inflammatory response and improvement of liver and extra-hepatic organ function) what</Teaser><TrialCategories><Category>Cell therapy</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>Liveradvance: Allogenic Bone Marrow Mesenchymal Stem Cell Therapy in Acute-on-chronic Liver Failure</TitleDisplay><BiomarkerNames><BiomarkerName>Ammonia </BiomarkerName><BiomarkerName> Bile acids and salts </BiomarkerName><BiomarkerName> Creatinine </BiomarkerName><BiomarkerName> Cytokines </BiomarkerName><BiomarkerName> Hepatic venous pressure gradient </BiomarkerName><BiomarkerName> Lactic Acid </BiomarkerName><BiomarkerName> Neutrophil gelatinase-associated lipocalin </BiomarkerName><BiomarkerName> Nitric oxide </BiomarkerName><BiomarkerName> Norepinephrine </BiomarkerName><BiomarkerName> Renin </BiomarkerName><BiomarkerName> Urea nitrogen </BiomarkerName><BiomarkerName> von Willebrand factor</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2018-02-28T00:00:00Z</PrimaryCompletionDate><TrialDuration>48 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Javier Fernandez, MD PhD</Name><Name>Javier Fernandez, MD, PhD</Name><Name>PERE GINES, MD PhD</Name><Name>Pere Ginès, MD, PhD</Name></ContactNames></Trial><Trial Id="86451"><Indications><Indication>HIV-1 infection</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>HIV GAG protein modulator</Action><Action>HIV gp120 protein modulator</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Antiviral</Action><Action>Prophylactic vaccine</Action><Action>Recombinant viral vector vaccine</Action><Action>Therapeutic vaccine</Action><Action>Unspecified virus based gene therapy</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Parenteral formulation unspecified</Technology><Technology>Virus recombinant</Technology></Technologies><CompaniesSponsor><Company>Hospital Clinic of Barcelona</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2017-08-09T00:00:00Z</DateChangeLast><DateEnd>2013-05-31T00:00:00Z</DateEnd><DateStart>2011-09-30T00:00:00Z</DateStart><Identifiers><Identifier>2009-016578-34</Identifier><Identifier>NCT01571466</Identifier><Identifier>RISVAC03</Identifier><Identifier>RisVac 03</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>MVA vaccine (HIV-1 infection), Esteve/IrsiCaixa Institute/Hospital Clinic Barcelona alone</Intervention><Intervention>disulfiram alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>30</PatientCountEnrollment><Phase>Phase 1 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>2015 [ 1690064 ]. In October 2016, results of a pooled analysis of two phase &lt;b&gt;I&lt;/b&gt; trials (R02; NCT00679497 and R03; NCT01571466) were presented. The aim of this pooled...doses [ 1730248 ]. In October 2016, results of a pooled analysis of two phase &lt;b&gt;I&lt;/b&gt; trials (R02; NCT00679497 and R03; NCT01571466) were presented. The aim of this pooled... The purpose of this phase &lt;b&gt;I&lt;/b&gt;, double-blind study was to evaluate the safety and efficacy of the HIV-1 vaccine, MVA HIV-B in chronic HIV-1 infected patients successfully</Teaser><TrialCategories><Category>Gene therapy</Category><Category>Vaccine</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Prevention</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>HIV Vaccine - Assessment of Antibody Responses</EndpointIndex><EndpointIndex>HIV Vaccine - Assessment of CD4 Cell Responses</EndpointIndex><EndpointIndex>HIV Vaccine - Assessment of CD8 Cell Responses</EndpointIndex><EndpointIndex>HIV Vaccine - Assessment of Immune Response - Assessment of cellular immunity</EndpointIndex><EndpointIndex>HIV Vaccine - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>HIV Vaccine - Assessment of Safety and Tolerability - Assessment of adverse events/serious adverse events</EndpointIndex><EndpointIndex>HIV Vaccine - Assessment of virological response - Virological breakthrough</EndpointIndex><EndpointIndex>HIV infection - Assessment of CD4 Cell Responses - Assessment of CD4 cell count/percentage</EndpointIndex><EndpointIndex>HIV infection - Assessment of CD8 Cell Responses - Assessment of CD8 cell count/percentage</EndpointIndex><EndpointIndex>HIV infection - Assessment of Immune Response</EndpointIndex><EndpointIndex>HIV infection - Assessment of Inflammatory &amp; Oxidative Stress Markers - Assessment of cytokines</EndpointIndex><EndpointIndex>HIV infection - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>HIV infection - Assessment of Safety and Tolerability - Assessment of adverse events/serious adverse events</EndpointIndex><EndpointIndex>HIV infection - Assessment of Viral Load - Assessment of HIV RNA levels</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>RISVAC03: A Study to Evaluate the Safety of the HIV-1 Vaccine MVA-B in Chronic HIV-1 Infected Patients Successfully Treated With HAART</TitleDisplay><PatientSegmentTerms><PatientSegment>HIV Vaccine - Subjects with HIV Infection - Subjects with HIV-1 infection</PatientSegment><PatientSegment>HIV infection - Subjects on Prior/Concurrent Antiretroviral Therapy - Subjects on prior/concurrent HAART</PatientSegment><PatientSegment>HIV infection - Subjects with HIV Infection - Subjects with HIV-1 Infection</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Cytokines </BiomarkerName><BiomarkerName> Human immunodeficiency virus RNA </BiomarkerName><BiomarkerName> T-Lymphocytes </BiomarkerName><BiomarkerName> T-cell surface glycoprotein CD4 </BiomarkerName><BiomarkerName> T-cell surface glycoprotein CD8 alpha chain</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2013-05-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>20 Months</TrialDuration><NumberOfSites>3</NumberOfSites><ContactNames><Name>Bonaventur Clotet</Name><Name>Felipe Garcia</Name><Name>Josep Gatell</Name><Name>Juan Quiros</Name></ContactNames></Trial><Trial Id="176830"><Indications><Indication>HIV infection</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>HIV GAG protein modulator</Action><Action>HIV gp120 protein modulator</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Antiviral</Action><Action>Prophylactic vaccine</Action><Action>Recombinant viral vector vaccine</Action><Action>Therapeutic vaccine</Action><Action>Unspecified virus based gene therapy</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Parenteral formulation unspecified</Technology><Technology>Virus recombinant</Technology></Technologies><CompaniesSponsor><Company>Hospital Clinic of Barcelona</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2017-07-15T00:00:00Z</DateChangeLast><DateEnd>2010-12-31T00:00:00Z</DateEnd><DateStart>2008-06-30T00:00:00Z</DateStart><Identifiers><Identifier>EUDRACT: 2007-002367-27</Identifier><Identifier>NCT00679497</Identifier><Identifier>R02</Identifier><Identifier>RISVAC02</Identifier><Identifier>RisVac02</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>MVA vaccine (HIV-1 infection), Esteve/IrsiCaixa Institute/Hospital Clinic Barcelona alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>30</PatientCountEnrollment><Phase>Phase 1 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>In October 2016, results of a pooled analysis of two phase &lt;b&gt;I&lt;/b&gt; trials (R02; NCT00679497 and R03; NCT01571466 ) were presented. The aim of this pooled analysis was to compare the safety and immunogenicity of MVA-B in HIV-uninfected and HIV-infected... In October 2016, results of a pooled analysis of two phase &lt;b&gt;I&lt;/b&gt; trials (R02; NCT00679497 and R03; NCT01571466 ) were presented. The aim of this pooled analysis was to compare the safety and immunogenicity of MVA-B in HIV-uninfected and HIV-infected</Teaser><TrialCategories><Category>Gene therapy</Category><Category>Vaccine</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Prevention</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>HIV Vaccine - Assessment of Antibody Responses</EndpointIndex><EndpointIndex>HIV Vaccine - Assessment of Immune Response - Assessment of cellular immunity</EndpointIndex><EndpointIndex>HIV Vaccine - Assessment of Safety and Tolerability - Assessment of adverse events/serious adverse events</EndpointIndex><EndpointIndex>HIV Vaccine - Assessment of Safety and Tolerability - Reactogenicity(local/systemic reactions)</EndpointIndex><EndpointIndex>HIV infection - Assessment of Immune Response - Assessment of anti-body titers/antibody responses</EndpointIndex><EndpointIndex>HIV infection - Assessment of Immune Response - Assessment of peripheral blood mononuclear cells (PBMC)</EndpointIndex><EndpointIndex>HIV infection - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>HIV infection - Assessment of Safety and Tolerability - Assessment of adverse events/serious adverse events</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Healthy volunteers accepted</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term></TermsPatientSelection><TitleDisplay>RisVac02: A Phase I Study of Modified Vaccinia Virus Ankara (MVA-B) in Healthy Volunteers at Low Risk of HIV Infection</TitleDisplay><PatientSegmentTerms><PatientSegment>HIV Vaccine - HIV Seronegative Subjects</PatientSegment><PatientSegment>HIV infection - Subjects at risk of developing disease</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Cytokines</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2010-03-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>30 Months</TrialDuration><NumberOfSites>2</NumberOfSites><ContactNames><Name>Josep M Gatell, MD</Name></ContactNames></Trial><Trial Id="64569"><Indications><Indication>HIV infection</Indication></Indications><ActionsSecondaryInterventionsPrimary><Action>Antiviral</Action><Action>Dendritic cell vaccine</Action><Action>Genetically engineered autologous cell vaccine</Action><Action>Therapeutic vaccine</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Cell therapy</Technology><Technology>Parenteral formulation unspecified</Technology></Technologies><CompaniesSponsor><Company>Hospital Clinic of Barcelona</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2018-08-23T00:00:00Z</DateChangeLast><DateEnd>2011-12-31T00:00:00Z</DateEnd><DateStart>2006-11-30T00:00:00Z</DateStart><Identifiers><Identifier>DCV-02/MANON07</Identifier><Identifier>NCT00402142</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>autologous dendritic cell vaccine (HIV-1 infection), University of Barcelona alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>60</PatientCountEnrollment><Phase>Phase 1/Phase 2 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser> Confirmed HIV infection CD4&gt; 450 x 10(6)/l Baseline VL&gt; 10,000 c/ml before any HAART Part &lt;b&gt;I&lt;/b&gt;, patients off HAART at least during 6 months Part II, patients on HAART with PVL&amp;lt; 200 copies/ml at least during 6 months Written informed consent</Teaser><TrialCategories><Category>Cell therapy</Category><Category>Gene therapy</Category><Category>Vaccine</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacodynamics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>HIV Vaccine - Assessment of Antibody Responses</EndpointIndex><EndpointIndex>HIV Vaccine - Assessment of CD8 Cell Responses</EndpointIndex><EndpointIndex>HIV Vaccine - Assessment of Immune Response</EndpointIndex><EndpointIndex>HIV Vaccine - Assessment of Immune Response - Assessment of cellular immunity</EndpointIndex><EndpointIndex>HIV Vaccine - Assessment of Viral Load</EndpointIndex><EndpointIndex>HIV Vaccine - Assessment of virological response</EndpointIndex><EndpointIndex>HIV infection - Assessment of Immune Response</EndpointIndex><EndpointIndex>HIV infection - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>HIV infection - Assessment of Viral Load</EndpointIndex><EndpointIndex>HIV infection - Assessment of virological response</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Dendritic Cell Vaccine in HIV-1 Infection</TitleDisplay><PatientSegmentTerms><PatientSegment>HIV Vaccine - Subjects with HIV Infection - Subjects with HIV-1 infection</PatientSegment><PatientSegment>HIV infection - Subjects on Prior/Concurrent Antiretroviral Therapy - Subjects on prior/concurrent HAART</PatientSegment><PatientSegment>HIV infection - Subjects with HIV Infection - Subjects with HIV-1 Infection</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2011-12-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>61 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Felipe García, MD, PhD</Name></ContactNames></Trial><Trial Id="247707"><Indications><Indication>Crohns disease</Indication></Indications><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Cell therapy</Technology><Technology>Parenteral formulation unspecified</Technology></Technologies><CompaniesSponsor><Company>Fundacion Clinic per a la Recerca Biomédica</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2019-02-19T00:00:00Z</DateChangeLast><DateEnd>2019-06-30T00:00:00Z</DateEnd><DateStart>2015-11-30T00:00:00Z</DateStart><Identifiers><Identifier>2014-001083-35</Identifier><Identifier>NCT02622763</Identifier><Identifier>TOLDEC-CD-INTRA</Identifier><Identifier>TolDecCDintra</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>tolerogenic dendritic cell therapy (injectable, Crohns disease), Hospital Clinic of Barcelona/Fundacio Clinic alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>20</PatientCountEnrollment><Phase>Phase 1 Clinical</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>The main objective is to evaluate the safety and clinical response of intralesional injection of autologous peripheral blood differentiated adult dendritic cells expanded tolerogenic ( tolerogenic dendritic cell therapy ) in patients with refractory Crohn's disease treatment.</Teaser><TrialCategories><Category>Cell therapy</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Single Blind</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Crohns disease - Assessment of Clinical Response - Clinical response measured by crohn's disease activity index (CDAI) score by &gt; or = 100 points</EndpointIndex><EndpointIndex>Crohns disease - Assessment of Remission - Crohn's disease activity index (CDAI) score &lt; 150</EndpointIndex><EndpointIndex>Crohns disease - Assessment of Safety and Tolerability - Drug related adverse event</EndpointIndex><EndpointIndex>Crohns disease - Crohn's Disease Activity Assessed by Capsule Endoscopy/Endoscopy - Crohn's disease endoscopic index of severity (CDEIS) score</EndpointIndex><EndpointIndex>Crohns disease - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Inflammatory Bowel Disease Questionnaire (IBDQ)</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>TolDecCDintra: Intralesional Tolerogenic Dendritic Cells in Crohn's Disease Treatment</TitleDisplay><PatientSegmentTerms><PatientSegment>Crohns disease - Subjects with Active Crohns Disease</PatientSegment><PatientSegment>Crohns disease - Subjects with Treatment Resistant Disease</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Anticipated">2019-06-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>43 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Daniel Benitez, BS (Biology) PhD</Name><Name>Elena Ricart, MD PhD</Name><Name>Elena Ricart, MD, PhD</Name><Name>Sara Varea</Name><Name>Sara Varea, BS (Biology)</Name></ContactNames></Trial><Trial Id="73490"><ActionsPrimaryInterventionsPrimary><Action>5-HT 2 receptor antagonist</Action><Action>Dopamine D2 receptor antagonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Antipsychotic</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Film coating</Technology><Technology>Oral formulation</Technology><Technology>Orally disintegrating tablet</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesCollaborator><Company>Fundacio Privada I Institut De Recerca De L'Hospital De La Santa Creu I Sant Pau</Company><Company>Fundacion Clinic per a la Recerca Biomédica</Company><Company>Universitat de Barcelona</Company></CompaniesCollaborator><CompaniesSponsor><Company>Hospital Clinic of Barcelona</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2019-04-12T00:00:00Z</DateChangeLast><DateEnd>2011-12-31T00:00:00Z</DateEnd><DateStart>2011-02-28T00:00:00Z</DateStart><Identifiers><Identifier>2009-016519-40</Identifier><Identifier>APSEP</Identifier><Identifier>NCT01259973</Identifier><Identifier>TRA-065</Identifier><Identifier>TRA-065</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>haloperidol alone</Intervention><Intervention>risperidone alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>24</PatientCountEnrollment><Phase>Phase 1 Clinical</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>h and until +24 h (depending on each scale used). Subjects would be hospitalized for 3 complete days (separated between them by 1 wash-out week after each treatment) from 8.00 h to 8.00 h of the following day at phase &lt;b&gt;I&lt;/b&gt; unit of '&lt;b&gt;Hospital&lt;/b&gt; &lt;b&gt;de&lt;/b&gt; Sant Pau &lt;b&gt;i&lt;/b&gt; &lt;b&gt;de&lt;/b&gt; la Santa Creu', in &lt;b&gt;Barcelona&lt;/b&gt;, in order to monitor the results obtained after each treatment. During their hospitalization, subjects would be given food and drink every 2-h.</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Crossover Assignment</Term></TermsDesign><TermsEndpoint><Term>Pharmacokinetics</Term><Term>Pharmacodynamics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Schizophrenia - Assessment of Hormone Levels - Assessment of prolactin levels</EndpointIndex><EndpointIndex>Schizophrenia - Assessment of Neuropsychological Function - Assessment of attention</EndpointIndex><EndpointIndex>Schizophrenia - Assessment of Pharmacokinetic/Pharmacodynamic Parameters</EndpointIndex><EndpointIndex>Schizophrenia - Assessment of Psychiatric Symptoms - Assessment of subjects by PANSS (Positive And Negative Syndrome Scale)</EndpointIndex><EndpointIndex>Schizophrenia - Assessment of Safety and Tolerability - Assessment of adverse events(AEs)/side effects</EndpointIndex><EndpointIndex>Schizophrenia - Assessment of Safety and Tolerability - Assessment of extra pyramidal symptoms</EndpointIndex><EndpointIndex>Schizophrenia - Assessment of Safety and Tolerability - Assessment of subjects by Barnes Akathisia Rating Scale (BARS)</EndpointIndex><EndpointIndex>Schizophrenia - Assessment of Safety and Tolerability - Assessment of subjects by Simpson Angus Scale (SAS)</EndpointIndex><EndpointIndex>Schizophrenia - Assessment of Sleep</EndpointIndex><EndpointIndex>Schizophrenia - Assessment of Symptoms of Schizophrenia - Assessment of aggressive symptoms</EndpointIndex><EndpointIndex>Schizophrenia - Assessment of Symptoms of Schizophrenia - Assessment of negative symptoms</EndpointIndex><EndpointIndex>Schizophrenia - Assessment of Symptoms of Schizophrenia - Assessment of positive symptoms</EndpointIndex><EndpointIndex>Schizophrenia - Assessment of Symptoms of Schizophrenia - Assessment of psychotic symptoms</EndpointIndex><EndpointIndex>Schizophrenia - Assessment of Symptoms of Schizophrenia - Assessment of subjects by BPRS (Brief Psychiatric Rating Scale)</EndpointIndex><EndpointIndex>Schizophrenia - Assessment of Symptoms of Schizophrenia - Assessment of subjects by SANS (Schedule for Assessment of Negative Symptoms)</EndpointIndex><EndpointIndex>Schizophrenia - Assessment of Vital Signs</EndpointIndex><EndpointIndex>Schizophrenia - Assessment of ocular function</EndpointIndex><EndpointIndex>Schizophrenia - Gene variants involved in outcome measures - CYP2D6_HUMAN_Duplication</EndpointIndex><EndpointIndex>Schizophrenia - Gene variants involved in outcome measures - CYP3A5_HUMAN_rs776746(A)</EndpointIndex><EndpointIndex>Schizophrenia - Gene variants involved in outcome measures - CYP3A5_HUMAN_rs776746(G)</EndpointIndex><EndpointIndex>Schizophrenia - Patient Reported Outcomes/Quality of Life Assessments - Assessment of subjects by VAS scale</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Healthy volunteers only</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TitleDisplay>APSEP: Typical Versus Atypical Antipsychotics; Occupation of Striatal Receptors and the Appearance of Extrapyramidal Symptomatology, in Healthy Volunteers</TitleDisplay><PatientSegmentTerms><PatientSegment>Schizophrenia - Others - Healthy Subjects</PatientSegment><PatientSegment>Schizophrenia - Subjects with gene variants - CYP2D6_HUMAN_Mutation</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Cytochrome P450 2D6 </BiomarkerName><BiomarkerName> Cytochrome P450 3A5 </BiomarkerName><BiomarkerName> Prolactin</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2011-11-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>10 Months</TrialDuration><NumberOfSites>2</NumberOfSites><ContactNames><Name>Amalia Lafuente Flo, Pharmacology professor</Name><Name>Analía Azaro, Clinical Pharmacologist</Name><Name>Eva Ferrando Martorell, Pre-doc</Name><Name>Gemma Trias Lafuente, Psychologist</Name><Name>Ignasi Carrió Gasset, Head of Nuclear Med Service</Name><Name>Miquel Bernardo Arroyo, Head of Psychiatry</Name><Name>Rosa M Antonijoan, Clinical Pharmacologist</Name><Name>Sergi Mas Herrero, Pos-doc assistant professor</Name></ContactNames></Trial><Trial Id="221060"><Indications><Indication>Schizophrenia</Indication></Indications><CompaniesCollaborator><Company>Universitat de Barcelona</Company></CompaniesCollaborator><CompaniesSponsor><Company>Hospital Clinic of Barcelona</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2017-09-13T00:00:00Z</DateChangeLast><DateEnd>2016-03-31T00:00:00Z</DateEnd><DateStart>2012-01-31T00:00:00Z</DateStart><Identifiers><Identifier>NCT02341131</Identifier><Identifier>PI 11/01958</Identifier></Identifiers><InterventionsControlDisplay><Intervention>psychoeducation alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>cognitive remediation therapy alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>70</PatientCountEnrollment><Phase>Phase Not Applicable</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The main objective of this study was to analyze the role of a neurotrophic factor (brain-derived neurotrophic factor [BDNF]) as a putative biological marker of the cognitive recovery in schizophrenia following a Cognitive Remediation Therapy (CRT). Additionally, the role as outcome predictors of BDNF serum levels and the val66met polymorphism and data from functional and structural neuroimaging would be studied.</Teaser><TrialCategories><Category>Behavioral intervention</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Single Blind</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Schizophrenia - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Schizophrenia - Assessment of Psychiatric Symptoms - Assessment of subjects by PANSS (Positive And Negative Syndrome Scale)</EndpointIndex><EndpointIndex>Schizophrenia - Assessment of Symptoms of Schizophrenia</EndpointIndex><EndpointIndex>Schizophrenia - Cognitive, Global and Functional Assessments</EndpointIndex><EndpointIndex>Schizophrenia - Pharmacogenetic/Pharmacogenomics Analysis</EndpointIndex><EndpointIndex>Schizophrenia - Protocol Specified Other Endpoints - Assessment of sociodemographic outcomes</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Healthy volunteers accepted</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>Cognitive Remediation Therapy in Schizophrenia: Effects on BDNF Levels</TitleDisplay><PatientSegmentTerms><PatientSegment>Schizophrenia - Others - Healthy Subjects</PatientSegment><PatientSegment>Schizophrenia - Subjects with Neurocognitive Impairment</PatientSegment><PatientSegment>Schizophrenia - Subjects with gene variants - BDNF_HUMAN_rs6265(A)</PatientSegment><PatientSegment>Schizophrenia - Subjects with gene variants - BDNF_HUMAN_rs6265(G)</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Brain-derived neurotrophic factor</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2015-12-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>50 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Rafael Penadés, Ph.D.</Name></ContactNames></Trial><Trial Id="295871"><Indications><Indication>Keratitis</Indication></Indications><CompaniesSponsor><Company>Banc De Sang I Teixits</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2018-10-13T00:00:00Z</DateChangeLast><DateEnd>2019-04-07T00:00:00Z</DateEnd><DateStart>2017-02-24T00:00:00Z</DateStart><Identifiers><Identifier>2016-001841-23</Identifier><Identifier>I.2016.010</Identifier><Identifier>NCT03084861</Identifier></Identifiers><InterventionsControlDisplay><Intervention>Air Optix Night and Day contact lens alone</Intervention><Intervention>Lubristil alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>Cord Blood Eye Drops alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>42</PatientCountEnrollment><Phase>Phase 1/Phase 2 Clinical</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser> This is a multicenter, randomized, open-label, two-arms phase &lt;b&gt;I&lt;/b&gt;/II, clinical trial, in which 42 patients will be enrolled with the principal objective to evaluate the efficacy through changes in lesion size and, secondary, to evaluate the safety and efficacy through corneal sensibility, corneal opacity, visual acuity</Teaser><TrialCategories><Category>Cell therapy</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Other ocular disease - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Other ocular disease - Assessment of Laboratory/Diagnostic Measures - Assessment of corneal opacity</EndpointIndex><EndpointIndex>Other ocular disease - Assessment of Safety and Tolerability - Assessment of adverse events/treatment emergent adverse events</EndpointIndex><EndpointIndex>Other ocular disease - Assessment of Visual Function - Assessment of visual acuity(VA)</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>A Clinical Trial to Asses Efficacy and Safety of Cord Blood Eye Drops in Neurotrophic Keratopathy</TitleDisplay><PatientSegmentTerms><PatientSegment>Other ocular disease - Subjects with specific disease</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Visual acuity</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2019-03-17T00:00:00Z</PrimaryCompletionDate><TrialDuration>25 Months</TrialDuration><NumberOfSites>10</NumberOfSites><ContactNames><Name>Antonio Sabala, MD</Name><Name>Daniela Ortiz, MD</Name><Name>Dinara Samarkanova, MD</Name><Name>Javier Puig Galy, MD PHD</Name><Name>Josep Torras, MD</Name><Name>Marta Calatayud, MD</Name><Name>Miriam Barbany, MD</Name><Name>Pablo Martí, MD</Name><Name>Ruth Coll Bonet, MD</Name><Name>Sergi Querol Giner, MD PHD</Name><Name>Teresa Torrent, MD</Name><Name>Zoraida Del Campo Carrasco, MD</Name></ContactNames></Trial><Trial Id="104381"><Indications><Indication>Obesity</Indication></Indications><CompaniesCollaborator><Company>Fundacio Clinic Per A La Recerca Biomedica</Company></CompaniesCollaborator><CompaniesSponsor><Company>Hospital Clinic of Barcelona</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2018-01-09T00:00:00Z</DateChangeLast><DateEnd>2009-05-31T00:00:00Z</DateEnd><DateStart>2007-11-30T00:00:00Z</DateStart><Identifiers><Identifier>EudraCT: 2006-000567-28</Identifier><Identifier>NCT00555074</Identifier><Identifier>TROTA-1</Identifier><Identifier>TROTA-1</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>sodium tungstate alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>44</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser> The purpose of this study was to compare the efficacy and safety of sodium tungstate versus placebo in patients with obesity (grade &lt;b&gt;I&lt;/b&gt; and II).</Teaser><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Obesity - Anthropometric Assessments - Assessment of body composition</EndpointIndex><EndpointIndex>Obesity - Anthropometric Assessments - Assessment of weight loss</EndpointIndex><EndpointIndex>Obesity - Assessment of Dietary Intake - Assessment of caloric intake</EndpointIndex><EndpointIndex>Obesity - Assessment of Metabolic Parameters - Assessment of basal metabolic rate</EndpointIndex><EndpointIndex>Obesity - Assessment of adverse events</EndpointIndex><EndpointIndex>Obesity - Assessment of lipid profiles</EndpointIndex><EndpointIndex>Obesity - Hematological Assessments - Changes in hormonal parameters</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>TROTA-1: Sodium Tungstate in Obesity</TitleDisplay><PatientSegmentTerms><PatientSegment>Obesity - Obese Class I Subjects</PatientSegment><PatientSegment>Obesity - Obese Class II Subjects</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Lipids</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2009-05-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>18 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Josep Vidal, MD</Name></ContactNames></Trial></SearchResults></ns2:com.thomsonreuters.ls.service.contract.soap.trials.v2.TrialResultsOutput>